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Considerable species variations exist in the metabolism 
of xenobiotics3 consequently one of the most difficult problems 
in examining the safety of a drug for human use lies in finding 
a suitable animal model in which the toxicity and metabolism of 
the drug can be usefully examined. This thesis describes an 
investigation of some pathways of xenobiotic metabolism in the 
marmoset (Oallithrix .jacchus), a small primate known to be 
suitable as a model for man in the study of teratogenic effects 
of drugs but for which few detailed studies of drug metabolism 
have been reported. The biotransformations studied were mainly 
conjugation reactions involving the combination of xenobiotics 
with glycine, glucuronic acid and acetic acid. Mercapturic acid 
formation which involves an initial conjugation with glutathione 
was also examined. During this work techniques were devised for 
the oral dosing of the marmosets, for housing the animals under 
study in conditions allowing the separate collection of urine 
and faeces and for the collection of small serial samples of 
blood. The regular breeding by the adults made it possible to 
study drug metabolism in the neonates, novel methods being 
developed for this study.
1 4Examination of the fate of C-labelled benzoate showed that
the availability of glycine was probably the limiting factor in
hippuric acid synthesis in the adult marmoset, the proportion of
the dose excreted as benzoylglucuronide increasing with increasing
dose level; considerable individual variation was observed. In
contrast to the marmoset, availability of glycine did not limit
hippuric acid synthesis by the mature rat at the dose levels
1 4studied. Relatively small proportions of O-labelled aspirin
were excreted as salicyluric acid by either species, the extent 
of this reaction being variable also. By the use of high 
pressure liquid chromatography the excretion of small amounts of 
unchanged drug by man and marmoset after the oral administration 
of aspirin at the same dose level was detected.
Acetylation of p-aminob enzoi c acid, sulphadiazine and 
sulphadirnidine was effected by the marmoset. The major 
metabolite of p-aminobenzoate was p-acetamidobenzoate; less 
p-aminohippuric acid was excreted than by similarly dosed rats 
or than reported for man. The extent of acetylation of 
sulphadiazine was similar to that reported for man and was found 
to be greater than that observed in the rat and less than that in 
the rabbit. The proportion of administered sulphadimidine 
excreted as the acetyl derivative and the proportion of this 
metabolite found in the blood indicated that all the marmosets 
in the colony corresponded to 'fast acetylators' in human 
populations.
Benzylmercapturic acid was excreted by marmosets as a major 
metabolite of benzyl chloride and 2-hydroxybutylmercapturic acid 
was detected in the urine of marmosets to which 1,2-epoxybutane 
had been dosed. Wide inter-individual variation in the 
conversion of benzyl chloride to hippuric acid by the marmoset 
was observed while traces of metabolites arising from the 
deamination of benzylcysteine also appeared to be excreted by 
this species. Pentylcysteine was extensively acetylated and 
excreted as pentylmercapturic acid. Some evidence of the 
formation of mercapturic acid sulphoxides by the marmoset was 
obtained.
A short study of the metabolic fate of orally administered 
quinic acid and cyclohexanecarboxylic acid suggested that the
marmoset behaved as a typical Few World monkey in its inability 
to aromatize the former compound but to metabolise the latter to 
hippuric acid. In this respect the marmoset is different from 
the higher primates, including man, in which the ability to 
reduce quinic acid is attributed to the action of the gut 
micro-flora.
The metabolic fates of benzoic acid and p-aminobenzoic acid 
were also studied in neonatal marmosets and rats. Hippuric acid 
synthesis was strongly dose dependent in the young of both species 
this being more marked in the marmoset where at high dose levels 
benzoylglucuronide became the major metabolite excreted. In 
this species the availability of glycine for conjugation with 
benzoate was clearly limiting. In both species glucuronidation 
was significantly more important in the neonates than in the 
adults. Evidence that the liver of the neonatal marmoset 
possessed UDPGrT activity towards bilirubin was obtained. The 
metabolic fate of p-aminobenzoate in the developing marmoset 
followed an opposite trend to that in either the rat or to that 
reported for man, the overall results suggesting that the 
observed metabolic profiles were governed mainly by the acetylase 
system.
The results obtained indicate that the marmoset possesses 
the ability to carry out the Phase II reactions studied although 
the relative importance of these reactions in the metabolic fate 
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Chapter 1 - Introduction
Today organic compounds which are foreign to the animal 
body in the sense that they are neither utilised for the 
production of energy nor for synthesis, are employed on a vast 
scale in the service of mankind. Thus synthetic organic 
compounds are used as drugs in the treatment of illness, as food 
additives, as emulsifiers in drink manufacture, as pesticides in 
agriculture, as dyes, as cleansing agents and as cosmetics.
All these foreign compounds (xenobiotics) are potentially toxic 
to man and it is essential that before any such compound is 
manufactured and released for general use, its toxicity should 
be evaluated so that safety levels for its use can be clearly- 
stated. The tests involved in establishing whether there is an 
acceptable level at which a compound can be safely used are 
normally carried out first on laboratory animals such as the ' 
rat, rabbit, guinea pig, dog, cat and occasionally non-human 
primates and it is on the evidence obtained from these investiga­
tions that the final decision to proceed to examine the effect of 
the compound in man depends. However scientists concerned in 
extrapolating the results from animal experiments to man are 
faced with the problem of species variations in both the 
therapeutic and toxic action of foreign compounds.
It is becoming increasingly recognised that the effect of a 
drug, therapeutic and/or toxic, may be due not only to the parent 
drug administered but to its metabolites and a study of the 
metabolic profile of the drug in various animal species may 
indicate the basis of any observed species variations in its 
effects. The ultimate aim of such studies is to find an animal 
in which the absorption, distribution, excretion and the rate
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and route of metabolism of the substance are closely similar to 
those in man. New regulations for drug safety require inform­
ation on the metabolic fate of the drug in man and in at least 
two other animal species, and that toxicity studies have been 
carried out in animals in which the drug has been shown to have 
a similar metabolic profile to that in man. Knowledge so far 
accumulated indicates that the existence of a perfect animal 
model for man is very unlikely, so the search must continue for 
the species which most closely resembles man in its metabolism 
of foreign compounds.
Although this is the main reason for studying species 
variations in the metabolism of xenobiotics, such studies are 
also interesting from an academic point of view for variations 
in the metabolic fate of a xenobiotic in different species may 
reveal biochemical relationships between the species which can 
be of importance in the problem of taxonomy. This applies 
particularly to primate taxonomy since some pathways of xeno­
biotic metabolism occur only in primate species and in some 
cases only in particular groups of primates and these can be 
correlated with the evolutionary status of the groups. Williams, 
(1977) coined the self-explicit term ’pharmacozootaxonomy' for 
the relationship between xenobiotic metabolism and taxonomic 
classification. Studies on species variations in the meta­
bolism of xenobiotics are furthermore of academic interest in 
that they may lead to the discovery of previously unknown 
biochemical pathways peculiar to one or a limited number of 
species. In this connection studies of the metabolism in the 
more exotic animal species are of interest and it may well be 
that such investigations could have some importance to clinical 
studies. A recent WHO report (1975) on guidelines for the
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evaluation of drugs for use in man considered that one future 
research need for the development of efficacious and safe drugs 
is the use of new or seldom used species of test animal.
Several other factors, apart from species, help determine 
the overall metabolic profile of a xenobiotic, and when study­
ing the effects of species variations these other factors must 
be recognised and controlled as far as possible. These factors 
are listed later in Table 1.4 and the extent to which any one 
of them influences the apparent metabolic fate of a drug is 
itself species dependent. A detailed discussion of how these 
factors can or cannot be controlled between species is contained 
in a later section.
The fate of foreign compounds in animals
In general when a foreign compound enters the body it may 
be disposed of in three ways:
(i) It may be excreted unchanged.
(ii) It may undergo chemical reactions which do not involve 
enzymes.
(iii) It may be metabolised by appropriate enzyme systems.
The physical and chemical properties of the compound
determine the extent to which it is distributed among these 
three possibilities, bearing in mind that the fate of any one 
compound will probably be a result of the operation of more than 
one of the possibilities. Furthermore the metabolic fate of a 
compound can vary depending on its route of administration to 
the animal. Orally administered strong acids and strong bases 
are poorly absorbed from the gut and consequently large 
proportions of the dose appear unchanged in the faeces of the 
animal. Compounds which are absorbed from the gut encounter the
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xenobiotic metabolising enzymes of the gut wall, an environment 
not encountered by compounds administered either by intravenous 
or intraperitoneal injection.
Polar, water-soluble compounds are excreted by the kidney 
and are not re-absorbed by the kidney tubules in contrast to 
the less polar more lipophilic compounds. Consequently many 
polar compounds, acids and bases are excreted unchanged. How­
ever a few cases are known where relatively non-polar compounds 
are excreted unchanged, or are only metabolised to a limited 
extent by animals. Very few compounds are known that are not 
metabolised at all in various animal species, but some are 
excreted mainly unchanged with only a small degree of metabolism. 
One would not expect species variations to occur in the fate of 
foreign compounds that are not metabolised at all. It is 
however difficult to establish that a compound is excreted 
entirely unchanged since the accuracy of the statement is 
dependent on the sensitivity of the methods employed for the 
detection of the compound and its metabolites. It may be that 
the compound is poorly metabolised and that the methods of 
detection used are not sufficiently sensitive to detect the low 
concentrations of the metabolites formed or are not specific and 
do not distinguish between the unchanged compound and its 
metabolites. 5,5'-Methylenedisalicylic acid (pKa 3 .5 ) (I) was 
found by Davison and Williams (1968) to be excreted entirely 
unchanged by the mouse, rat, guinea pig, hamster, chicken, 
rabbit and rhesus monkey; so far this seems to be the best
( I )
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example of a compound which is excreted entirely unchanged.
Some compounds undergo non-enzymic chemical reactions 
within the animal body. A compound may be unstable under 
physiological conditions and decompose or it may react spontane­
ously with a normal chemical constituent of the body. An 
excellent example of a compound undergoing spontaneous change 
within the body is thalidomide which has a half-life of about 
5h at pH 7.4 in phosphate buffer at 37°C and undergoes hydrolysis 
at physiological pH values to give some twelve products 
(Schumacher et al., 1965; Williams, 1968).
One would not expect to find species differences in the fate 
of compounds undergoing such spontaneous changes and indeed the 
fate of thalidomide is much the same in several animal species. 
However any further metabolism of the breakdown products may be 
species dependent and this must always be considered. If a 
normal body constituent is involved in the spontaneous reaction 
of a xenobiotic then the relative amounts of the normal constit­
uent within different species may result in a species variation 
in the metabolic fate of the administered compound. In cases 
where the normal body constituent is present in limiting 
quantities, a situation which itself may also vary with species, 
the metabolic fate of the administered compound may well be 
dependent on the dose level.
Most foreign compounds on entering the body are metabolised, 
although the extent to which this occurs varies over a wide range 
and is strongly species dependent. For example cyclohexylamine 
is only slightly metabolised in man, rat and guinea pig but 30% 
of the administered base is metabolised in the rabbit, (Renwick 
and Williams, 1972); in man norephedrine is only slightly 
metabolised but in the rat 30%, and in the rabbit 90% of the
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administered dose is metabolised, (Sinsheimer et al., 1973); in 
man and the rhesus monkey 4-nitrophenylacetic acid is excreted 
largely unchanged but in the rat 61 $ of the dose is excreted 
conjugated with glycine (James et al., 1972a).
Metabolism increases the rate of excretion of a xenobiotic 
since in this process lipophilic compounds are converted into 
more polar, water-soluble compounds which are readily excreted 
by the kidney in the urine and under certain circumstances by 
the liver in the bile. The importance of metabolism is seen 
in the case of the organohalogenic pesticides which are only 
poorly metabolised and which accumulate in the tissues e.g. DDT 
(Hayes, 1965; Hart et al., 1972).
The therapeutic action of many xenobiotics is terminated by 
their conversion to more polar, water-soluble compounds which 
are usually physiologically inactive and which are more readily 
excreted than the parent compound. In certain cases however, 
metabolism may also convert a pro-drug into a pharmacologically 
active substance, and similarly metabolism can also change the 
pharmacological activity of a drug, converting it from a compound 
with one kind of activity to another substance with a different 
pharmacological activity. Table 1.1 contains examples of how 
the pharmacological activity of a substance can be altered by 
its metabolism.
Outline of xenobiotic metabolism
The metabolism of xenobiotics is usually considered to 
occur in two phases (Williams, 1959). In the first phase the 
xenobiotic undergoes one or more asynthetic reactions which may 
be classified as hydrolyses, reductions, or oxidations. These 
reactions introduce into the xenobiotic, or expose within its
Dru§ Metabolic reaction Metabolite Pharmacological conseauence
DEACTIVATION
Phenobarbitone aromatic hydroxylation 4-hydroxy
phenobarbitone
Loss of hypnotic activity
Chlorcyclizine N-oxidation chlorcyclizine N- 
oxide
Loss of antihistamine activity
ACTIVATION
Prontosil azo reduction sulphanilamid e Becomes antibacterial
Prednisone cyclic ketone
reduction
prednisolone Becomes corticosteroid immuno­
suppressive
CHANGE IN ACTIVITY
Iproniazid N-dealkylation isoniazid Antidepressive--> antitubercular
Codeine O-demethylation morphine Analgesic-- => narcotic
Table 1.1 The effect of metabolism on the pharmacological activity of various medicinal drugs
(Examples from Gorrod and Beckett 1978)
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structure, biochemically reactive groups such as hydroxyl, 
carboxyl, amino and sulphydryl groups. Many of the Phase I 
reactions are carried out by enzymes situated in the endoplasmic 
reticulum of the liver cell.
In Phase II of xenobiotic metabolism the Phase I products, 
having acquired biochemically reactive groups, undergo synthetic 
reactions which are carried out by enzyme systems located mainly 
in the liver cell but which also occur in other tissues such as 
the kidney, the intestinal mucosa and the lung. During the 
Phase II reactions the xenobiotic is conjugated through its 
biochemically reactive group(s) with a normal physiological 
molecule, the resulting conjugate being relatively more polar 
than the parent xenobiotic and therefore more readily excreted 
from the body. In many cases the xenobiotic may possess at 
least one biochemically reactive group within its parent 
structure and may undergo Phase II reactions directly. In 
general it is likely that a xenobiotic is distributed along all 
the possible metabolic pathways, the extent to which a particular 
pathway is followed being dependent upon the affinities of the 
enzymes for the particular substrate, the relative amounts of 
the enzymes present and the availability of the endogenous 
compound for conjugation with the xenobiotic. With some complex 
molecules many metabolites may be formed as in the case of 
chlorpromazine where more than 35 metabolites have been detected 
(Turano et al., 1973)*
The common conjugating mechanisms in mammals are those 
utilising glucuronic acid, amino acids (in particular glycine, 
glutamine and taurine), acetate, sulphate and glutathione. 
Conjugation with phosphate, methyl groups and the conversion of 
cyanide to thiocyanate also occur (Williams and Millburn, 1975).
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In some avian species, ornithine conjugation replaces glycine 
conjugation while in insects glucose conjugation replaces that 
with glucuronic acid. Table 1.2 is a summary of the types of 
Phase II reactions and the biochemically reactive groups with 
which they occur. Conjugation with glucuronic acid is the most 
widespread and versatile Phase II reaction probably because the 
glucuronic acid moiety can be transferred to many different 
biochemically reactive groups and is itself readily available 
from a variety of carbohydrate sources within the animal.
Phase II reaction
Conjugation with glucuronic 
acid
Conjugation with sulphate 
Conjugation with amino acids
Conjugation with acetate
Conjugation with methyl groups 
Conjugation with glutathione
Biochemically reactive groups 
with which reaction occurs
hydroxyl, carboxyl, amino, 
sulphamido and sulphydryl 
groups.
hydroxy compounds (usually 
phenolic) and aromatic amines.
carboxylic acid groups (in 
particular those contained in 
a molecule which has a hetero­
cyclic or carbocyclic 
aromatic system within its 
structure).
aromatic and aliphatic amino 
groups, sulphonamido and 
hydrazine groups, and -amino 
groups of S-substituted 
cysteines.
hydroxyl, sulphydryl amino or 
substituted amino groups.
aromatic hydrocarbons, aryl, 
alkyl and aralkyl halides, 
nitro compounds, epoxides, 
esters and unsaturated 
carboxylic acids.
Table 1.2 The group specificity of the various
Phase II reaction types
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Conjugation reactions are biosynthetic and involve the 
formation of an activated intermediate from either the 
xenobiotic or the endogenous conjugating agent. Conjugation 
reactions which involve an amino acid as the endogenous compound 
usually proceed via an activated xenobiotic intermediate and 
appear to be restricted to the liver and/or kidney (type (i) 
reaction), whereas glucuronidation, sulphation, acetylation and 
methylation reactions proceed via an activated conjugating agent 
intermediate and occur not only in the liver and kidney but also 
in the lung and intestine (type (ii) reaction). Both of these 
reaction types are employed in the metabolism of benzoic acid
as follows,
Reaction type (i) Hippuric acid formation involving the
activation of benzoic acid.
Acylthiokinase A
C6H5COOH + ATP -----------------> C6H5CO.AMP +
benzoic acid Adenyl benzoate
Acylthiokinase
C6E5CO.AMP + CoASH----------------- > CgH^CO.SOoA + AEP
Ooenzyme A benzoyl Coenzyme A
N-acyltransferase
CgH^CO.SCoA + H2NCH2C00H-----------------> C6H5C0NHCH2C00H+CoASH
glycine hippuric acid
Reaction type (ii) Benzoylglucuronide formation involving the
activation of glucuronic acid.
Uridyl transferase A_




UDPG + 2NAD+ ---------------------------------> UDPGA + 2NADH + 2H+
UDP-D-glucuronic acid
UDP glucuronyl




In both sequences, a transferase enzyme is used for the
11
final step. Table 1.3 is a summary of both reaction types, 
including the activated intermediates and transferase enzymes 
employed.
Reaction





Glutamine conjugation Arylacetyl CoA 
Ornithine conjugation Aroyl OoA 



















Sulphate conjugation 3 1-Phosphoadenosine- 
5 '-phosphosulphate Sulphotransíerase
Acetyl group






Table 1.3 Summary of the Phase II conjugation mechanisms 
(Information taken from Williams, 1974)
As may be seen from Table 1.3 the different amino acid 
conjugation systems have different substrate specificities.
This is an important aspect of amino acid conjugation and will 
be mentioned in later sections. Conjugation of arylacetic acids 
with taurine was discovered as recently as 1972 (James et al.b), 
and consequently the mechanism of this reaction is not definitely
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established although it would appear logically to follow the 
mechanisms already established for the other amino acids.
Conjugation with glutathione follows neither type (i) nor 
type (ii) reaction sequences. Specific glutathione-S-transfer­
ases are known which catalyse the conjugation of electrophilic 
compounds with the nucleophilic glutathione. Some compounds, 
for example aromatic hydrocarbons, are converted to epoxides 
which then combine with glutathione, the reaction being catalysed 
by glutathione-S-epoxide transferase although the conjugation 
may to' some extent occur spontaneously.
The detoxication of cyanide to thiocyanate appears to be 
the result of a direct reaction between cyanide and thiosulphate, 
catalysed by the enzyme thiosulphate sulphurtransferase 
(rhodanese). This reaction does not involve an activated 
intermediate although PAPS (3'-phosphoadenosine-5'-phospho- 
sulphate) may be involved in the formation of the thiosulphate 
used in the reaction (Roy and Trudinger, 1970). The metabolism 
of cyanide is a classic example of detoxication since a 200 fold 
decrease in toxicity is achieved by converting cyanide to 
thiocyanate. The occurrence of rhodanese throughout nature is 
widespread and the enzyme is thought to have developed in 
response to the high cyanide content in the atmosphere at the 
time of early life forms. Today the detoxication of cyanide 
is only of use for the small amounts of cyanide that may be 
encountered in the diet. Rhodanese will only convert the 
cyanide ion to thiocyanate and has no activity towards unhydrolysed 
organic cyanides.
Metabolism of 2-naphthylamine
The complete metabolism of 2-naphthylamine in the animal
13
body provides good examples of both Phase I and Phase II 
reactions, many of which have been described above (Fig 1.1).
Species variation in the factors affecting the overall pattern 
of drug metabolism.
The complete study of the metabolism of a xenobiotic takes 
into account the absorption, distribution, excretion, protein 
binding and membrane permeability of the compound as well as 
its biotransformation. Any or all of these factors may vary 
with species and the combined result of the interaction of these 
processes constitutes the metabolic profile of the xenobiotic in 
a particular species. Most studies concerned with species 
variations in xenobiotic metabolism have reported the differ­
ences observed in the metabolites excreted, less attention 
having been paid to the possible differences in the underlying 
biochemical pathways which would result in the observed in vivo 
results.
The fate of a foreign compound may be affected by factors 
influencing either the asynthetic or synthetic phases of drug 
metabolism. Of these factors, which are listed in Table 1.4, 
probably the greatest effect is due to species variations 
although when examining the metabolism of any xenobiotic the 
other factors listed must be controlled wherever possible.
Most of the factors listed in Table 1.4 can be standardised 
within experiments but some are difficult to control. For 
example in studying the metabolism of a xenobiotic in a 
herbivorous and a carnivorous species of animal it is obviously 
not possible to maintain the animals on the same diet. The 
importance of the dietary factor, in affecting the routes of 

















Fig 1.1 Metabolic fate of 2-naphthylamine
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(Basu et al., 1971; Woodcock and Wood, 1971; Dickerson e_t al., 
1976; Campbell, 1977; Conney et al., 1977). Again the 
composition of the gut flora varies with the animal species 
(Drasar et; al., 1970), and differences in xenobiotic metabolism 
may be due to biotransformations brought about by the gut flora. 
To eliminate this factor as a cause of variation it is necessary 
to kill the gut bacteria by pre-treatment with antibiotics or to 
breed germ-free animals. It may then be argued that the animals 
are no longer normal since the xenobiotic metabolising activity 
of the gut flora may contribute significantly to the overall 
observed metabolic profile and represents an integral part of 
the ability of the whole animal to deal with foreign compounds.
It is therefore advisable to leave the gut flora intact when 
studying xenobiotic metabolism within an animal and to treat the 














Presence of other xenobiotics 
Route of excretion (urine, bile) 
Season 
Time of day
Table 1.4 Factors affecting the metabolism of a drug
(From Williams, 1974)-
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The influence of sex on the metabolism of xenobiotics is 
itself species dependent being manifested to a marked extent 
only in the rat (Inscoe and Axelrod, 1960; Kato et al., 1962; 
Kato and Gillette, 1965; Macleod et al., 1972) and mouse (Catz 
and Yaffe, 1967), whereas only minor sex differences have been 
reported in man (Guidicelli and Tillement, 1977). Furthermore 
this effect appears to be age dependent also, being absent in 
immature rats (Macleod et_ al., 1972). An example of the 
influence of sex on the metabolism of biphenyl in the rat was 
reported by Rahman (1970). In male rats the increase in hepatic 
biphenyl 4-hydroxylase activity induced by $  -ionone given at a 
dose level of 100mg/kg body weight for three days, paralleled 
the increase in hepatic cytochrome P ^ q . However, although the 
increase in hepatic cytochrome P ^ q content observed in the 
female rat was similar to that in the male, the hepatic biphenyl 
4-hydroxylase activity was increased to a much greater extent 
even at a lower dose level of ¡3 -ionone. The sex differences 
have since been attributed to the greater induction of NADPH- 
cytochrome c reductase activity in the female rat. Similar sex 
differences have been shown in the metabolism of. amphetamine 
(Dingell et al., 1973; Williams, 1974).
The effect of age on the metabolism of xenobiotics is very 
important since the enzymes concerned with the metabolism of 
xenobiotics undergo developmental changes, particularly in the 
early life of the animal. This will be discussed in more- 
detail in a later section.
The metabolism of a xenobiotic depends on the enzyme make-up 
within the tissues and variations in the enzymic complement 
between species is the main reason for many observed species 
variations in the overall metabolism of foreign compounds. In
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some cases these differences are quantitative, in others 
qualitative, depending on whether different amounts of the same 
metabolite are produced in different species or whether a 
metabolite is peculiar to a limited number of species only. 
Furthermore the enzyme activity can also be affected by other 
factors including the presence or absence of a specific enzyme 
inhibitor, the activity of any enzyme competing for the same 
substrate and the activity of any enzyme reversing the biotrans­
formation reaction. In most cases the pattern of urinary 
metabolites is governed by the relative extent of the enzymic 
reactions responsible for converting the xenobiotic into these 
metabolites. Many of the overall reactions involve several 
steps requiring more than one enzyme and hence species differ­
ences may be due to the number of enzymes that catalyse the 
metabolism of a xenobiotic, their activity and their relative 
amounts.
Two examples where species differences occur in normal body 
processes as a direct result of the absence of enzyme activity 
are the synthesis of L-ascorbic acid and the production of 
allantoin as the end product of purine metabolism. The absence 
of the enzyme L-gulonolactone oxidase in man, monkeys and in 
evolutionary distant animals such as the guinea pig, the Indian 
fruit bat and the red-vented bulbul explains the inability of 
these animals to synthesise L-ascorbic acid. Similarly man, 
monkeys, birds and reptiles excrete uric acid as the end product 
of purine metabolism since they lack the enzyme uricase necessary 
for the conversion of uric acid to allantoin (Truszkowski and 
Goldmanowna, 1933), the excretory product in other animal 
species (see Williams, 1974).
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Species variations in the metabolism of xenobiotics
When discussing examples of species variations in the 
metabolism of xenobiotics it is difficult to deal with Phase I 
and Phase II reactions as separate sections since many molecules 
undergo metabolism by both types of reaction, either at the same 
centre or at different centres within the molecule. However 
some examples of species variations in the metabolism of 
xenobiotics which are known to be essentially metabolised by 
either Phase I or Phase II reactions only are given below.
Species differences in Phase I reactions
Species variations in the oxidative, reductive and 
hydrolytic reactions of xenobiotic metabolism are widespread and 
often unpredictable. Prom all the data so far accumulated 
concerning species differences in these reactions, it is still 
not possible to discern any well-defined pattern. All that can 
be tentatively concluded is that two structurally related 
compounds that are metabolised by similar Phase I reactions are 
likely to have a similar metabolic fate within one particular 
species. Any such similarity is much more likely to be 
qualitative rather than quantitative. It appears that any one 
compound undergoing Phase I metabolism is likely to show 
quantitative and/or qualitative differences in its metabolic fate 
in two different species of test animal. In many cases such 
species differences in Phase I metabolic processes can be shown 
by in vitro as well as by in vivo studies.
Metabolism of amphetamine and related compounds
Amphetamine (1-amino-2-phenylpropane) is metabolised 
essentially by a combination of aromatic hydroxylation via an
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epoxide intermediate and oxidative deamination to benzyl methyl 
ketone which, in the majority of animal species studied, under­
goes further side chain oxidation to benzoic acid which is then 
further metabolised by Phase II reactions to hippuric acid and 
benzoylglucuronide (Dring et al., 1970; Caldwell et al., 1972) 
(Fig 1.2). In the rabbit however large quantities of an acid- 
labile conjugate of the enolic form of benzyl methyl ketone are 
excreted together with appreciable amounts of conjugated phenyl- 
propan-2-ol (Dring et al., 1970).
The aromatic hydroxylation reaction is specific for the 
para position producing 4-hydroxyamphetamine which may be 
excreted in the urine conjugated with either glucuronic acid or 
sulphate. The extent to which aromatic hydroxylation and 
oxidative deamination occur can be determined by the measurement 
of 4-hydroxyamphetamine in the urine together with the amount of 
deaminated metabolites. In both cases any conjugates must also 
be taken into account. The relative importance of aromatic 
hydroxylation and oxidative deamination of amphetamine varies 
with species as shown in Table 1.5. which
It is evident that aromatic hydroxylation^is the major route 
of amphetamine metabolism in the rat, is a minor route in the 
rabbit and in primates including man, and is absent from the 
guinea pig. In those animals in which aromatic hydroxylation 
is a minor metabolic route, oxidative deamination is the pre­
dominant route of amphetamine metabolism, except in the case of 
the marmoset. In both man and the marmoset, and to a lesser 
extent in the rhesus monkey, the major excretory product of 
amphetamine is the unchanged drug. Therefore the metabolic 
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Rhesus monkey 11 33
Data taken from Williams et al., (1973) and adapted from 
Smith and Caldwell (1977). In all cases the dose unaccounted
for was excreted unchanged.
Table 1.5 The metabolic fate of amphetamine in various species
Table 1.6 summarises data for the metabolism of other 
members of the amphetamine series in man, rat, rabbit and guinea 
pig. The basic formula used for the identification of the 
different compounds listed in the table is,
R' NHR
It can be seen that in the rat ring hydroxylation is the 
major metabolic reaction for all the compounds listed and that 
oxidative deamination is the major reaction in the guinea pig 
and rabbit. In man however, the relative importance of the 
two reactions varies but it appears that the presence of an 
ct-hydroxyl group excludes any further hydroxylation of the 
molecule.
Table 1.7 shows the metabolic fate of norephedrine (II),
Percentage of the dose which is excreted as hydroxylated 













(r 1=r 2=r 5=h ) 2 24 60 3 6 54 0 62
Me thamphetermine 
(r 1=r 2=H,R3=OH3) 18 6 53 4 — - 0 74
Norephedrine
(r 1=o h ,r 2=r 3=h ) 0 3 28 1 3 76 - -
Ephedrine
(r 1=o h ,r 2=h ,r 5c h5) 0 10 14 3 11 91 1 ■ -
Pondinil
(R1=r 2=h ,r 5=c i (c h2)2 ) 37 58 - 6 - 15 -
Mephentermine
(r 1=h ,r 2=r 3=c h 3) _ — 32 — 5 - — -
- data not available
Data from Williams et al. (1973) adapted as in Williams (1974)-
Table 1 . 6  Metabolism of amphetamine and some amphetamine derivatives in various species.
Compound metabolite guinea nig man marmoset rat rhesus monkey
Norephedrine unchanged - 79 70 44 —
ring hydroxylated — 1 1 25 -deaminated conjugates
“
2 2.5 2
Phenmetrazine unchanged 6 19 31 9ring hydroxylated 0 2 2 13 44 -Lactam derivative 50 2 0 11 6 —
Chlorphent ermine unchanged 27 2 2 2 2 24 2 0
hydroxylamine 25 15 0 0 63
Conjugate 0 0 30 7 0
Figures represent the percentage of the dose excreted in each form 
- data not available
Data adapted from Smith and Caldwell (1977) using reports of Williams et al. (1973)» Caldwell 
et al. (1975a, 1977)- '
Table 1 .7 Metabolic fate of norephedrine, phenmetrazine and chlorphentermine
in various species
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phenmetrazine (III) and chlorphentermine (IV) in man, rat, 
guinea pig and two species of primate.
Ill
Norephedrine is metabolised by the same pathways as 
amphetamine (Williams et al., 1973)» and the data show that as 
with amphetamine its metabolic fate in the marmoset and man are 
similar. Aromatic hydroxylation is the main reaction occurring 
in the rat, again paralleling the situation found with 
amphetamine in this species.
Phenmetrazine can undergo aromatic hydroxylation or 
oxidation at the methylene carbon <*. - to the nitrogen atom, 
giving rise to a lactam derivative namely 5-methyl-6-phenyl- 
morpholin-3-one. The metabolic fate of phenmetrazine is again 
similar in the marmoset and man, although slightly less of the 
dose is metabolised in the marmoset. In the rat, ring hydroxyl­
ation is again the predominant reaction, but no such reaction is 
seen in the guinea pig, a situation encountered with both 
amphetamine and methamphetamine (Table 1.6).
The p-chloro atom of chlorphentermine excludes ring 
hydroxylation in this position, and furthermore the lack of a
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proton in the substituted side chain excludes any oxidative 
deamination. The major metabolic route available for this 
molecule is N-oxidation followed by conjugation of the hydroxyl- 
amine derivative formed. A study of the metabolic profile of 
chlorphentermine in various species exemplifies the problem of 
species variations since the marmoset in which the metabolism of 
amphetamine and several of its derivatives resemble that in man, 
shows a defect in N-oxidation and forms no hydroxylamine 
derivative, the only metabolite excreted by man. It is interest 
ing that the rat also shows a deficiency in its ability to form 
the hydroxylamine derivative despite this species' large 
capacity to carry out aromatic hydroxylation.
Thus in comparing the metabolism of amphetamine and related 
compounds in various species it is possible to distinguish 
various trends in Phase I metabolism e.g. the high degree of 
aromatic hydroxylation in the rat; to show similarities in the 
metabolic profiles of various compounds in different species 
e.g. man and the marmoset; and to show how these similarities 
can suddenly disappear as a result of a slight alteration in the 
structure of the molecule. The whole study illustrates how 
structurally related compounds undergoing Phase I metabolism may 
be expected to have similar metabolic profiles in any one species 
but that any one compound studied in more than one species may 
give rise to wide variations in both the quantitative and 
qualitative spectrum of metabolites. The differences which 
occur are at present unpredictable and arise as a result of minor 
structural changes within the molecule.
The anticoagulant coumarin (V) is a further example of a 
compound in the Phase I metabolism of which wide and pronounced 





clusively via hydroxylation, in the aromatic ring system. four 
positions namely the 5-» 6-, 7-, and 8 - positions being known to 
undergo hydroxylation in various species. In man 90$ of a 
coumarin dose is converted to 7-hydroxycoumarin (Shilling et al., 
1 9 6 9 ) whereas in the rat the corresponding figure is only 0 .3$> 
hydroxylation of the other three positions also being equally 
low (Kaighen and Williams, 1961). The rabbit on the other hand 
converts 13$ of a coumarin dose to 7-hydroxycoumarin, the other 
three positions also being hydroxylated to some extent (Kaighen 
and Williams, 1961). Therefore coumarin and amphetamine, 
although both undergoing aromatic hydroxylation, show completely 
different trends of metabolism in the species studied. With 
amphetamine aromatic hydroxylation in the rat far surpasses that 
in the rabbit and man, but with coumarin aromatic hydroxylation 
in the 7- position of the molecule is 3 0 0 times greater in man 
than in the rat, while in the rabbit all four positions known 
to undergo aromatic hydroxylation in the coumarin molecule, do 
so to a greater extent than in the rat. Creaven et al., (1965a) 
and Greaven and Williams (1963) demonstrated that the species 
differences in the metabolism of coumarin can be shown in vitro 
since liver preparations from man, cat, guinea pig, rabbit, 
pigeon and coypu but not from rat and mouse convert coumarin to 
its 7-hydroxy derivative.
The species differences observed in the aromatic hydroxyl­
ation of drugs are probably due to different enzyme levels within
the tissues. In the case of amphetamine, the hydroxylation that
5
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occurs is specific for the 4 - position of the molecule, while 
with coumarin the 7- position of the molecule appears to he 
preferentially hydroxylated. Thus it is probable that the species 
variation seen in the hydroxylation of these compounds is due to 
differing levels of hydroxylating enzymes which catalyse 
hydroxylation reactions at particular positions in the molecules. 
The observed differences in the degree of hydroxylation of 
amphetamine and coumarin in the rat indicate that the reactions 
are catalysed by different enzyme systems.
Greaven et al. (1 9 6 5b) have shown that the extent of 2- and 
4-hydroxylation of biphenyl depends on species and age. This is 
an example of a species variation occurring as a result of the 
presence of two sites within a molecule, both known to be 
hydroxylated to a significant extent. Furthermore the enzymic 
basis of these orientated hydroxylations is probably different 
since the 4-hydroxylation of biphenyl in rats and hamsters is 
preferentially stimulated by phenobarbitone whereas the 2- 
hydroxylation is preferentially stimulated by carcinogens in 
general, including aromatic hydrocarbons such as 3-methylcholan- 
threne (Creaven and Parke, 1966). Recent work has suggested 
that phenobarbitone exerts its stimulatory effect on cytochrome 
P ^ q , whereas 5-methylcholanthrene does so by inducing cytochrome 
?448 ^:i-ssues* Parke and Rahman (1970) reported that the
increase in the 4-hydroxylation of biphenyl following the 
administration of safrole and isosafrole was true enzymic 
induction, inhibited by actinomycin D, whereas the 2-hydroxylation 
was an activation not dependent on protein synthesis. The 
increase in biphenyl 2-hydroxyla.se activity brought about by 
induction, is now thought to be a biphasic reaction, the initial 
stimulation occurring within 0 - 1 5  min of treatment with the
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inducing agent probably representing a conformational change in 
the cytochrome to cytochrome P 4 4 3 , followed later by true
enzymic induction. These observations suggest that two 
different enzyme systems are involved in the hydroxylation of 
biphenyl in the animal body, a suggestion which is further 
strengthened by the observation that the 2-hydroxylation of 
biphenyl has a pH optimum of 7.8, whereas that for the 4-hydroxyl- 
ation is 7.4 (Bridges and Burke, 1971). The relative importance 
of the two hydroxylase systems in different species is undoubt­
edly responsible for the overall species differences in the 
metabolism of biphenyl reported by Greaven et al. (1 9 6 5 b).
Trends in the Phase I metabolism of xenobiotics in different 
species.
The large degree of species variation seen in Phase I 
metabolic reactions makes it difficult to reach any general 
conclusions, but a few tentative conclusions can be drawn from 
the metabolic profiles of amphetamine and related compounds, 
coumarin and biphenyl in various species. For instance 
amphetamine and norephedrine, which are structurally very 
similar, have a similar metabolic fate within a particular 
species, possibly implicating the involvement of a common enzyme 
or enzymes in their metabolism. Thus the species differences 
seen in the metabolism of norephedrine would be expected to be 
similar to those seen with the metabolism of amphetamine. How­
ever these similarities are lost when the structure of the 
molecule is changed so that a different enzyme system is used in 
its metabolism, as seen in the case of chlorphentermine. A 
comparison of the metabolic fate of amphetamine and coumarin in 
the same species indicates that although both molecules are
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metabolised by aromatic hydroxylation, their different structures 
necessitates the use of at least two different enzymes resulting 
in totally different metabolic profiles. That such enzymes have 
vastly different activities and properties is shown by the 
detailed investigations of biphenyl 2- and 4 -hydroxylase.
Species differences in Phase II metabolism
Compared with the variety of Phase I reactions relatively 
few types of conjugation reactions are known to occur in mammals. 
Each type of Phase II conjugation reaction occurs with a limited 
number of biochemically reactive groups (see Table 1.2) and 
consequently patterns of species variations in Phase II reactions 
might be expected to be more easily discernible than with the 
more numerous types of Phase I reactions. In the field of 
comparative metabolism of xenobiotics, great interest focuses 
around the Phase II reactions since certain of these reactions 
are peculiar to a limited number of species while others are 
known to occur in all except a limited number of species. It 
is known for example that the cat has a low capacity to conjugate 
various substrates with glucuronic acid while the pig has a 
limited ability to conjugate various substrates with sulphate.
ftlucuronide formation in the cat
Despite the fact that glucuronide formation is the most 
common and versatile Phase II reaction in mammals, the cat seems 
unable to synthesise more than trace amounts of glucuronic acid 
conjugates from a range of xenobiotic substrates. Hartiala 
(1 9 5 5 )» using tissue slices from various animal species, first 
showed that cat tissues did not convert o-aminophenol to 
o-aminophenylglucuronide. These in vitro studies were later
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confirmed by the in vivo investigations carried out by Robinson 
and Williams (1958) using a range of xenobiotic substrates. The 
reason for the low capacity of the cat to conjugate various 
xenobiotic substrates with glucuronic acid was shown to be due 
to a lack of the transferase enzyme, UDP-glucuronyltransferase 
(Dutton and Greig, 1957) and not to a deficiency of the activated 
intermediate UDP-glucuronic acid nor to the occurrence of any 
natural inhibitor.
Using liver preparations from a number of species, Lathe 
and Walker (1958) confirmed the poor glucuronidation of 
o-aminophenol in the cat, but showed that the liver preparations 
from this animal could form bilirubin glucuronide normally, 
indicating that more than one form of UDP-glucuronyltransf erase 
may be present in the tissues and that the cat is probably 
deficient in at least one of these forms. Similar conclusions 
were drawn from the work of Zakim et al. (1973) and Vessey et al. 
(1973) where four forms of UDP-glucuronyltransferase were 
implicated. Since the work of Hartiala, many workers have 
confirmed the cats' low capacity for forming phenolic glucuronides 
(Yeh et al., 1971; Capel et al., 1972, 1974a; Miller et al.,
1973; Smith et al., 1973). As a result of this low capacity, 
cats are much more susceptible to the toxic effects of phenols 
than are other species (see Spector, 1956). As well as bilirubin 
glucuronide the cat is able to synthesise phenolphthalein 
glucuronide (Capel et al., 1974a)and also glucuronide conjugates 
of iopanoic acid, tyropanoic acid and bunamiodyl (McChesney,
1964). The cat can also conjugate various arylacetic acids 
with glucuronic acid but this will be discussed in more detail 
later. Other members of the Feloidea also have a limited 
capacity to form various glucuronide conjugates but this will
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also be considered in a later section.
Sulphate conjugation in the pig
The inability of the cat to form significant quantities of 
glucuronide conjugates from various phenolic compounds results 
in administered phenols being excreted mainly as sulphate esters 
in this species. In the pig, the opposite situation is seen 
since this animal is unable to form significant quantities of 
sulphate conjugates from a variety of administered phenols 
(Capel et al.. 1972; Gapel, 1973; Capel et al., 1974a) which 
consequently are excreted as glucuronic acid conjugates in the 
urine. However, as with glucuronide formation in the cat, the 
extent of sulphate conjugation in the pig varies with the 
administered phenol good examples being 1-naphthol and 2-naphthol 
(see page 38). Thus the pig, like the cat is probably deficient 
in one or more of the forms of a transferase enzyme in this case 
sulphotransferase (Spencer, 1960, and McEvoy and Carroll, 1971,have 
described various sulphotransferases and their acceptors).
Acetylation of aromatic amines and hydrazines in the dog 
Acetylation is a major route of biotransformation of 
compounds containing amino groups, and five types of such groups 
are known to be acetylated in mammals. These are the aromatic 
and aliphatic amino groups, the sulphonamide group, the hydrazine 
group and the «t-amino group of S-substituted cysteines. The 
dog and fox are unable to acetylate the aromatic amino group 
(Boyer et al., 1956; Bridges and Williams, 1963) or the 
hydrazine group (see Williams, 1967). Furthermore, Weber and 
Cohen (1967) presented evidence suggesting that the -amino 
group (i.e. the aromatic amino group) of sulphanilamide and the
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amino group of isonicotinic acid hydrazide were acetylated by a 
common N-acetyltransferase enzyme, known as arylamine N-acetyl- 
transferase, which is absent in the dog. Evidence was obtained 
earlier that the apparent inability of the dog to acetylate 
aromatic amines was due to the presence of an active deacetylase 
system (Krebs et al., 1947; Brodie and Axelrod, 1948; Smith 
and Williams, 1948b; Bray et al., 1950a). Such a deacetylase 
system was not found in the rabbit (Smith and Williams, 1948a; 
Bridges and Williams, 1963), an animal with a high capacity to 
acetylate aromatic amines (Bridges and Williams, 1963)» Evidence 
has also been obtained that dog liver contains a thermolabile, 
non-diffusable inhibitor of N-acetyltransferase (liebman and 
Anaclerio, 1962).
The formation of mercapturic acids in the guinea pig
The guinea pig, compared with the rabbit and the rat, 
excretes a small proportion of a mercapturic acid precursor as 
mercapturic acid (Bray et al., 1959a and b). It was suggested 
(Bray et al., 1959b) that since only a small proportion of 
S-substituted cysteines administered to the guinea pig was 
acetylated and excreted as mercapturic acid, that this species 
was defective in its ability to acetylate the S-substituted 
cysteines. Furthermore Bray and James(1960) showed that the 
guinea pig did not deacetylate administered mercapturic acids 
indicating that the low excretion of mercapturic acids by this 
species was not due to the presence of an abnormally high 
deacetylase activity. More recent work in this laboratory 
(unpublished) has indicated that a defect in the ability of the 
guinea pig to acetylate S-substituted cysteines may not be the 
whole explanation for this animals’ low capacity to form and
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excrete mercapturic acid conjugates, but that the mercapturic 
acid formed may to a large extent be further metabolised and 
excreted as a sulphoxide.
Examples of species differences in Phase II reactions 
The metabolism of phenol and related compounds
The metabolism of phenolic compounds proceeds mainly by 
Phase II reactions, the phenolic group being conjugated with 
either glucuronic acid or with sulphate; more rarely the 
phenolic hydroxyl groups undergo méthylation. The extent to 
which ether glucuronide and sulphate ester formation occurs is 
usually high, other reactions contributing to a minor extent 
in the overall metabolism of a phenolic compound. The relative 
proportions of glucuronide and sulphate conjugates excreted in 
the urine after the administration of a phenol is both species 
and dose level dependent (Williams, 1938; Bray et al., 1952a,b; 
Capel et al., 1972; Mehta et al., 1978).
Baumann and Preusse (1879) first reported the in vivo 
conjugation and oxidation of phenol, the metabolites of which 
are now known to be phenylglucuronide, phenyl sulphate and 
conjugated catechol and quinol. In a quantitative study of the 
metabolism of phenol, Parke and Williams (1953) showed that in 
the rabbit 50% of a O.5 3mmol/kg body weight oral dose of
sulphate; conjugated quinols accounted for up to 1 0% of the dose, 
and conjugated catechols for up to 1%. More recently a
in man and 18 other species was reported by Capel et al. (1972). 
Some of the results obtained for the mammalian species are shown 
in Table 1.8.
was excreted as phenylglucuronide and 4 5 % as phenyl-
comprehensive quantitative study of the metabolism of
Percentage of excreted dose' in 24h as
Species Dose phenyl- quinol phenyl- quinol(mmol/kg) sulphate sulphate glucuronide glucuronide
Man (3M) 1 .1x 1 0 “ 4 77 1 16 tr
Old World nrimates
Rhesus monkey (2F) 0.53 65 — 35 —Oynomolgus monkey 0.27 80 - 1 2 - (1 )
New World primates
Squirrel monkey (3F) 0.27 7 — 6 8 25Capuchin (1F) 0.27 14 - 65 21
Non-primatesCat (3F) 0.27 87 13 - —Fig (3F) 0 . 2 2 1 0 0 —Fruit bat (2F) 0.27 1 0 — 90 —Rabbit (3F) 0.27 45 9 46 —Rat (3F) 0.27 54 1 42 2
Data from Capel et al. (1972) except (l) - Smith and 'Williams (1974) 
- means not detected, F - female, M - male.
Table 1 . 8 The metabolism of U  4Cjphenol in various animal species
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The extent of glucuronic acid and sulphate conjugation of 
both phenol and quinol in those primate species studied is very- 
interesting from a taxonomic point of view. It may be seen that 
in man and the more closely related Old World monkeys, sulphate 
conjugation predominates over glucuronide formation, whereas in 
the more distantly related New World monkeys glucuronide 
formation is the main metabolic pathway. The metabolism of 
1-naphthol, administered at a dose level of 0 .0 7 mmol/kg body 
weight, in various primate species showed a similar trend (Mehta 
et al., 1978). In the rhesus and cynomolgus monkeys 1-naphthol 
was excreted mainly as its sulphate ester whereas in the tamarin 
and capuchin monkey it was excreted mainly as the glucuronic acid 
conjugate.
Williams, (1938) showed that in the rabbit the extent to 
which phenol was conjugated with sulphate decreased with 
increasing dose levels and similar dose dependent effects have 
been reported for salicylamide in man (Levy and Matsuzawa, 1967). 
George et al. (1974) found that the percentage of isoprenaline 
conjugated with sulphate by isolated loops of dog gut decreased 
dramatically if the dogs were pre-treated with salicylamide.
By feeding sulphate precursors such as L-cystine and sodium 
sulphite to rabbits, the proportion of a 2 .6 6mmol/kg body weight 
dose of phenol excreted conjugated with sulphate was increased 
from 15 to 3 0$, the glucuronide conjugation being reduced 
accordingly (Williams, 1938; Porteous and Williams, 1949; Bray 
et al.. 1 9 5 2a and b).
The marked capacity of Old World primates to form phenylsulph- 
ate is emphasised by the results obtained for the metabolism of 
phenol in the rhesus monkey (Table 1.8); although the dose 
level of administered phenol was twice that given to the other
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species studied and five thousand times that administered to 
man, the percentage of the dose excreted as the sulphate ester 
was not substantially lower than that excreted in this form by 
man and the cynomolgus monkey at the lower dose levels employed.
The inability of the cat to form significant quantities of 
glucuronide conjugates is reflected in the results for the 
metabolic fate of phenol in this animal. The data for the cat 
show that phenol, together with any quinol that may be formed 
from the administered phenol, is excreted conjugated exclusively 
with sulphate. However a detailed analysis of the results 
showed that the cat did in fact excrete trace amounts of phenyl- 
glucuronide indicating that this animal has a low capacity to 
form phenylglucuronide rather than an absolute inability to do 
so. Other members of the Feloidea have also been shown to 
have a low capacity to conjugate phenol with glucuronic acid 
(French et al., 1974; Caldwell et al., 1975b). The limited 
capacity of the sulphate conjugation mechanism together with the 
low capacity of the cat to conjugate various substrates with 
glucuronic acid may account for the increased toxicity of phenols 
in this species (Miller et al., 1973)* Capel et al. (1972) 
reported that up to 8% of the phenol administered to cats was 
excreted as an unidentified metabolite, later identified as the 
phosphate conjugate, phenyl dihydrogen phosphate (Capel et al., 
1974b).
Investigations into the fate of phenol in the pig revealed 
the relative inability of this animal to form sulphate esters 
since not more than trace amounts of phenylsulphate were excreted. 
Capel et al. (1972) using pig liver preparations showed that 
phenol was conjugated with glucuronic acid at a much faster rate 
than with sulphate, but that under the same conditions rat liver
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preparations conjugated phenol with glucuronic acid and sulphate 
with equal facility. These in vitro results agree with the 
in vivo results for the metabolism of phenol in the two species.
The excretion of a high percentage of administered phenol 
as phenylglucuronide in the fruit bat is interesting. The 
high percentages of doses of o(.-naphthylacetic acid (Dixon et al., 
1974, 1977a), diphenylacetic acid (Dixon et al., 1977c) and 
benzoic acid (Bridges et al., 1970; Idle et al., 1975), excreted 
as ester glucuronides in this species were attributed to a 
limited capacity to conjugate these compounds with an amino acid. 
Although only trace amounts of benzoic acid administered to the 
fruit bat were excreted as hippuric acid, more was excreted as 
benzoylglutamate, while phenaceturic acid was excreted in 
significant amounts as a metabolite of phenylacetic acid (Ette 
et al., 1974). Except for phenylacetic acid, glucosiduronic 
acid formation was the major pathway followed regardless of the 
type of amino acid conjugate formed. With phenol however, -where 
amino acid conjugation is not an alternative pathway, the high 
percentage of the administered dose excreted as phenylglucuronide 
by the fruit bat, coupled with the low excretion of phenyl sulphate, 
suggests that this species also has a higher capacity to conjugate 
various substrates with glucuronic acid than with sulphate.
The metabolism of (l-^(J-1-naphthol and [j3-^cJ-2-naphthol, 
administered by intraperitoneal injection, has been studied 
extensively in the cat and pig (Capel et al., 1974a). Both these 
compounds were excreted almost entirely as sulphate esters in the 
cat, not more than trace amounts of glucuronic acid conjugates 
being detected. With 2-naphthol, approximately 20$ of the 
sulphate conjugates excreted by the cat could not be accounted 
for as 2-naphthylsulphate but appeared to be an unidentified
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hydroxynaphthylsulphate ester. 2-Naphthol injected into the
pig was excreted as 2-naphthylglucuronide and 2-naphthylsulphate 
in the ratio of 15 s1 - However, when 1-naphthol was administered 
by the same route to the pig, the ratio of 1 -naphthylglucuronide 
to 1-naphthylsulphate excreted in the urine was 2:1. Since the 
24h recovery of both doses were high (84 and 81 fo respectively) 
the results suggest that the pig can form substantial amounts of 
1-naphthylsulphate but not of 2-naphthylsulphate. These results 
are evidence for the existence of more than one form of sulpho- 
transferase in mammalian tissues and indicate that in the pig 
the activity of at least one of these forms is low.
A study of the metabolism of 1-naphthol in the marsupial 
opossum, Trichosuros vulpécula (Roy, 1963) showed that the major 
metabolite excreted in the urine was 1-naphthylglucuronide, only 
traces of 1-naphthylsulphate being detected. Furthermore in 
vitro experiments showed that opossum liver synthesised 
4-nitrophenylsulphate only very slowly and no synthesis of steroid 
sulphates was detected under the same conditions used for their 
assay with liver preparations from eutherian mammals. It would 
appear that the opossum, like the pig, has a low capacity to form 
sulphate esters, but that unlike the pig it does not possess the 
sulphotransferase necessary for the formation of 1-naphthyl- 
sulphate.
There is evidence (unpublished - see Hirom et al., 1977a) 
that in the cat the low capacity to form 1-naphthylglucuronide 
is compensated for by the presence of a sulphate ester synthetase 
system, the activity of which is higher in the cat than in the 
rat which excretes approximately equal quantities of 1-naphthyl­
glucuronide and 1-naphthylsulphate (Capel et al., 1974a). The 
apparent Michaelis constant (Km) for the glucuronidation of
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1-naphthol by rat liver preparations was found to be 12piM, 
whereas the corresponding value for cat liver preparations was 
approximately 3000p.M. For sulphation, using the same substrate, 
the apparent Km values for the rat and cat were 20piM and less 
than 1jiM respectively indicating the greater affinity of cat 
liver sulphotransferase for 1-naphthol compared with that of 
the rat.
The metabolism of phenacetin (jq-ethoxyacetanilide) in 
various mammalian species resembles that of phenolic compounds, 
since the major metabolic reaction of this compound in many 
species involves oxidative de-ethylation to jq-acetamidophenol 
(paracetamol) which then undergoes Phase II conjugation to form 
£-acetamidophenylglucuronide and jq-acetamidophenylsulphate 
(Brodie and Axelrod, 1949; Smith and Williams, 1949a,b;
Jagenberg and Tocyko, 1964; Smith and Timbrell, 1974) (see 
Figure 1.3)* Deacetylation of phenacetin can also occur and 
the extent of this reaction is also species dependent.
Capel et, al. (1974a)showed that the cat excreted large 
quantities of administered |"i .J ̂ c-acetyl)-phenacetin as jo-acetamido- 
phenylsulphate with only small amounts of jq-acetamidophenyl- 
glucuronide, whereas the pig excreted large quantities of the 
same dose as jq-acetamidophenylglucuronide, but only small 
quantities as jq-acetamidophenylsulphate, results which are in 
agreement with the limited capacity of the cat and pig to form 
glucuronide and sulphate conjugates respectively. Also using 
[l-"*^c-acetyljphenacetin Smith and Timbrell, (1974) showed that 
glucuronide conjugation of p-acetamidophenol was the dominant 
pathway of metabolism in the guinea pig, ferret and rabbit, 
whereas sulphate conjugation was the main pathway in the rat.
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(1972) for the metabolism of phenol in these species shows that 
the Phase II metabolism of £-acetamidophenol and phenol in both 
the rat and guinea pig is similar but whereas phenylsulphate was 
the main metabolite of phenol in the urine of rabbits and ferrets, 
p-acetamidophenylglucuronide was the main metabolite of 
ja-acetamidophenol (administered as phenacetin) in the urine of 
these species. The main reason for this observed difference in 
metabolism was probably the different dose levels employed in 
the two studies. Capel et al. (1972) administered phenol at a 
dose level of 0.27mmol/kg body weight in all the animals except 
man, whereas the dose level of phenacetin administered by Smith 
and Timbrell (1974) was 0.70mmol/kg body weight. The data 
obtained by Smith and Timbrell showed that the administered 
phenacetin was predominantly de-ethylated to £-acetamidophenol 
and consequently the administered dose of phenacetin on a molar 
basis can be considered as an indicator as to the equivalent 
dose of jo-acet ami do phenol encountered by the Phase II enzymes.
The proportion of administered phenol excreted as a glucuronic 
acid conjugate in the rabbit has been shown to increase with 
increasing dose (see earlier) and therefore the higher dose 
level employed in the studies with phenacetin may be expected to 
cause an increase in the proportion of the dose excreted as a 
glucosiduronic acid. In man phenacetin and phenol were 
administered in the ratio 420:1 (on a mol/kg body weight basis) 
in these studies and the results showed that the metabolism of 
phenacetin proceeded mainly by glucuronidation whereas the 
administered phenol was excreted predominantly as sulphate 
conjugates. In the rat no such dose dependent characteristics 
were seen,. conjugation with sulphate being the main metabolic 
fate of both xenobiotics. However, when the dose level of
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phenacetin administered to the rat was increased to 11.17mmol/kg 
body weight, there was a change in the pattern of conjugation of 
p-acetamidophenol away from sulphate conjugation towards 
glucuronic acid conjugation (Smith and Timbrell, 1974) indicating 
that more dramatic changes in dose level are required to alter 
the conjugation patterns of certain phenols in this species.
It was also shown by Smith and Timbrell (1974) that at a higher 
dose level of phenacetin, a greater proportion of the administered 
dose was deacetylated to phenetidine thus decreasing the 
relative proportion of the dose being metabolised via £-acetamido- 
phenol.
jo-Acetamidophenol may also be metabolised to a mercapturic 
acid derivative (Jagenburg and Toczko, 1964) as shown in Fig 1.3» 
Although this is a minor pathway of metabolism it is very 
important from a toxicological point of view since at high dose 
levels of paracetamol (p-acetamidophenol) the glutathione levels 
of the liver become depleted and the postulated N-hydroxylated 
intermediate binds to tissue macromolecules resulting in hepatic 
necrosis. The susceptibility of different species to para­
cetamol induced liver necrosis depends on their capacity to 
conjugate the dose with glutathione thereby deactivating the 
active intermediate. Hence in mice the proportion of a dose of 
paracetamol that is excreted as the mercapturic acid is about 
10% when non-toxic doses of the drug are administered, this 
proportion decreasing as the dose level is increased (Jollow 
et al., 1974). On the other hand a relatively high dose of 
3 0 0mg/kg body weight administered to rats does not significantly 
decrease the hepatic glutathione levels (Davis et al., 1974) and 
the proportion of the dose that is excreted as the mercapturic 
acid derivative is only about 4^ when low doses are given and
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does not significantly change when the dose is increased (Jollow 
et al., 1974). These differences in the capacity of mice and 
rats to form the mercapturic acid derivative explains why less 
than 1 0$ of rats dosed with paracetamol at a dose level of 
1 5 0 0mg/kg body weight showed signs of liver necrosis whereas all 
mice, dosed at a level of 750mg/kg body weight, developed hepatic 
necrosis (Mitchell et al., 1973).
Although conjugation with glucuronic acid and/or sulphate 
is the main metabolic reaction undergone by many phenolic 
hydroxyl groups, a third type of reaction, O-methylation also 
occurs with some compounds. The phenols undergoing methylation 
are usually polyphenols, with at least two of the hydroxyl groups 
being vicinal. The extent of O-methylation of 4-hydroxy-3>5- 
diiodobenzoic acid to 3 ,5-hiiodo-4-methoxy benzoic acid has been 
shown to be species dependent (Wold et al., 1973)» and shows a 
remarkable taxonomic trend. Administered as the n-butyl ester 
to man, the rhesus and cynomolgus monkeys (Old World primates) 
and capuchin and squirrel monkeys (New V/orld primates), 4-hydroxy-
3 .5- diiodobenzoic acid was excreted in the urine partly as
3 .5- diiodo-4-methoxy benzoic acid and its glycine conjugate, 
whereas the rat and rabbit excreted neither the methoxy 
derivative nor its glycine conjugate, the only metabolites 
present in the urine being the unchanged acid and its glycine 
conjugate. Therefore the ability to methylate 4-hydroxy-3,5- 
diiodobenzoic acid appears, so far, to be present in man, Old 
World and New World primates and not in rats and rabbits. How­
ever, only when studies have been conducted into the metabolism 
of 4-hydroxy-3 ,5-diiodobenzoic acid in prosimian species can it 
be seen whether the ability to methylate this compound is a 
characteristic of all primates.
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Tomita et al. (1964) showed that preparations of liver and 
kidney from both rabbit and rat were able to methylate 4 -hydroxy-
3.5- diiodobenzoic acid using S-adenosylmethionine as the methyl 
donor. This observation suggests that in vivo the enzyme may 
not be accessible to the substrate or that in the rabbit and 
rat tissues there exists an active O-demethylase enzyme system, 
which is not active under the in vitro conditions used by Tomita 
et al. The observed species variations in the excretion of
3 .5- diiodo-4 -methoxybenzoic acid might therefore be reflecting 
species variations in the net balance of O-methylation and 
O-demethylation as well as some differences in membrane 
permeabilities.
Comparative metabolism of arylacetic acids
Arylacetic acids are metabolised in vivo by conjugation of 
the carboxylic acid group with either glucuronic acid, to form an 
ester glucuronide, or with an amino acid. Amino acid conjugation 
of carboxylic acid groups occurs in particular when such groups are 
present in molecules whose structure incorporates a carbocyclic or 
heterocyclic aromatic system. The particular amino acid utilised 
depends not only on the animal species in which the study is made, 
but also on the structure of the acid administered. Thus benzoic 
acid is conjugated with glycine and glucuronic acid in the 
majority of mammalian species studied (Bridges et al., 1970), 
whereas phenylacetic acid is conjugated with glycine, glutamine, 
taurine and glucuronic acid, the combination of endogenous 
compounds used depending on the species (James et, al., 1972b).
Both these acids also undergo conjugation with ornithine in some 
avian species, a metabolic process not seen in other animal 
species. The metabolism of benzoic acid in various animal
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species is described in a later chapter.
Extensive comparative studies have been carried out on the
indol-5-ylacetic acid (VII), 1-naphthylacetic acid (VIII), 
hydratropic acid (IX) and diphenylacetic acid (X) (Pig 1.4).
Great interest centres around the metabolic fate of arylacetic 
acids in mammals because of their conjugation with glutamine.
The conjugation of a xenobiotic with glutamine was first observed 
by Thierfelder and Sherwin (1915) who reported that the main 
urinary metabolite of phenylacetic acid in man was phenacetyl- 
glutamine. Sherwin (1917) was unable to detect phenacetyl- 
glutamine as a metabolite of phenylacetic acid in the rhesus 
monkey, although this metabolite was detected in the urine of 
chimpanzees (Power, 1956). These early observations suggested 
that the ability to convert phenylacetic acid to its glutamine 
conjugate was present only in anthropoid apes, a theory which 
was dispelled by the work of James et al. (1972b). These 
authors conducted a comprehensive study of the metabolism of
human primates and eleven non-primate species. Table 1.9 
contains a selection of their results.
In the primates studied, the degree of conjugation of 
phenylacetic acid with glutamine and glycine was correlated with 
the evolutionary status of the species. Thus man excreted only 
phenacetylglutamine, Old World monkeys phenacetylglutamine plus 
small quantities of phenaceturic acid, New World monkeys 
phenacetylglutamine together with significant quantities of 
phenaceturic acid, while the prosimians excreted phenaceturic 
acid only. Phenacetylglutamine was not excreted by non-primate 
species in this study but more recent studies (Idle et_ al., 1976;
metabolism of five arylacetic acids namely phenylacetic acid (71),
man, fourteen species of sub-
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X
1 .4 The structures of various srylacetic acids
Percentage of 
phenylacetic
radioactivity excreted in the 
acid or conjugated with the







Man - 93 tr 6 - -
Old World Monkeys (8 ) 5-65 22-90 1 1 - 2 6 - -
New World Monkeys (4) 4 33-79 1-19 0.4-44 - -
Prosimii (2 ) 0 , 1 0 - 87,80 1 3 , 1 0 - -
Cat 1 - 98 1 - -
Ferret 3 - 63 21 - -
Hen - - 6 - - 80
Pigeon - - 59 38 - -
Rat - - 99 1 - -
- not detected.
Figures in parentheses show the number of species studied. Where more than two species are 
studied the range of the results are shown; for two species the separate results are given. 
In all other cases the average results for a particular species are shown.
Table 1.9 The metabolism of carboxyl ^cjphenylacetic acid in various species
Data from James et al. (1972b)
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Hirom et al., 1977b) showed that traces of phenacetylglutamine 
were excreted by the ferret which had been dosed with phenyl- 
acetic acid. 4-Chlorophenacetylglutamine was also detected as 
a metabolite of 4-chlorophenylacetic acid in the cat (unpublished, 
see Hirom et al., 1977a), and ferret (Idle et al., 1978). There­
fore the conjugation of phenylacetic acid with glutamine shows a 
taxonomic variation, being a major metabolic reaction only in 
man, the anthropoid apes, Old World and New World primates.
The work of James et al. (1972b) demonstrated for the first 
time the conjugation of a xenobiotic with taurine. Phenacetyl- 
taurine was present in the urine of all the species studied apart 
from the hen and vampire bat, although the percentage of the dose 
excreted in this form was found to be variable and unpredictable. 
Significant quantities were found in the urine of some Old World 
and New World monkeys, the pigeon, the ferret and the bushbaby.
The relatively high excretion of phenacetyltaurine by the ferret 
may be a compensatory mechanism for the limited capacity of this 
species to utilise glycine for conjugation processes. Hirom 
et al. (1977b) showed that in the ferret, the proportion of 
administered phenylacetic acid excreted as phenaceturic acid 
decreased with an increase in dose level while the proportion 
excreted as phenacetyltaurine increased. By contrast, at a high 
dose level (400mg/kg body weight) the rabbit excreted the 
majority of administered phenylacetic acid as phenaceturic acid, 
no phenacetyltaurine being detected. James et al. (1972b) did 
not detect the excretion of a glucuronide conjugate by ferrets or 
rabbits which had been given phenylacetic acid at a dose level of 
80mg/kg body weight but at a higher dose (4 0 0mg/kg body weight), 
Hirom et al. (1977a,b) showed that small amounts of phenacetyl- 
glucuronide were present in the urine of both species indicating
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that the conjugation of phenylacetic acid with glucuronic acid 
may become increasingly important at higher dose levels.
The conjugation of carboxylic acids with ornithine is 
unique to certain avian species. The conversion of benzoic 
acid to ornithuric acid (N2 :N5-dibenzoylornithine) in the hen was 
discovered by Jaffe (1877) and later Totani (1910) reported a 
similar conjugation of phenylacetic acid in the same species.
The results of James et al. (1972b) showed that phenacetyl- 
ornithuric acid was the major metabolite of phenylacetic acid 
excreted by the hen, but that no such metabolite was excreted by 
the pigeon. Similar results have been obtained for the meta­
bolism of benzoic acid (Bridges et_ al., 1970) and indicate how 
the conjugation of xenobiotics with ornithine is peculiar to 
only certain species of birds.
The comparative pattern of metabolism of indol-3-yla-cetic 
acid was shown to be similar to that for phenylacetic acid 
(Patel and Crawford, 1963; Bridges et al., 1974). Conjugation 
of indol-3-ylacetic acid with glutamine was confined to man,
Old World and New World monkeys although the extent to which it 
occurred was less than that for phenylacetic acid. In general, 
the extent of glycine conjugation was less than that observed 
with phenylacetic acid in most species, with the exception of 
some New World monkeys. The lower excretion of both glutamine 
and glycine conjugates of indol-3-ylacetic acid as compared with 
phenylacetic acid was compensated by a larger proportion of the 
administered acid being excreted unchanged. The excretion of 
the taurine conjugate was again found to be variable, being high 
in some New World monkeys, the ferret and the pigeon. The 
significant quantities of indol-3 -ylacetyltaurine excreted in the 
urine of the green monkey, a species of Old World monkey, possibly
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suggests that taurine conjugation within this species is 
structurally dependent since only a small, amount of administered 
phenylacetic acid was excreted conjugated with taurine (James 
et al., 1972b).
Perhaps the most significant result from the work with 
indol-3-ylacetic acid was the excretion by man of a large 
proportion of the administered dose conjugated with glucuronic 
acid, the actual percentage varying widely between subjects.
No conjugation of indol-3-ylacetic acid with glucuronic acid was 
detected in any of the other species studied. However the dose 
level of indol-3-ylacetic acid in man was less than 1 0mg/kg body 
weight compared with 1 0 0mg/kg body weight in the other species 
studied and this difference may be responsible in part for the 
appearance of the glucuronide conjugate in the urine of man.
If this were so then it would be in direct contrast to the 
results already mentioned for the metabolism of phenylacetic acid 
in the rabbit and ferret where the glucuronide conjugate is only 
detected in the urine at high dose levels. This problem of the 
effect of dose level on the metabolism of indol-3-ylacetic acid 
can only be solved when comparable dose levels are studied in 
man and other species. Furthermore, the dose was administered 
orally to man and by intraperitoneal injection to the other 
species. It is now accepted that the gut wall has a high 
capacity to conjugate certain substrates with glucuronic acid 
and it may well be that indol-3-ylacetic acid is one such 
substrate. Therefore comparable results can only be obtained 
if the compounds under study are administered by the same route.
The metabolism of 1-naphthylacetic acid in various species 
has been investigated by Dixon et al. (1974, 1977a) whose 
results are summarised in Table 1.10.
io of dose excreted unchanged or conjugated with the agent listedglucuronic
Species unchanged glutamine glycine taurine acid
PRIMATES
Man (2M) — 7.8,3.4 88,94
Rhesus Monkey (1F,1M) 1 2 , 6 - - 3.5, 1 83,94
Oynomolgus Monkey (1F) 35 2 . 6 - 3*5 29
Squirrel Monkey (2F) 13,7.3 2 .0 ,0 .9 7.5,5.0 7.5,5.0 9«4,3. 1Gapuchin (2F) 16,4.5 0.9,3-0 2 .2 ,8 . 8 14,15 2.2,13
Marmoset MM) 5.4 1 . 6 1 . 8 9.0 49




y Gat (2F, 1M) 1 . 8 — 37 25 -
Rabbit (3F) 6 . 2 — 4.5 — 71
Rat (3F) 17 - 15 — 33
Fruit Bat (1F ,1M) 6 .6 ,2 . 0 “* 6 2 , 5 6
- not detected.
Where more than two animals were used, the average results are recorded.
M Male, F Female
Data from Dixon et al. (1977a)
Table 1.10 The c o m p a r a t iv e  m e ta b o l i s m  o f  1- N a p h t h y l a c e t i c  a c i d
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The pattern of metabolism seen with phenylacetic acid and 
indol-3-ylacetic acid was not observed in the case of 1-naphthyl- 
acetic acid, since this compound showed very little conjugation 
with glutamine in-all the species studied, the main metabolite 
in the urine being the glucuronic acid conjugate. In this 
study, all the animals were given the dose orally so no differ­
ences due to the route of administration arose. In all species, 
except the bushbaby and the cat, the glucuronide was the major 
metabolite excreted in the urine in contrast to the metabolism of 
indol-3-ylacetic acid where only man excreted the glucuronide.
Only the cat was unable to conjugate 1-naphthylacetic acid with 
glucuronic acid indicating yet again this animals low capacity 
to form glucuronides from a variety of substrates. The in­
ability of other members of the Feloidea to conjugate 1-naphthyl- 
acetic acid with glucuronic acid had previously been demonstrated 
(French et al., 1974). The extent to which 1-naphthylacetic acid 
was conjugated with taurine in the various species was again 
variable. It was again high in the ferret and also in the cat, 
where it may be compensating for the low capacity of this species 
to conjugate the dose with glucuronic acid. However the degree 
of taurine conjugation with 1-naphthylacetic acid in other 
members of the Feloidea (French et al., 1974) was low suggesting 
that taurine conjugation may not be a compensatory mechanism.
The extent to which 1-naphthylacetic acid was excreted conjugated 
with glycine varied with species but appeared to be significant 
only in Hew World monkeys, prosimians and non-primates. The 
Indian fruit bat was the only non-primate species investigated 
which did not conjugate 1-naphthylacetic acid with glycine 
indicating again this animals low capacity to conjugate certain 
carboxylic acids with glycine, glucuronidation being the major
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pathway of metabolism.
The data reported for the metabolism of 1-naphthylacetic 
acid in the rat was obtained from urinary analysis only (Dixon 
et al., 1977a) whereas a complete study of the metabolism of this 
compound in the rat should include investigations of the biliary 
excretion of the conjugates. Dixon et al. (1977a) demonstra.ted 
that at a dose level of 5mg/kg bod;y weight the urine contained, 
as the major excretory product, 1-naphthylaceturic acid (8 8$ of 
the dose excreted). It is generally recognised that for 
significant biliary excretion ( > 1 0$ of the dose) of an aromatic 
anion to occur in the rat, the molecular weight should be in the 
region of, or in excess of, 325 + 50 (Millbum et al., 1967).
The molecular weight of 1-naphthylaceturic acid (246) is below 
the threshold requirement, whereas that of 1-naphthylacetyl- 
glucuronide (3 6 1 ) is above this requirement so that this 
conjugate is likely to be excreted in rat bile in appreciable 
amounts. The values in Table 1.10 for the proportions of a 
1 0 0mg/kg body weight dose excreted as the glycine or glucuronic 
acid conjugates in the urine of the rat show that the proportion 
of the dose excreted conjugated with glycine is less than that 
conjugated with glucuronic acid, in contrast to the results 
mentioned above for a dose level of 5mg/kg body weight. Dixon 
et al. (1977a) showed that for the rat, the proportion of the 
dose excreted in the urine conjugated with glycine decreased with 
increasing dose level whereas the proportion conjugated with 
glucuronic acid increased. This relationship was not seen in 
the bile presumably because the extent of 1-naphthylaceturic acid 
excretion by this route is severely limited by its relatively low 
molecular weight.
Dixon et al. (1977b) investigated the metabolism of
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[methyl-1^CJ2-phenylpropionic acid (hydratropic acid) in man, the 
rhesus monkey, the cat, the rabbit and the rat. In all these 
species, 2-phenylpropionylglucuronide was the major metabolite 
excreted in the urine over a 24h period. The cat also excreted 
small amounts of both the glycine and taurine conjugates possibly 
indicating that although glucuronide formation from 2-phenyl- 
propionic acid occurs in the cat, it may not be as efficient as 
in the other species studied. In the rat, 20-30$ of the dose 
was excreted in the bile but the pattern of the excretory 
products was the same as that in the urine.
The metabolism of [carboxy-1 4 c]diphenylacetic acid in man, 
six. species of sub-human primates and four species of non-primates 
including the cat, was shown to proceed exclusively via glucuronic 
acid conjugation (Dixon et al., 1977c) only trace amounts of 
glycine and taurine conjugates being detected in the urine of 
some lower primates and non-primate species. As in the case of
2-phenylpropionic acid, the rat was shown to excrete significant 
amounts of both the unchanged acid and its glucuronide in the 
bile; 2-phenylpropionic acid and diphenylacetic acid are there­
fore two examples of compounds which are excreted extensively as 
glucosiduronic acids by the cat.
The data presented above for the metabolism of various 
arylacetic acids in different species demonstrates not only 
species differences in the metabolism of a particular compound, 
but also how such species differences may alter or disappear with 
the modification of the structure of the arylacetic acids 
investigated. In general it would appear for all species studied, 
that as the structure of the arylacetic acid becomes more complex 
there is a general movement away from amino acid conjugation 
towards conjugation with glucuronic acid. The point at which
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glucuronic acid conjugation takes over from amino acid 
conjugation as the major pathway of metabolism, occurs, for the 
majority of species, between indol-3-ylacetic acid and 1-naphth- 
ylacetic acid. The whole problem of the relationship between 
the type of conjugation involved in the metabolism of arylacetic 
acids and the structure and chemical properties of the acid was 
studied by Dixon et al. (1976, 1977d). The two most important 
points, offering explanations for the observed in vivo results 
to emerge from these studies were:
i) The substitution of the oC-methylene group of phenyl- 
acetic acid (as in the cases of hydratropic acid and diphenyl- 
acetic acid) results in loss of specific binding to mitochrondria, 
the sites of amino acid conjugation (Schachter and Taggart, 1954), 
and an inability to undergo glycine conjugation both in vivo and 
in vitro.
ii) 1-Naphthylacetic acid, hydratropic acid and diphenyl- 
acetic acid exhibit an extensive non-specific entrapment by 
isolated rat liver microsomes, the site of glucuronic acid 
conjugation (Dutton, 1966a).
In conclusion it can be seen that phenylacetic acid, indol-
3-ylacetic acid and 1-naphthylacetic acid show marked species 
variations in their metabolism, differences which can be related 
to the evolutionary status of the species. The species differ­
ences observed in the metabolism of the three compounds are not 
the same partly because the metabolism of the compounds is 
influenced by their detailed chemical structure. The sub­
stitution of the <A -methylene group of phenylacetic acid in 
general abolishes any qualitative species differences seen in the 
metabolism of the parent compound and its derivatives which are 
not substituted in this position.
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Species differences in the metabolism of sulphadimethoxine
Sulphadime thoxine (2,4-dimethoxy 6-sulphanilamidopyrimidine),
a member of the sulphonamide group of anti-bacterial drugs, is
metabolised in most animal species by a combination of l'T̂~
1 Aacetylation and IT -glucuronidation (Pig 1.5); IT -glucuronidation 
and sulphation also occur to a minor extent in some species, the 




Sulphadimethoxine N^-sulphate r' “glucuronide
Sulphadimethoxine F^-glucuronide
F ig  1 .5
The degree to which sulphadimethoxine is excreted in the
4 1urine as its IT -acetyl derivative or its IT -glucuronide
conjugate has been reported for numerous species including man 
(Bridges et. al., 1965, 1 9 6 6 , 1968, 1969a; Adamson et al., 1966, 
1970a; Uno et a2., 1967; French et al., 1974). Adamson £t al. 
(1 9 7 0a) studied the metabolism of sulphadimethoxine in man, eight 
species of sub-human primates and nine non-primate species. The 
main metabolite of the drug in the urine of man, rhesus monkey, 
baboon, squirrel monkey, capuchin monkey, bushbaby, slow loris
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and treeshrew was sulphadimethoxine N'-glucuronide. In the
4Africs.n green monkey, although the main metabolite was N - 
acetylsulphadimethoxine, the N^-glucuronide was also a major 
metabolite. In dog, rat, mouse, guinea pig, Indian fruit bat 
and the hen, sulphadimethoxine N'-glucuronide was a minor 
metabolite excreted in urine, whereas in the cat, ferret and 
rabbit this metabolite was not detected. However Uno et al.
(1 9 6 7 ) detected small but significant amounts of sulphadimethoxine 
N1-glucuronide in the urine of rabbits dosed with sulphadimethoxine. 
It appears therefore that sulphadimethoxine N^-glucuronide is the 
main urinary metabolite of sulphadimethoxine in primate species 
only.
All the species studied, except the dog, excreted some 
N^-acetylsulphadimethoxine which was a major metabolite in the 
green monkey, the rabbit and the guinea pig. The absence of 
any detectable quantities of N^-acetylsulphadimethoxine in the 
urine of the dog is further evidence for this animals low 
capacity to acetylate aromatic amines. Of all the non-primate 
species studied the dog excreted the highest proportion of the 
administered sulphadimethoxine as the N^-glucuronide conjugate, 
suggesting that in this species the process of N^-glucuronidation 
may be a compensatory mechanism for N^-acetylation. The absence 
of sulphadimethoxine N^-glucuronide in the urine of cats dosed 
with sulphadimethoxine indicates that this animal is unable to 
form significant quantities of N-glucuronide conjugates and that 
the low capacity of the cat to conjugate many substrates with 
glucuronic acid is not only limited to the formation of 0 -glucu- 
ronides. French et al. (1 9 7 4 ) have shown that other members of 
the Feloidea Superfamily, namely the lion, the civet and the genet 
were unable to conjugate sulphadimethoxine with glucuronic acid.
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The observation that sulphadimethoxine F -glucuronide is 
the major urinary metabolite of sulphadimethoxine in primate 
species only, can be used to verify the classification of animal 
species. Thus the treeshrew (Tupaia), an animal at the foot 
of the primate evolutionary scale as defined by Fapier and 
Napier (1967) (see Fig 1.6) is sometimes classified as a primate and 
sometimes as a non-primate. From its ability to excrete
isulphadimethoxine F -glucuronide as the main metabolite of
sulphadimethoxine the treeshrew should be classified as a primate.
That F -glucuronide formation occurs with a limited number of
sulphanilamidopyrimidines has been reported (Bridges et. al., 1966,
1969a and b; Walker and Williams, 1972), and consequently care
must be taken to ensure that the particular sulphanilamido-
■1pyrimidine under study is capable of undergoing F -glucuronidation 
before any taxonomic conclusions are drawn from the results 
obtained.
The observed urinary excretion of sulphadimethoxine
F -glucuronide by the rat is not a true indication of this
1animals ability to carry out the F -glucuronidation of sulphadi­
methoxine since the physico-chemical properties of the conjugate 
are such that in the rat considerably more of the metabolite is 
excreted in the bile than in the urine (7% and 1 % of the dose 
respectively) (Adamson et ad.., 1970a).
The excretion of sulphadimethoxine F^-glucuronide and 
N^-sulphate as minor metabolites of sulphadimethoxine has received 
relatively little attention. Bridges et al. (19 6 8 ) investigated 
the metabolism of several methoxy-6-sulphanilamidopyrimidines in
various species but the combined excretion of the F^-glucuronide 
4and F -sulphate derivatives did not exceed 11% of the dose in any
of the species studied. While Adamson et al. (1970a.) did not 
detect sulphadimethoxine F^-glucuronide in the urine of rabbits
1
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dosed with sulphadimethoxine, Uno et al. (1 9 6 7 ) reported that 1 3a> 
of a low dose of sulphadimethoxine was excreted in the urine of 
rabbits as the N^-glucuronide conjugate. The instability of 
N-glucuronide conjugates formed from primary amines and the 
observation that such conjugates can be formed spontaneously in 
the urine (Bridges et al., 1968) probably accounts for the 
variations in the above results. However, overall insufficient 
data is available for conclusions to be drawn about species 
differences in the formation of both sulphadimethoxine N^-glucu- 
ronide and sulphadimethoxine H^-sulphate.
Species differences in the formation of mercapturic acids
Only one comparative study has been carried out of species 
variations in the formation of mercapturic acids (see Smith and 
Williams, 1974). Using chlorobenzene, French et al. (un­
published) showed that man, the rhesus monkey, the squirrel 
monkey, the capuchin monkey together with a number of non-primate 
species excreted varying amounts of p-chlorophenylmercapturic 
acid. The percentage of the dose excreted in the urine by non­
human primates as the mercapturic acid was fairly constant 
between 40 and 5 0$, but that for the non-primate species varied 
widely between 21 and 65$. The figure for man was 19$ but in 
this case the dose level was considerably lower than in the 
other species studied making a true comparison with the other 
species difficult. However the excretion of significant amounts 
of p-chlorophenylmercapturic acid after a dose of chlorobenzene 
in man is interesting since previous studies (Boyland and Simms, 
1958; Wainer and lorincz, 1963) have indicated that mercapturic 
acid formation in man was low.
In conclusion it is possible to discern species patterns in
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the Phase II reactions of drug metabolism. In some cases these 
patterns show a remarkable taxonomic trend particularly amongst 
primates. These patterns observed in the conjugation reactions 
appear to be dependent, in many cases, on the dose level of the 
xenobiotic used and on its route of administration.
Neonatal development of xenobiotic metabolising enzyme systems
Growth to maturity is accompanied by changes in the 
activities of various enzyme systems, changes which are not 
nearly so apparent as the more striking morphological changes.
The developmental patterns of enzymes concerned with intermediary 
metabolism have been studied in some detail (Driscoll and Hsia, 
1958; Greengard, 1971; Walker, 1971), the levels of these 
enzymes increasing suddenly within periods of hours or days 
around the time of birth or weaning. Three main 'clusters' of 
enzymes have been described for the mammalian liver; the late 
foetal cluster, the neonatal cluster and the late suckling cluster 
(around the time of weaning), the development of these clusters 
being associated with major changes in diet or environment.
The detoxication of xenobiotics has been shown to be affected 
by enzyme developmental changes. The specific activities of 
many drug metabolising enzymes are known to be low in the foetus 
and neonate, and to undergo characteristic developmental patterns 
between birth and maturity (for reviews see Done, 1964; Hanninen, 
1 9 7 5 ), and the increased sensitivity of the foetus and neonate to 
many xenobiotics has been attributed to their low drug meta­
bolising capacities (Done, 1964) an early example being the high 
toxicity of chloramphenicol in the premature human infant (Weiss 
et_ al_., 1960). If however biotransformation is required before 
the toxic effects of a xenobiotic are manifested the low xeno-
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biotic metabolising capacity of the foetus and neonate may 
afford some protection against the potential toxicity of that 
compound.
The earliest studies of xenobiotic metabolism in the foetus 
and newborn were carried out by Jondorf et al. (1958) and Fouts 
and Adamson (1959). Jondorf et al., showed that newborn mice, 
when injected with amidopyrine, phenacetin, or hexobarbitone, 
still contained most of the dose in the unmetabolised form three 
hours after administration but that three week old mice contained 
much less of the unchanged drug after a similar period. This 
suggested that three week old mice had a greater capacity to 
metabolise these drugs than had newborn mice. These workers 
also demonstrated that liver preparations from newborn guinea 
pigs were virtually unable to carry out the N-demethylation of 
aminopyrine, the O-dealkylation of phenacetin, the side chain 
oxidation of hexobarbital or the conjugation of phenolphthalein 
with glucuronic acid. The enzyme activities required for these 
reactions appeared in the first week of life and. increased until 
the guinea pigs were about eight weeks old. Fouts and Adamson, 
(1 9 5 9 ) showed that newborn rabbits were virtually unable to 
metabolise acetanilide, aminopyrine, amphetamine, chlorpromazine, 
hexobarbital and £-nitrobenzoic acid. Since these early studies 
many laboratory animal species including the rat (Klinger et al., 
1968; Eling e_t al., 1970; Henderson, 1971; Wilson and Frohman, 
1974), rabbit (Fouts and Adamson, 1959; Rane et al., 1973;
Vainio, 1975), mouse (Pomp et al., 1969; Stalhandske et al., 1969), 
guinea pig (Jondorf et. al., 1958; Kuenzig et al., 1974), hamster 
(Nebert and G-elboin, 1969), swine (Short and Davis, 1970; Short 
et al., 1972) and ferret (Ioannides and Parke, 1975) have been 
shown to be deficient in hepatic microsomal xenobiotic oxidising
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activity during early development and to have a low capacity to 
metabolise xenobiotics until a few days after birth.
The pattern of development followed by the xenobiotic 
metabolising systems from the foetal period to maturity in 
various species has received much attention (Kato et al., 1964; 
Heinrich and Klinger, 1968; Yaffe et al., 1968; Gram et al., 
1969; Berte et al., 1970; Short and Davis, 1970; Basu et al., 
1971; Henderson, 1971; Uehleke et al., 1971; Fouts and 
Devereux, 1972; Kuenzig, 1972; Macleod et al., 1972; Short 
et al., 1972; Rane et al., 1973; Yeary _et al., 1973). This 
work, carried out using tissue preparations, suggested that 
although there were individual variations between species and 
substrates, the development of the hepatic xenobiotic metabolis­
ing enzyme systems in the animals studied were similar. The 
most rapid phase of development occurred in general between the 
first 2 0 and 40 days after birth regardless of the length of the 
gestational period, the size of the species, the degree of 
maturity at birth, or the life span of the species. Two notable 
exceptions to this general trend of development are known.
Firstly the maturation of xenobiotic oxidative systems in the 
guinea pig is very rapid occurring within a few days of birth; 
this may be attributed to the high degree of development of this 
species at birth; secondly the ability to synthesise glucuronides 
in the rat is not low at birth and may increase substantially 
within a few days.
More recent studies using less common laboratory animals 
have shown that the xenobiotic oxidation capacity of the stump- 
tail monkey during early gestation is considerable (Dvorchick 
et al., 1974). Furthermore Quattropani et al. (1975) reported 
the presence of smooth endoplasmic reticulum in the foetal liver
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of the stumptail monkey which is in agreement with its capacity 
to carry out the oxidative reactions since it has been shown 
that in adult liver, xenobiotic oxidising enzymes are associated 
with the smooth endoplasmic reticulum (Remmer and Merker, 1963; 
Oonney, 1967; Remmer, 1972). The presence of benzo-JjaJ-pyrene 
hydroxylase in the foetal tissue of the pig-tailed monkey was 
also shown (Juchau and Pedersen, 1973)*
Fouts (1973) emphasised the importance of extra-hepatic 
xenobiotic metabolism and showed that the microsomal xenobiotic 
oxidising capacity of rabbit lung increased gradually with age 
and did not exhibit the sudden burst in activity observed with 
the corresponding hepatic development. Furthermore the time 
taken to reach adult enzyme levels was considerably longer for 
the lung than for the liver. These observations suggest that 
the factors governing the development of the xenobiotic meta­
bolising enzyme systems of the lung and liver are different, or 
that the same factors have a much more pronounced effect in the 
liver.
Human foetal liver has been shown to contain cytochrome 
P ^ q and certain xenobiotic metabolising enzymes as early as the 
first half of gestation (Yaffe et ad.., 1970; Pelkonen et al., 
1971 c; Rane et al., 1973) observations which suggest that the 
human foetus may be able to metabolise certain xenobiotics and 
that the development of these enzymes in the human may be 
different from that in experimental animals. Due to the socio- 
legal difficulties encountered in obtaining foetal tissue 
throughout gestation, relatively few reports exist on the 
activities of the Phase I enzymes in the human foetus (Pelkonen 
et al., 1969, 1971a, b; Arvela e_t al., 1970; Yaffe et al.,
1970; Juchau, 1971).
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The human newborn is able to metabolise various substrates 
(O'Donaghue, 1971; Kanto et al., 1 9 7 3 ; Krauer et al., 1973; 
Sereni et al., 1973; Rane et al., 1974; Horning et al., 1975; 
Mandelli et al., 1975). However in those studies where the 
xenobiotic is transplacentally transferred after administration 
to the mother, it was not completely certain whether a particular 
metabolite was formed in the newborn rather than in the mother. 
Even so the studies strongly suggest that foetal metabolism of 
these compounds may be significant in vivo. Pouts (1973) 
suggested that the levels of the xenobiotic metabolising enzymes 
in the human foetus and newborn were due to the exposure of the 
mother to various inducers throughout pregnancy. It has been 
shown (Basu et al., 1971; Chadwick et al., 1975; Mathur et al., 
1 9 7 5 ) that the xenobiotic metabolising enzymes of young animals 
show a greater response to inducers than do their adult counter­
parts and there is evidence that the induction of these enzyme 
systems can occur in humans during the last period of gestation 
and shortly after birth (Sereni et al., 1973)*
Although the development of the enzyme systems responsible 
for the conjugation reactions have in general received less 
attention than those concerned with Phase I type metabolic 
reactions, considerable work has been carried out on the 
development of the enzyme system responsible for glucuronide 
formation. One of the reasons for this interest is that a low 
capacity to conjugate bilirubin with glucuronic acid is a possible 
cause of unconjugated hyperbilirubinaemia frequently seen in 
humans as jaundice of the newborn (Brown and Zuelzer, 1958).
Karunairatnam et al. (1 9 4 9 ) showed that liver slices from 
newborn mice had a low capacity to conjugate o-aminophenol with 
glucuronic acid, and that adult levels of conjugation were not
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attained until the end of the first postnatal month. Since 
this initial report, many detailed studies have been carried out 
in laboratory animals to confirm the impairment of glucuronide 
synthesis in the neonate. These investigations have involved 
many animal species including the chick (Dutton, 1963), guinea 
pig (Brown and Zuelzer, 1958; Jondorf et al., 1958; Dutton, 
1959, 1963; Gartner and Arias, 1963), mouse (Dutton, 1 9 5 9 , 1963 
and 1966b),pig (Short and Davis, 1970; Short et al.. 1972), 
rabbit (Hartiala and Pulkkinen, 1955; Flint et al., 1964;
Yaffe et al., 1968) and rat (Lathe and Walker, 1958; Inscoe and 
Axelrod, I960; van Leusden et .al., 1962; Stevens, 1962; Arias 
et al., 1963; Gartner and Arias, 1963; Dutton et al., 1964; 
Dutton, 1966b; Halac and Sicignano, 1969; Berte et al., 1970; 
Basu et al., 1971; Henderson, 1971; Yeary et al., 1973).
These investigations indicated that for all the animal species 
studied, with the possible exception of the rat, an impairment 
of the enzyme UDP-glucuronyltransferase (UDPGT) (EG.2.4.1.17) 
was common to the neonates. Flint et al. (1964) showed the 
presence of low hepatic levels of UDPGT in neonatal rabbits, 
hamsters and rats, and concluded that it was the low levels of 
this enzyme and not any deficiency in the hepatic content of 
UDP-glucuronic acid (UDPGA) which was responsible for the low 
level of glucuronidation in those animals. However it has been 
reported that compared to adult levels, the foetal level of 
hepatic UDPGA is low in many mammals (Dutton, 1959; Flodgaard 
and Brodersen, 1967; Flodgaard, 1968; Zhivkov et al., 1975), 
but high in embryo chick (Dutton and Ko, 1966; Fyffe and Dutton, 
1975), suggesting that the subsequent development which occurs 
much more rapidly in the hatched chick than in mammalian neonates 
is related to the supply of UDPGA (Dutton and Burchell, 1974;
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Fyffe and Dutton, 1973» 1975). Furthermore the activity of 
hepatic UDP-glucose dehydrogenase has been found to reflect the 
levels of UDPGA in the foetal tissues, being low in foetal 
mammals (Brown and Zuelzer, 1958; Fyffe and Dutton, 1975), and 
high in embryo chick (Dutton and Burchell, 1974; Fyffe and 
Dutton, 1973, 1975). Brown and Zuelzer (1958) reported that 
the activity of both UDP-glucose dehydrogenase and UDPGT was low 
in foetal guinea pig liver but increased gradually during the 
first few days of life, an observation which probably explains 
the low levels of hepatic UDPGA found in mammalian foetuses but 
the higher levels found in the corresponding neonates. Overall 
the results suggest that mammalian neonatal development of 
glucuronidation is governed by the activities of both UDP- 
glucose dehydrogenase and UDPGT around the time of birth, but 
that after a few days when the activity of UDP-glucose dehydrogen­
ase is such that the supply of UDPGA is no longer rate limiting, 
the observed development of glucuronidation is related to the 
activity of UDPGT only. Although the factors governing the 
natural perinatal development of glucuronidation and UDPGT are 
not known, Wishart and Dutton (1977) have presented evidence that 
in foetal rat tissue the precocious development of UDPGT and of 
overall glucuronidation can be brought about both in culture 
and in utero by the long-acting synthetic glucocorticoid 
dexamethasone indicating that perinatal development of glucu­
ronidation and UDPGT activity towards certain substrates may be 
brought about in vivo by glucocorticoids. More recently Dutton 
et al. (1978) have presented further evidence that fetal 
adrenocorticotrophin and 1\ j2 (OH)-corticosteroids are triggers 
for UDPGT activity towards o-aminophenol in the rat.
Although it is generally accepted that foetal and newborn
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animals of various species have a low capacity to form glucu- 
ronide conjugates from a variety of substrates, the situation 
in the rat is confused. While some reports indicate that the 
newborn rat has a relatively poor ability to synthesise 
glucuronic acid conjugates, there is an increasing body of 
evidence which suggests that the development of UDPGT in the 
rat exhibits what is termed the 'overshoot' phenomenon, whereby 
infant levels of UDPGT activity rise temporarily above adult 
levels. Such an increase is typical of an hormonal induced 
rise in enzymic activity (see Greengard, 1971) and has been shown 
to occur for UDPG-T in the rat using a variety of substrates 
(Gartner and Arias, 1963; Dutton, 1964, 1966b; Tomlinson and 
Yaffe, 1966; Halac and Sicignano, 1969» Henderson, 1971;
Sanchez and Tephly, 1974; Lucier e_t al., 1975). The peak level 
of activity attained, together with the time at which the peak 
occurs varies with substrate, strain and to some degree with 
the report.
Using rats of the Wistar strain, Henderson (1971) reported 
that the hepatic activity of £-nitrophenol UDPGT (PEP-UDPGT) was 
low at birth, but that one week post partum the activity had 
risen to three times the adult level. On the other hand Sanchez 
and Tephley (1974) using rats of the Sprague-Dawly strain, 
reported that the activity of hepatic PNP-UDPGT was four times 
the adult level at one day of age. Whether or not these 
observed differences in the pattern of PEP-UDPGT development are 
due to the strain of rat used is not certain, since both groups 
of workers reported that the activity of hepatic UDPGT using 
morphine as the substrate was similar in one day old and adult 
rats. Similar results for the activity of morphine UDPGT in 
neonatal and adult rats have recently been reported (Yeh, 1978).
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Kupferberg and Way (1963) noted differences in the ability of 
16 and 3 2 day old rats to conjugate and excrete morphine but 
concluded-that the increased toxicity of this drug in the 16  
day old rats as compared to the 3 2 day old rats could best be 
correlated with differences in the permeability of the brain to 
morphine. Hence the developmental patterns in glucuronidation 
seem to vary with the substrate which suggests that different 
substrate-specific types of UDPGT reported by lathe and Walker 
(1958) and Yaffe et al. (1968) each have their own particular 
characteristic pattern of development.
Using jD-nitrophenol (PNP) as substrate, Dutton et al. (1964)» 
Henderson (1971) and Lucier et al. (1975) have shown that in the 
rat there occurred a peak in UDPGT activity, above adult levels, 
about 4 days post partum. Furthermore the overall patterns of 
development for this enzyme, as reported by these different 
authors, were in good agreement. A similar pattern of develop­
ment for PNP-UDPGT has also been reported for the rabbit 
(Tomlinson and Yaffe, 1966). Dutton et al. (1964) reported 
that the peak in activity of rat hepatic UDPGT using o-amino- 
phenol as substrate occurred 4 days post partum although Gartner 
and Arias (1963) claimed that Such a peak occurred one day 
post partum. Halac and Sicignano (1969) studied the development 
of hepatic UDPGT in rats using PNP and bilirubin as substrates.
A peak in activity of UDPGT towards both substrates occurred 
when the rats were about 18 days old. The pattern of develop­
ment of PNP-UDPGT reported by these authors differed from that 
outlined above in that there was a sharp drop in enzyme activity 
between 1 and 4 days post partum followed by a gradual rise to a 
peak of activity around 18 to 20 days post partum. Therefore 
while some authors report a peak in the activity of hepatic PNP-
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UDPGT in the rat at 4 days post partum, others claim that a 
trough in activity occurs at this time. No such drop in the 
activity of bilirubin UDPGT between 1 and 4 days post partum was 
observed by Halac and Sicignano (1969) who reported a gradual 
increase in the activity of this enzyme from the low level at 
birth to a peak at 18 days post partum, after which the activity 
fell off to adult levels. In some of the newborn rats studied, 
no hepatic bilirubin-UDPGT was detected within the first 10h of 
life. Grodsky et al. (1958) did not detect bilirubin-UDPGT 
activity in foetal rat tissue and found that maximal levels of 
activity were not attained until 35-40 days after birth. Wong 
(1972) demonstrated a deficiency in hepatic bilirubin-UDPGT 
activity in young rats and reported that there was a gradual 
increase in the activity of this enzyme until 50fo of the adult 
level of activity was reached within 4 weeks of birth. However 
Henderson (1971) had reported that the hepatic bilirubin-UDPGT 
activity in 4 day old rats was more than twice that seen in 60 
day old animals indicating a much more rapid rate of development 
of this enzyme system.
Similar patterns of development for bilirubin-UDPGT as those 
reported for the rat, have also been reported for the mouse 
(Krasner et al., 1973)» and the rabbit (Tomlinson and Yaffe, 1966). 
while other investigations have shown low bilirubin-UDPGT 
activity in the newborn of the guinea pig (Brown and Zuelzer,
1958; Gartner and Arias, 1969), mouse (Oatz and Yaffe, 1968) and 
rabbit (Flint et al., 1964; Yaffe et al., 1968). Low bilirubin- 
UDPGT activities have also been found in tissues taken from human 
foetuses (Dutton, 1959) and from short-lived premature infants 
(Lathe and Walker, 1958). Catz and Yaffe (1962, 1968) have 
indicated that UDPGT enzymes can be induced in mammals as for
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other microsomal drug metabolising enzymes, a phenomenon which 
has been used in the relief of hyperbilirubinaemia in infants 
by the administration of barbiturates to the expectant mother, 
to the newborn infant or to both (Crigler and Gold, 1966; Yaffe 
et al., 1966; Maurer et al., 1968; Trolle, 1968; Vest et al., 
1970). An inverse relationship between the serum bilirubin 
levels and the ability to convert acetanilide to E-acetyl p- 
aminophenyl glucuronide in full term and premature infants was 
shown by Vest (1958) an observation further implicating the role 
of glucuronidation in the prevention of hyperbilirubinaemia.
The glucuronidation of substrates other than bilirubin in 
the human neonate, has been less extensively studied than in the 
neonates of other species. Vest and Rossier (1963) using 
acetanilide and N-acetyl p-aminophenol as the administered 
compounds showed that human neonates formed ether glucuronides 
at a reduced rate. Vest and Salzberg (1965) in a study on the 
metabolism of p-aminobenzoic acid in human neonates and children 
showed that only a small amount of the dose was excreted 
conjugated with glucuronic acid by the newborn infant. Both 
reports showed that although the rate and extent of glucuronid­
ation in human newborns was low, the reaction did occur. As 
mentioned earlier, this ability may be due to the induction of 
the foetal and also the neonatal enzymes by the exposure of the 
expectant mother and/or the newborn infant to inducing agents 
present in the environment.
The glucuronidation of a few substrates has been studied in 
human foetal tissue and the results show very low or absent 
UDPGT activity with respect to PEP (Pelkonen et al., 1971a;
Rane et al., 1973), p-aminophenol (Dutton, 1959), 1-naphthol 
(Rane et al., 1973), and 4-methylumbelliferone (Hirvonen, 19 6 6 ;
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Rane et al., 1973). On the other hand conjugation with gluta­
thione is fairly well developed in the human foetal tissues 
(Chasseaud, 1974) while Irjala (1972) reported that the rates of 
formation of salicyluric acid in foetal and adult tissues were 
similar.
Apart from glucuronidation the only other conjugation 
reaction that has been studied to any appreciable extent in 
neonatal animals is the conjugation of benzoic acids with glycine 
to form hippuric acids. Bridges et al. (1970) reported that in 
adult man and many mammalian species, benzoic acid is almost 
entirely excreted as hippuric acid whereas Test (1959) reported 
that the formation of hippuric acid was less efficient in the 
human infant than in the adult. The studies of Vest and Rossier 
(1963) and Vest and Salzberg (1965) showed that human infants 
conjugated p-aminobenzoic acid only very slowly with glycine, 
the excretion of the dose being maintained by the formation of 
acetylated derivatives. This is interesting since Fichter 
and Curtis (1956) indicated that newborn and premature infants 
had a poorly developed ability to acetylate the aromatic amino 
group of sulphonamides.
The enzymes responsible for catalysing the synthesis of 
hippuric acid and p-aminohippuric acid were characterised by 
Schacter and Taggart (1953> 1954) but their activity in rat 
liver was undetectable until the age of about 6 days (Brandt, 
1964), adult levels of activity not being reached until approx­
imately 30 days after birth. The pattern of activity during 
development, of glycine N-acyltransferase (EC.2.3*1•13) has been 
shown to resemble closely the activity of the whole p-amino- 
hippurate synthesising system (Brandt, 1966) suggesting that the 
activity of this enzyme is the rate limiting factor in p-
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aminohippuric acid synthesis by neonates. The development of 
the hippuric acid synthetase system in the mouse follows a similar 
pattern to that in the rat (G-orodischer et al., 1971) and it has 
also been shown (Irjala, 1972) that liver from foetal and neonatal 
rabbits has a very limited capacity to synthesise £-arriinohippuric 
acid.
The wide variations observed in the developmental patterns 
of the enzyme systems responsible for both Phase I and Phase II 
reactions of xenobiotic metabolism makes it difficult to state 
any well-defined outlines for this development, but in general 
it appears that in the majority of mammalian species, the 
activities of the drug metabolising enzymes are low in foetal 
and newborn animals and rise to adult levels within a few weeks 
of birth. However, the neonatal rat appears to have a large 
capacity to form glucuronides from certain aglycones, and in 
general the human foetus and neonate appear to have higher levels 
of drug metabolising enzyme systems than have the other species 
studied.
Animal species used in the study of xenobiotic metabolism
The vast number of existing animal species are divided into 
17 phyla of which only two, namely the Arthropoda whose members 
include insects and spiders, and the Chordata which includes 
fish, amphibia, birds, reptiles and mammals, have been used to 
any significant extent in the study of xenobiotic metabolism.
It is however significant that these two phyla contain animal 
species that are of interest to man from both an agricultural and 
a medical point of view (Williams, 1967). An idea of the number 
of extant animal species can be gained by considering that one 
class of the Chordata alone, the mammalia, contains over 4200
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species including 1729 species of rodent and over 200 species of 
primates (see Williams, 1974), and that there are about twice 
as many species of bird as mammals and approximately 23,000 
species of fish. Furthermore over 90$ of all animals are 
invertebrates, 75$ of them insects. The most common animals 
used in studying xenobiotic metabolism are rats, rabbits, guinea 
pigs, cats, dogs, and occasionally monkeys, although the type of 
xenobiotic under study may necessitate the use of other species, 
such as insects in the development of insecticides. In the 
development of selective weedkillers, xenobiotic metabolism in 
different plant species becomes important and the possible toxic 
effects of herbicides in man and animals must also be investigated.
The use of non-human primates in the study of xenobiotic metabolism 
It is likely that the best animal model for studying drug 
metabolism in man would be found among those species most closely 
related to man. For this reason the fate of foreign compounds 
in non-human primates has been investigated. The 200 known 
species of primates are divided into the sub-orders Anthropoidea 
and Prosimii, each of which is further sub-divided into six 
families. The Anthropoidea include man, the Greater and Lesser 
apes such as the chimpanzee and gorilla, the Old World monkeys 
for example the rhesus monkey and the baboon, and lastly the 
New World monkeys which include tamarins and marmosets. The 
Prosimii include the Tarsiers, Lorises, Lemurs and Treeshrews. 
Napier and Napier (1967) suggested the primate species could be 
organised into a series according to their increasing complexity 
of structural and behavioural organisation (Fig 1.6), Table 1.11 
shows a simplified classification of the primate species and 
indicates those species which have been used in the study of
Man
Fip; 1 .6 Successive grades of primate organisation (From Napier and Napier, 1967).
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Tnble 1.11 Classification of primates used in drug metabolism research (Taken from Napier and Napier
1967; Smith and Caldwell,
1977)
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xenobiotic metabolism. Of the 159 species of anthropoid primates 
only 12, including man, have been used in this way and only 3 
species of the 55 species of Prosimii have been used in such 
studies. It is important to note however, that primate species 
other than these 15 species may have been used in isolated 
studies of xenobiotic metabolism. It is obvious from Table 1.11 
that little is known of the metabolic capabilities of the majority 
of the non-human primate species, and that much work needs to be 
carried out particularly with the anthropoid ape species, the 
New World monkeys and the prosimian species.
The extrapolation of metabolic data obtained using laboratory 
animals to man, would be much easier and could be carried out 
with much more confidence if the animal species used was known 
in general to be a good metabolic model for man. That this 
species is more likely to be a primate than a non-primate species 
was indicated by Smith and Caldwell (1977) who gathered data 
from numerous reports, for the metabolic fate of 23 compounds in 
the rat, a second non-primate species (this varied with the 
report) and the rhesus monkey, and compared the results with those 
for man. With 17 of the 23 compounds, the rhesus monkey provided 
the best metabolic model for man, the rat being a good model for 
4 of the compounds and the other non-primate species for 5 
compounds. In general the rhesus monkey is the primate species 
of choice for metabolic studies but it has many drawbacks as an 
experimental laboratory animal. It is large, relatively 
expensive to purchase and keep and does not breed very well in 
captivity. Furthermore those animals that are bred in captivity 
do hot reach sexual maturity until about 4 years of age so 
although the rhesus monkey may be a useful species for the study 
of infantile metabolism, it is not a practical species for
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establishing self-sustaining colonies on the scale used in the 
average laboratory. This means that the regular purchase of 
large numbers of these animals for medical research is necessary. 
However the main source of supply for the rhesus monkey is the 
Indian sub-continent which from April 1978, has effectively 
stopped the export of these animals for scientific research 
(Wade, 1978). There exists as a result, a demand amongst those 
companies which develop and market products for human use, as 
well as amongst research institutions, for a new laboratory species 
of non-human primate which can overcome the present problems 
outlined above. A strong candidate to fill this position is the 
New World monkey Qallithrix jacchus, the common marmoset, which 
has already been shown to be an excellent animal model for 
teratogenic studies in man (Poswillo et al., 1972). However the 
xenobiotic metabolising capabilities of this animal have received 
relatively little attention.
The aim of the work presented in this thesis was to obtain 
detailed information about the fate of foreign compounds in the 
marmoset in order to compare the extent to which the known 
pathways of drug metabolism occurred with the extent to which 




Chapter 2 - Materials and Methods
Materials
The materials used in each study are described at the 
beginning of the relevant results chapter.
Animals
The rats used were of the Birmingham Vistar strain. Adult 
rats (250-300g) were fed on Heygates Oxoid pasteurised or 
modified cube diet with water ad libitum and maintained in 
conditions of constant temperature and light cycle. For 
neonatal studies litters were bred from previously unmated 
females. In vivo studies in the adult were carried out on 
female rats whereas males and females were used in the neonatal 
studies and for in vitro experiments.
The rabbits used were does of the Few Zealand white strain. 
They were fed on modified Oxoid diet 18 (Styles Ltd., Bewdley) 
with water ad libitum and maintained in conditions of constant 
temperature and light cycle.
Common 'cotton-eared* marmosets, Callithrix .is.cchus were 
used. The animals were members of the Birmingham colony which 
was founded by one breeding pair in 1973* Since that date two 
feral animals have been imported (Shamrock Farms G-.B. Ltd) and 
introduced into the colony in order to strengthen the genetic 
strain (see Fig 2.1). In their early attempts to set up 
marmoset colonies, Fitzgerald (1935) and Lucas et al. (1927,
1937) encountered many difficulties which are only to be 
expected with a new species of tropical primate. The animals 
were found to be susceptible to respiratory infections, parasites 
and dietary deficiencies. Eventually some of these problems
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Fig 2.1 The family structure of the Birmingham marmoset colon
Key: Numbers are code numbers of each individual
K - male F - female U - sex undetermined
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were solved; maintenance of the humidity above 60$ was found 
to reduce the risk of infection in the upper respiratory tract, 
while the omission of meal worms, a popular source of animal 
protein, from the diet reduced the risk of the marmosets being 
infected -with Prosthenorchus elegans, a dangerous parasite to 
which marmosets are hosts (Kingston, 1969). The Birmingham 
animals were housed under conditions of constant temperature 
(75°P) and light cycle. The humidity within the colony was 
kept above 65$.
Marmosets are omnivorous animals eating fruit, insects, 
eggs, small tree-dwelling lizards and the young of arboreal 
rodents, and consequently a well balanced diet in captivity is 
essential. Many such diets have been reported (levy and 
Artecona, 1964; Stellar, 1960; Kingston, 1969) all of which 
stressed the necessity to supplement the dietary intake with 
vitamins. A more exotic and expensive diet has been reported 
for those wishing to keep marmosets as pets (Fitzgerald, 1935).
The marmosets used in this study were maintained on Coopers 
Mazuri (vitamin fortified) Primate diet (B.P. Nutrition,
U.K., Ltd) together with liver-containing cat meat (Whiskas).
This diet was given to the animals in the morning together with 
diluted full-cream condensed milk (Nestle Co. Ltd). In late 
afternoon the animals were given diced fresh fruit consisting of 
orange, banana, apple and grapes. This fruit was sprinkled with 
a vitamin-mineral supplement, SA 37 (Intervet Lab. Ltd., Cambridge). 
They were allowed water ad libitum. Animals of both sexes were 
used in all experiments; a rota system was applied so that no 
animal was used too frequently in a given period of time.
Neonatal animals were used when available from the three regular 
breeding pairs within the colony.
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Dosing and collection of urine
Rats were dosed via a stomach tube made of polythene or 
transparent non-toxic vinyl. The external diameter of the tube 
was 5.Omm for the adult and 0.8mm for the neonatal animals.
The form of the dose administered, together with the dosing 
vehicle, was the same as that for the marmoset, including 
Cytacon (Glaxo Lab. Ltd), a vitamin ^containing blackcurrant 
syrup, where necessary (see below). Adult rats were housed in 
cages designed for the separate collection of urine and faeces. 
Control 24h-urine samples were collected from animals to which 
the dosing vehicle only had been administered.
Rats aged 7-11 days were kept in an incubator at 30°C after 
dosing. Rats in this age group do not urinate without 
stimulation and so the urine was collected at two hourly 
intervals by exerting a gentle pressure on the lower abdomen of 
the animal, the droplets which formed being collected with a 
Pasteur pipette. After each urine collection the rats were fed 
a solution (0.3ml) of glucose (2°/o w/v) in aqueous cows milk (40^ 
v/v).
Adult rabbits were dosed via a rubber stomach tube (external 
diameter 4.0mm), the dose form and vehicle being the same as that 
for the rat and marmoset. The animals were housed in large 
cages designed for the separate collection of urine and faeces.
Adult marmosets were dosed orally by placing the tip of a 
disposable syringe (1.0ml capacity) containing the dose firmly 
between the back teeth of the animal and slowly ejecting the 
dose to the rear of the throat. In the early work milk was 
used as the dosing vehicle but later Gytacon was found more 
suitable. Compounds were administered to the animals either as 
aqueous solutions mixed with Cytacon (0.5ml) or as suspensions
82
in diluted Cytacon. In the initial experiments the adult 
animals, after dosing, were housed in large cages which permitted 
the separate collection of urine and faeces. To avoid loss of 
urine, each cage was surrounded by a polythene sheet which was 
supported about 1" away from the cage with its lower edge within 
the metal funnel upon which the cage stood during the experiment. 
In later experiments the adult animals were housed in all-glass 
metabolism cages (R.B. Radley & Go. Ltd, Sawbridgeworth) which 
had a living chamber height of 12". Air was drawn through these 
glass cages using an electric pump (Charles Austen Pumps Ltd., 
Weybridge). A piece of steel gauze was placed inside the glass 
cages to act as a climbing frame for the animal, allowing it a 
greater freedom of movement. These glass cages allowed the 
separate collection of urine and faeces (Plate 1). The glass 
cages were designed originally for rodent use and although the 
marmosets could be fed while they were housed in them, they had 
great difficulty in obtaining water. Consequently the animals 
were removed from the glass cages at intervals and given a drink 
of diluted Cytacon.
Dose administration and urine collection in neonatal marmosets 
The prolific breeding capabilities of the common marmoset, 
Callithrix .jacchus have been recognised for a long time (Lucas 
et al., 1927; Fitzgerald, 1935; Kingston, 1969, 1972), the 
incidence of multiple births, especially twins, being high 
(Wislocki, 1939; Kingston, 1969). The breeding pairs within 
the Birmingham colony gave birth to either triplets or twins 
approximately every 5 to 6 months. Where triplets were born 
the weaker animal usually died within, a few days due to the 
inability of the mother to feed more than two offspring. There-
The apparatus used for the separate collection 
of urine and faeces from marmosets under study.
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fore by day four post partum the mother was carrying only two 
babies and to avoid causing undue anxiety with the possibility 
of a total rejection of the young by the mother the twins were 
used on successive days so that the parents always had one baby 
to look after. Our experience in attempting to hand rear baby 
marmosets, usually the rejected triplet, showed that they died 
during the long over-night period. Consequently in order to 
avoid losing the healthy offspring, the neonatal experiments were 
carried out for a maximum period of six hours, usually between 
the times of 10am and 4pm. The baby animals were dosed in a 
similar fashion to that described above for the adult animals 
except that in all cases diluted milk was used as the dosing 
vehicle. After dosing, the baby marmosets were placed on filter 
papers supported by a wire disc in the bottom of a small glass 
desiccator. The top, which had a large hole left open to allow 
adequate air circulation, was then fitted to the desiccator 
which was lagged and kept away from draughts.
It was discovered that like baby rats, baby marmosets do 
not urinate without stimulation of some kind. Three methods of 
stimulation were found to be suitable for these animals.
(i) The exertion of gentle pressure on the lower abdomen, a 
similar procedure to that applied in the rat.
(ii) Gently touching the genitalia with the tip of a ’rounded- 
off' Pasteur pipette.
(iii) Touching the genitalia with a piece of dampened tissue 
onto which the urine was directly absorbed.
Method (iii) was by far the most successful probably 
because it mimicked the natural method of stimulation used by 
the parents. The disadvantage lay in the necessity to extract 
the urine from the tissue. Urine was collected every two hours
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after dosing. At 2 and 4h after dosing, the baby animals were 
given a drink of diluted condensed milk (0 .4ml), and after 6h 
they were returned to their parents who, in no instances, showed 
any signs of rejecting them (see Kingston, 1972).
Chromatography
Paper chromatography was carried out on Whatman 5MM paper. 
Chromatograms were developed for about 15h by the descending 
method or for about 24h by the ascending method. The choice 
of technique depended upon the compound under study. Thin 
layer chromatography was carried out on either glass plates 
coated with a layer of silica gel G (E. Merck A-G, Darmstadt,
W. Germany) 0.3mm thick or on aluminium sheets pre-coated with 
silica gel 6OF2 5 4 (E. Merck A-G) 0.2mm thick.
Solvents
The solvents listed below were used 
A - Butan-1-ol-ethanol-water-acetic acid (30:10:10:1 by vol)
B - Chloroform-cyclohexane-acetic acid (8:2:1 by vol)
C - Benzene-acetone-acetic acid (6:2:1 by vol)
D - Benzene-acetone-acetic acid (2:2:1 by vol)
E - Butan-1-ol-ethanol-aq. MEU (sp.gr. 0.88)-water (10:10:1:4 by
D vol)
F - Butan-1-ol-acetic acid-water (4:1:2 by vol)
G - Ethanol-water (4:1 v/v)
H - Propan-2-ol-water (3:1 v/v)
I - Butan-1-ol-aq. (sp.gr. 0.88)-water (10:1:1 by vol)
J - Butan-1-ol-water-benzene-acetic acid (6:6:1 :2) (prepared by 
shaking the mixture for 5 min and using the upper layer 
which separated).
K - Butan-1-ol-acetic acid-butylacetate-water (120:25:10:50 by
vol)
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L - Butan-1-ol-acetic acid-water (4:1:1 by voi)
M - Propan-2-ol-water-aq. NH^ (sp.gr. 0.88) (20:1:2 by voi)
F - Butan-1-ol-ethanol-acetic acid-water (10:10:1:4 by voi)
0 - Benzene-diethylether-acetic acid-rnethanol (120;60:18:1 by voi)
P - Butan-2-one saturated with, aqueous 2M-EEL (prepared by 
shaking the ketone with aqueous ammonia (2 :1  v/v) for 2h 
and using the upper layer which separated).
The following detecting reagents were used
1 - Faphthoresorcinol for the detection of glucuronides (Elliot
et al., 1959). Chromatograms were sprayed with a 
solution of 2$ (w/v) 1 ,3-dihydroxynaphthalene in 3 3$ (w/v) 
aqueous TCA followed by heating for 5 min at 120°C. 
Glucuronic acid conjugates show up as blue spots on a pink 
background.
II - Diazotised-p_-nitroaniline for the detection of phenols.
A mixture of 3$ (w/v) p_-nitroaniline in 8$ (w/v) HC1 (25ml) 
and 5$ (w/v) sodium nitrite (1 .5ml) was sprayed onto the 
chromatograms, followed by 2 0$ (w/v) sodium carbonate. 
Phenols show up as coloured spots on a light yellow 
background.
III - 3$ (w/v) Ferric chloride in ethanol
Phenols show up as deep coloured spots on a yellow 
background.
IV - Ferric chloride/Ferricyanide for the detection of phenols
(Barton at al., 1952). A mixture of equal volumes of 5$ 
(w/v) aqueous ferric chloride and 5$ (w/v) aqueous 
potassium ferricyanide was sprayed onto the chromatograms. 
Phenols show up as blue spots on a yellow background.
V - AmmoniQcal silver nitrate for the detection of dihydroxy-
benzoic acids (Bray et ai., 1950b). Aqueous 0.1M silver
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nitrate (25ml) was added to aqueous ammonia (sp.gr. 0 .8 8 , 
8ml) and the volume adjusted to 50ml with water. Di- 
hydroxybenzoic acids show up as coloured spots on a beige 
background.
VI - The rhodizonate reagent of Schneider and Lewbart (1956)
was used for the detection of sulphates which show up as 
yellow spots against an orange/pink background.
VII - 10$ (w/v) £-Dimethylaminobenzaldehyde in acetic anhydride
(Gaffney et al., 1954). Both papers and thin layer plates 
were sprayed with the reagent and then heated for 8 - 1 0  min 
at 120°0. Hippuric acid showed up as a bright orange 
spot on a pale yellow background.
VIII- &-Dimethylaminocinnamaldehyde for the detection of aromatic 
amines and their conjugates (Bridges et al., 1965). 
Chromatograms were sprayed with a solution of 0.2$ (w/v) 
jo-dimethylaminocinnamaldehyde in 2M HC1, diluted 1 :4 (v/v) 
before use with ethanol. Aromatic amines showed up 
immediately as pink/purple spots on a very pale pink 
background. With compounds in which the amino group was 
conjugated the colour developed slowly (e.g. 6-2 4h for 
N-acetyl conjugates).
IX - Chloroplatinic acid reagent (Toennies and Kolb, 1951).
This reagent was used as modified by Barnsley et al.,
(1964). Compounds containing divalent sulphur showed up 
as the paper dried, as white areas on a pink background. 
Sulphoxide derivatives appeared as yellow spots after 8-24h.
X - Potassium dichromate - silver nitrate reagent (Knight and
Young, 1958). This reagent was used for the detection of 
divalent sulphur-containing compounds which show up as 
cream or yellow areas on a russet coloured background.
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XI - Ninh.yd.rin reagent (Moffat and Lytle, 1959)*
This was used to detect S-substituted cysteine derivatives 
which show up as dark bluish-grey spots on a pale back­
ground .
XII - 5$ (w/v) aqueous selenium dioxide for the detection of
phenols (Mitchell and Waring, 1978). Chromatograms were 
sprayed with the solution and then heated for 1 5 - 2 0  min 
at 120°C. Phenols appeared as brown spots on a pale
background.
Gas-Liquid Chromatography
Gas-liquid chromatography was carried out using a Pye 
Series 104, dual column chromatograph with a flame ionisation 
detector (FID). The columns consisted of acid washed silanized 
Chromosorb W, 50-60 mesh, coated with 15$ (w/w) high vacuum 
silicone grease or acid washed silanized Chromosorb W, 60-80 
mesh coated with 5$ (w/w) 0V101. In both cases the carrier gas 
used was argon at a flow rate of 40ml/min. The temperature 
conditions employed with each column are described in the 
relevant results chapters.
High Pressure Liquid Chromatography
Reverse-phase high pressure liquid chromatography was 
carried out using two high pressure solvent pumps (Waters 
Associates Inc., Milford MA) controlled by a Waters Associates 
Model 660 solvent programmer. The column used was a p  Bondapak 
C^g column of dimensions 30cm x 4mm diameter (Waters Associates), 
the packing consisting of a monomolecular layer of octadecyl- 
trichlorosilane bonded to fully porous rigid beads of less than 
10 microns diameter (p Porasil). Metabolites were detected
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using a CE 212 Variable wavelength UV monitor (Cecil Instruments 
Ltd., Cambridge), connected to a Servoscribe 1S chart recorder. 
The eluting solvents used were methanol (HPLC grade, Rathburn 
Chemicals Ltd., Walkerburn) and a solution of acetic acid (1$ 
v/v) in glass distilled water, at a combined flow rate of 
2ml/min. The solvent program used is described in the relevant 
results chapter.
Mass Spectrometry
Mass spectra of standard compounds and isolated metabolites 
were determined by Dr. J.R. Majer of the Department of Chemistry, 
University of Birmingham, using an A.E.I MB9 high resolution 
instrument.
Liquid Scintillation Counting
All quantitative determinations of radioactivity were 
carried out using a Philips automatic liquid scintillation 
analyser. The results were corrected for quench by the external 
standard ratio (ESR) method. All counting was carried out at 
1 1°C for 10 min or until 10^ counts had been recorded. Aliquots 
(0.05-1.0ml) of urine, standard solutions or aqueous faecal 
extracts were made up to a volume of 1ml with water and mixed 
with a scintillation cocktail (10ml) for counting. The 
scintillation cocktail used was similar to that described by 
Patterson and Greene (1965) and consisted of a solution of 2,5- 
diphenyloxazole (PPO) (4.0g/l) and 1,4-bis-Í2-(5-phenyloxazolyl)|- 
benzene (POPOP) (0.12g/l) in toluene, which was mixed with triton 
X-100 (2:1 v/v).
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Determination of radioactivity in blood samples
Blood samples taken from the tail vein of marmosets, were 
placed in pre-weighed, stoppered scintillation vials and the 
sample weight determined. Soluene-350 tissue solubilizer 
(0.5ml) (Packard Inst. Ltd) was then added and the samples 
digested for 48h at 40°C. The contents were de-colourised by 
the addition of hydrogen peroxide (100vols). The scintillant 
was then added and the radioactivity counted as described above.
Measurement of radioactivity by combustion
The measurement of radioactivity in freeze-dried faeces was
carried out by the exhaustive combustion of an aliquot (2 0 0mg)
in a Harvey Biological Oxidiser (ION Tracer Lab. Ltd., Horsham,
1 4Surrey), for 4 min. The ^ 0 0 2  so produced was trapped in 15ml 
of a scintillation cocktail containing the following components 
per litre: toluene, 4 3 0ml; methanol, 3 0 0ml; 2-phenethylamine, 
270ml; PPO, 5g; dimethyl POPOP, 0.5g; (Peterson, 1969).
The samples were counted as described above and the results 
corrected for quenching by the channels ratio method.
The distribution of labelled metabolites on chromatograms and 
their quantification
Samples of urine or urine extracts containing radioactive 
compounds were applied to paper and/or to thin layer plates.
The chromatograms were developed in a suitable solvent and the 
distribution of labelled metabolites was determined using a 
Packard radiochromatogram scanner model 7200.
The quantification of labelled metabolites on paper 
chromatograms was carried out by cutting the paper into strips 
either v" or 1 " wide, depending on the resolution, starting
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below the origin and proceeding to the solvent front. Each 
small strip was then cut in 5 or 6 further pieces which were 
placed in the bottom of a scintillation vial; 90^ methanol (1ml) 
was then added to the vial which was stoppered and allowed to 
stand for at least 24h to allow an efficient elution of the 
radioactive components from the paper. The scintillant (10ml) 
was then added and the stoppered vials were thoroughly shaken. 
After keeping for 48h, with occasional shaking, the radioactivity 
was counted. A similar technique was employed for the 
quantification of the labelled metabolites separated by thin 
layer chromatography, except that in this case, the silica 
surface was scraped off the plate in v" or 1" sections. Where 
possible the extraction efficiencies were checked using authentic 
compounds. The distribution of radioactivity along the 
chromatograms was plotted in the form of histograms.
Autoradiography
Dried chromatograms containing labelled metabolites were 
exposed to X-ray film (Kodirex - Kodak ltd., London) for periods 
of up to 3 months prior to development with a '19B' developer 
solution.
Determination of Bilirubin-UDPG-T activity
The activity of bilirubin-UDPG-T in liver and kidney 
homogenates from rats and marmosets was estimated by the method 
of Van Roy and Heirwegh (1968).
Protein determinations
These were carried out using the method of Lowry et al.
(1951) using bovine serum albumin as the standard.
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G-lucuronide estimation
Glucosiduronic acid was measured using the modified 
carbazole reaction as described by Bitter and Ewins (1961).
Sulphate determination
The sulphate content of urine samples was measured using 
the titrimetric method of Morrison (1973).
The determination of aromatic amines
Primary aromatic amines were determined by the colorimetric 
method of Bratton and Marshall (1939) using N-(1-naphthyl)- 
ethylenediamine dihydrochloride as the coupling agent.
CHAPTER 5
The metabolism of benzoic acid
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Chapter 3 - The metabolism of benzoic acid
Introduction
Conjugation of ingested benzoic acid with glycine to form 
hippuric acid was the first detoxication mechanism discovered 
(Keller, 1842). Investigations since then have shown that in 
the majority of mammals examined, administered benzoic acid is 
excreted as hippuric acid and benzoylglucuronide; in some 
species (e.g. rats and guinea pigs) small amounts of hydroxy- 
benzoic acids are also excreted (Acheson and Gibbard, 1962).
In 1877, Jaffe discovered that the hen converted benzoic acid to 
ornithuric acid (N2 :N^-dibenzoylornithine) a conversion now known 
to occur in many species of birds and reptiles. The conjugation 
of aromatic acids with arginine and glutamine in arachnids, and 
with agmatine in the scorpion was reported by Hitchcock and 
Smith (1964, 1966). It is considered that the arginine and 
glutamine conjugates are primary metabolites and that the 
agmatine and glutamic acid conjugates are formed from these by 
further metabolism. A glutamic acid conjugate has also been 
found in the urine of Indian fruit bats which had been dosed with 
benzoic acid (Idle et al., 1975)*
In mammalian species the proportion of administered benzoic 
acid excreted conjugated with glycine or glucuronic acid varies 
not only with species but also with the dose level used and the 
age of the animal.
Species variations in the metabolic fate of benzoic acid
benzoic acid in man and 20 other species of animal. The results
Bridges et al. (1970) studied the metabolic fate of
relevant to the present study, taken from their report, are shown
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in Table 3«1 •
Dose level
Percentage of radioactive components 
excreted in urine as
Species (mg/kg Benzoic Hippuric Benzoyl- Benzoyl-
body wt.) acid acid glucuronide ornithine
Man 1 0 100 0 0
Rhesus monkey 20 0 100 0 0
Squirrel monkey 50 16 82 tr 0-fCapuchin 50 0 10 0 tr 0
Rabbit 49 0 100 0 0
200 tr 98 2 0
Rat 50 tr 99 tr 0
Mouse 56 tr 95 5 0
Cat 51 tr 10 0 0 0
Dog 51 0 82 18 0
Ferret 50 9 70 22 0
198 9 47 44 0
400 2 2 30 49 0
Chicken 50 2 2 21 3 54
Pigeon 50 15 84 1 0
Turtle* 50 10 16 2 72
Gecko 19 3 6 6 85
Indian fruit
bat** 50 1 2 , 3 0 tr 8 8 , 7 0 0
Data taken from Bridges et al. (1970)
Where three or more animals were used the results are expressed 
as averages. Where only one ( + ) or two animals (++) of a species 
were used the individual results are given. Animals of mixed 
sexes were used.
Table 5.1 Metabolites of benzoic acid in urine
of various species
This comparative study is particularly useful since in all
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but three species the dose level was standardised. Thus at a 
dose level of 50mg/kg body weight administered benzoic acid was 
excreted by rodents, the cat, the rabbit and the capuchin monkey 
almost exclusively as hippuric acid whereas in the dog and 
ferret significant quantities of benzoylglucuronide were 
excreted; small but significant quantities of this metabolite 
were also excreted by mice.
In the Indian fruit bat benzoylglucuronide was the major 
metabolite excreted accounting for not less than 70% of the 
radioactive components excreted in the urine. The data in 
Table 3*1 suggest that in this species the remainder of the 
administered dose was excreted unchanged, but Idle et al. (1975) 
later showed that apart from benzoylglucuronide the only other 
product excreted by this species was benzoylglutamate. As 
mentioned earlier, the Indian fruit bat also excretes 1-naphthyl- 
acetic acid (Dixon et al., 1 9 7 4 , 1977a) and diphenylacetic acid 
(Dixon et, al., 1977o) chiefly as their glucosiduronic acids.
With the exception of the cat, the carnivorous species 
studied excreted substantial quantities of administered benzoic 
acid as benzoylglucuronide whereas those herbivorous species 
studied excreted a similar dose almost entirely as hippuric acid. 
The results reported for the metabolic fate of benzoic acid in 
Indian cattle (Gupta, 1932), the goat (Ringer, 1911)» and sheep 
(Magnus-Levy, 1907), fit into this general pattern of metabolism. 
Williams (1959) suggested that the metabolic fate of benzoic 
acid in omnivorous species might occupy an intermediate position 
between that in herbivorous and carnivorous animals. later 
results did not fit into this simple scheme. Of those species 
listed in Table 3*1 only the primates can be classed as omnivorous, 
and of these only two have been studied at a dose level which is
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comparable to that in the other species. These two species, 
the squirrel monkey and the capuchin monkey, both require 
omnivorous diets when kept in captivity (Napier and Napier, 1967) 
and the results indicate that both excreted traces of administered 
benzoic acid as benzoylglucuronide and can hardly be described 
as occupying the intermediary position suggested. It is now 
firmly established that the effect of the diet on the metabolic 
fate of benzoic acid in various species is mediated through the 
dietary supply of glycine for hippuric acid formation.
In the chicken, in which glycine is an essential amino acid, 
the major metabolite of administered benzoic acid was ornithuric 
acid whereas hippuric acid was the main metabolite in the pigeon. 
Baldwin et al. (I960) studied the metabolic fate of benzoic acid 
in different avian species and showed that in the Galliformes 
and Anseriformes ornithuric acid, and in the Columbiformes 
hippuric acid,were the only amino acid conjugates excreted. In 
all these Orders varying quantities of the administered benzoic 
acid were excreted as benzoylglucuronide. The Passeriformes 
and Psittaciformes on the other hand excreted no amino acid 
conjugates of benzoic acid, only benzoylglucuronide. Ornithuric 
acid was also the major metabolite excreted by reptiles dosed 
with benzoic acid (Table 3*1) which, when considered with the 
avian results, suggests that the conjugation of benzoic acid 
with ornithine may be correlated with the excretion of uric acid 
as the end product of amino acid metabolism. Those reptiles 
which have the most uricotelic nitrogen metabolism (e.g. lizards 
such as the gecko) would be expected therefore to use mainly 
ornithine for detoxication but more primitive reptiles such as 
the turtle which are partly ureotelic and partly uricotelic 
would use both ornithine and glycine for amino acid conjugation
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as indicated in Table 3.1.
Effect of dose level on the metabolic fate of benzoic acid in 
different species
Bridges et al. (1970) (see Table 3*1) showed that by 
increasing the dose level of administered benzoic acid in the 
ferret, the proportion of the excreted dose conjugated with 
glucuronic acid increased while that conjugated with glycine 
decreased. Since the recoveries of the different doses were 
similar, these data suggest that the ability of the ferret to 
form hippuric acid is limited by the supply of glycine, while 
the ability to form benzoylglucuronide is under no such limita­
tions. In the rabbit no significant difference in the metabolic 
fate of benzoic acid was seen at the different dose levels 
employed. The increased importance of benzoylglucuronide 
formation at higher dose levels of administered benzoic acid 
has been shown in sheep (Magnus-levy, 1907), in the pig (Csonka, 
1924), and in man (Magnus-Levy, 1907; Dakin, 1909-10; Quick, 
1931).
Csonka (1924) showed that in the pig the proportion of a 
high dose of benzoic acid excreted as benzoylglucuronide could 
be decreased by feeding glycine or a glycine-rich protein such 
as gelatin, suggesting that the supply of glycine for hippuric 
acid synthesis was the main factor in determining the metabolic 
fate of benzoic acid in this species. Furthermore the work of 
Griffith and Lewis (1923) had shown that the simultaneous 
administration of glycine and a very large dose of sodium 
benzoate (1g/kg body weight) to the rabbit caused an increase in 
the rate of hippuric acid excretion above that seen when sodium 
benzoate was administered alone. Bray et al. (1951 a)calculated
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that the excretion of hippuric acid by rabbits which had 
received sodium benzoate, took place at a constant rate varying 
with different animals from 115-166mg/h and showed that the 
administration of glycine increased this rate. Simkin and 
White (1957a, b) showed that the administration of benzoic acid 
to the rat and rabbit caused a decrease in the concentration of 
free glycine in the blood of both species and in the liver of 
the rat (the liver of the rabbit was not studied). Quick,
(1 9 3 1 ) reported that the rate of glycine mobilisation was 
species dependent and calculated that in the dog the rate was 
3 .5 , in man, 9 , in the pig, 15 and in the rabbit 24mg/kg/h 
while Bray et al. (1951 a)reported that the formation of benzoyl- 
glucuronide in the rabbit followed the kinetics of a first-order 
reaction with a velocity constant of 0.08h . Using these
values, together with derived equations, Bray et al. (1951a) 
were able to calculate the theoretical percentage of benzoic 
acid that might be expected to be excreted as benzoylglucuronide 
in different animal species at a given dose level. These 
percentages correlated well with the experimentally determined 
values which showed that in those species where the rate of 
glycine mobilisation was highest the percentage of an administered 
dose of benzoic acid (500mg/kg body weight) excreted as benzoyl­
glucuronide was lowest.
Bray et al. (1952b)derived a mathematical model to explain 
the metabolic fate of benzoic acid at different dose levels.
They showed that in general where a dose is metabolised to two 
products only (e.g. hippuric acid and benzoylglucuronide in the 
case of benzoic acid) the proportion of that conjugate formed 
by a first-order reaction only (i.e. benzoylglucuronide), 
increases with increasing dose levels while that formed by zero-
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order reaction (i.e. hippuric acid) decreases. This only 
applies at dose levels above a critical value and not at very 
low dose levels where,for instance, glycine conjugation can 
adequately cope with the whole of the administered compound.
Therefore both the experimental and derived kinetic models 
suggest that at a given dose level of administered benzoate, 
the proportions of the dose excreted as hippuric acid and 
benzoylglucuronide by different animal species is dependent 
upon the availability of free glycine for conjugation in each 
species and that in any one species, the proportion of a 
relatively large dose of benzoic acid excreted conjugated with 
glucuronic acid increases with increasing dose level.
Effect of age on the metabolic fate of benzoic acid
Whereas many adult mammalian species conjugate benzoic acid 
almost entirely with glycine (Bridges etal., 1970), Vest 
(1959 ) reported that the human infant was less able to carry 
out this conjugation reaction. Alimova (1958) reported the 
detection of hippuric acid in the urine of both full-term and 
premature infants from the second post natal day onwards and 
that throughout the first year of life urinary hippuric acid 
gradually increased with age.
Baines (1975) studied the metabolism,in vivo;of sodium 
L1 4 c]benzoate in 5 and 10 day old rats and found that hippuric 
acid constituted a markedly lower proportion of the radioactive 
components in the urine of the young rats than in their adult 
counterparts. Furthermore two labelled unidentified metabolites, 
one of which was not detected in the urine of adult rats, were 
excreted by these young rats.
This chapter describes the investigations of the metabolic
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fate of sodium L1 4 c] benzoate in the marmoset at different dose 
levels. The metabolic profile of the compound was also 
examined in the neonatal marmoset and compared with that found 





Two ampoules of [carboxyl-*^G~]benzoic acid (100;iCi;
465}iCi/mg) were obtained from the Radiochemical Centre Ltd. The 
contents of the ampoules were diluted with unlabelled benzoic 
acid as follows!
(i) A solution of unlabelled sodium benzoate was prepared by 
adding benzoic acid (2 .00g) to water (8ml) followed by an 
equimolar quantity of NaHCO^. Aliquots of this solution were 
used to transfer the contents of one ampoule to a standard 
flask; the pH was adjusted to 7.0 and the volume to 10ml. The 
activity of this solution was 7.1)iCi/ml (0.036jiCi/mg benzoic acid) 
giving a radioactive recovery from the ampoule of 71%.
(ii) A solution of unlabelled sodium benzoate was prepared as 
described above using 50mg of benzoic acid in a final volume of 
10ml. An aliquot (3*0ml) of this solution was added to the 
second ampoule and allowed to stand overnight. After trans­
ferring the sample to another container, a further aliquot 
(1 .0ml) of the unlabelled solution was used to wash out the 
ampoule. The extracts were then combined. The final activity 
of the solution was 27°8)iCi/ml (5 *56uCi/mg benzoic acid) giving 
a radioactive recovery from the ampoule of 1 1 1 %.
Using these solutions of differing specific activity 
suitable quantities of radioactivity could be administered to 
both adult and neonatal animals at dose levels of benzoic acid 
ranging from 1 to 10 0mg/kg body weight.
Benzoyltaurine (sodium salt) was a kind gift from 
Dr. P. Millburn. The melting point of the sample supplied was
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280-285°C.
All other chemicals used in this study were freely 
available from the laboratory stores.
Methods
Administration of dose
Sodium ij benzoate was administered as an aqueous 
solution either mixed with Cytacon or milk as described in the 
general methods (p.S1 ). The dose levels reported in this 
chapter, unless otherwise specifically stated, refer to the 
amount (mg) of benzoic acid administered per kg body weight 
regardless of whether the compound was administered as the free 
acid or as its sodium salt.
Ghromat ography
Paper chromatography was carried out using the descending 
technique in solvents A, E and F while glass plates coated with 
a thin layer of silica gel G (see p.85) were developed in 
solvents A, B, C and E. Aluminium backed 6OF254 ^ayer
chromatography plates, used for the detection of benzoyltaurine 
were developed in solvent D. The chromatographic properties 
of metabolites and reference compounds as determined in these 
different systems are shown in Table 3*2. The use of either 
solvents A and B to develop glass silica gel G-coated thin layer 
plates gave a good resolution of benzoylglucuronide, hippuric 
acid and benzoic acid and these two systems were used for the 
quantitative work (see p • 91 and 106).
Identification of metabolites
a) Hippuric acid was detected on chromatograms by its
Compound
Descending paper chromatography 
in solvent
A E F
Thin layer chromatography in




Hippuric acid 0.83 0.55 0.85 0.70 0.17 0.51 0.57 0.51
Benzoic acid 0.89 0 . 5 8 0 .8 8 0.85 0.87 0.89 0 . 6 2 0.79
Benzoyltaurine ne ne ne ne ne ne ne 0.15
Urinary metabolites
+Benzoylglucuronide 0.55 0.61 0 .0 0 0.42 0 .0 0 nd 0.45 0.16
Hippuric acid 0.85 0.57 0.83 0.71 0.17 0.51 0.59 0.50
++Benzoic acid 0 . 9 2 0.59 0.89 0.85 0.87 0 .8 6 0.62 0.79
fa)v 'Glass plates coated with silica gel G 
f b )' 'Aluminium plates pre-coated with silica gel 60P2^^
+detected by reagent I and liquid scintillation counting
++detected by co-chromatography
ne - not examined nd - not detected.
Table 5.2 Chromatographic properties (Rp values) of reference compounds
and metabolites of benzoic acid
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characteristic colour reaction with detecting reagent VII. It
benzoate by its Rg, value obtained by co-chromatography using an 
authentic sample of hippuric acid.
b) Benzoylglucuronide was detected by reagent I. Where more 
than one positive spot appeared, due to the presence of normal 
urinary glucuronides, the benzoylglucuronide was identified by 
radio chromatogram scanning and the extraction of the spray 
positive areas of the chromatogram (usually thin layer) for 
liquid scintillation counting. Further identification of 
benzoylglucuronide was obtained by digesting the urine samples 
from dosed animals with P  -glucuronidase type H- 1  (Helix pomatia; 
Sigma Chemical Co.Ltd.) in an equal volume of 0.4M sodium acetate 
buffer pH 5^0 at 37°C for 24-36h. A control digest containing 
D-saccharic acid-1 ,4-lactone, a potent inhibitor of the enzyme
glucuronidase (Lewy, 1952) was incubated at the same time.
resorcinol positive spot, together with a loss of radioactivity 
in the region of the plate that gave a positive reaction with 
this reagent before digestion and a corresponding increase in 
the quantity of labelled benzoate, confirmed the identification 
of benzoylglucuronide.
c) Benzoic acid was identified by its value obtained by 
radiochromatogram scanning and liquid scintillation counting.
compound. Co-chromatography of the urine samples with sodium
was identified in the urine of animals dosed with sodium
The disappearance on P -glucuronidase treatment of the naphtho
Further evidence for the presence of
of dosed animals or in P  -glucuronidase digests was obtained by 
preparing autoradiographs of samples of urine and P -glucuronid- 




Benzoyltaurine when chromatographed on aluminium backed 
6OF254 thin layer plates in solvent D, appeared as a blue 
quenching spot on a yellow fluorescent background when the 
plates were viewed under light of wavelength 254nm. The R^ 
value in this solvent was very similar to that of benzoyl- 
glucuronide (Table 3«2) (see also Idle et al., 1975) and it was 
necessary to treat the urine with -glucuronidase to hydrolyse 
any excreted benzoylglucuronide before attempting the identifi­
cation of benzoyltaurine. After such treatment of the urine 
from dosed animals no quenching spot was observed in the area 
occupied by benzoylglucuronide in the untreated urine.
The gas-chromatographic method described by Kirkland (i960) 
for the separation of sulphonic acids as their sulphonylchloride 
derivatives was also tried for the identification of benzoyl­
taurine. The reference compounds benzene sulphonic acid, 
toluene p-sulphonic acid and benzoyltaurine were converted to 
the corresponding sulphonylchlorides and the derivatives were 
applied to the gas-liquid chromatographic column described by 
Kirkland (i960) except that a 15$ rather than a 20$ column 
coating was used; a sample of authentic toluene p-sulphonyl- 
chloride was also examined. The retention times for benzene 
sulphonylchloride, toluene p-sulphonylchloride, prepared and 
authentic samples, and benzoyltaurine sulphonylchloride were 
2 .0 , 3 *6 , 3 * 7 and 26 minutes respectively. No success however 
was achieved in extracting an authentic sample of benzoyltaurine 
which had been applied to the thin layer plate described above 
so the method was of no use for the detection of benzoyltaurine 
which might have been present in the urine only in traces as a 
metabolite of benzoic acid.
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Quantification of metabolites
For every urine sample collected from animals which had 
received sodium ij ̂ ojbenzoate three identical silica gel Gr thin 
layer chromatography plates were run in solvent A and a similar 
set in solvent 33• The radiochemical distribution on each plate 
was determined by radiochromatogram scanning. One plate from 
each set was then used to detect hippuric acid, a second to 
detect benzoylglucuronide and the third plate was used to 
quantify the metabolites as follows.
Urinary metabolites of sodium [j ̂ cjbenzoate separated by 
chromatography on glass plates coated with a thin layer of 
silica gel G and developed in either solvent A or B were 
quantified by the procedure described in the general methods 
(p.91). Those thin layer plates run in solvent A were scraped 
into 0 .5cm sections starting 1 .0cm below the origin and proceed­
ing to the solvent front (for all plates this was about 1 5 cm 
above the origin). Those thin layer plates developed in solvent 
B were scraped into 0.5cm sections starting again 1.0cm below 
the origin and proceeding up to 5cm above the origin. Above 
this point, the remainder of the plate was scraped into 1 .Ocm 
sections since only benzoate was present in this region.
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Results
The metabolic fate of sodium K ]  benzoate in the adult rat and 
marmoset
The proportions of the radioactive components in the urine 
of animals dosed with sodium K ]  benzoate as determined in 
solvents A and B were in good agreement as indicated by the 
histograms obtained in a typical experiment (Pigs 3*1 and 3«2). 
Table 3*3 is a summary of the data obtained for the distribution 
of radioactive components in the urine of adult rats and 
marmosets to which sodium [^c]benzoate had been administered at 
three different dose levels* The values shown are averages of 
the results from both chromatographic systems. When the 
benzoate was administered at a dose level of 1mg/kg body weight, 
the urine was collected for 6h after dosing since Bridges et al. 
(1970) reported that 97$ of a similar dose in man was excreted 
within 4h. This shorter collection period had the advantage 
of reducing the time in which any benzoylglucuronide might 
hydrolyse.
The results show that the rat excreted administered sodium 
D^c]benzoate almost entirely as hippuric acid even at dose 
levels of 100mg/kg body weight. The relative proportions of 
the radioactive compounds excreted were not significantly 
different over the range of dose levels employed.
The marmoset, even at the low dose level of 1mg/kg body 
weight, excreted an appreciable proportion of the dose conjugated 
with glucuronic acid, the major metabolite being hippuric acid 
with only small amounts of unchanged benzoate. At a dose level 
of 40mg/kg body weight a wide variation in the proportions of the 





















Distribution of radioactivity along a silica gel coated 
thin layer chromatography plate developed in solvent A 
of urine from a marmoset dosed v;ith sodium [ ^C]benzoate. 
(31 = benzoylglucuronide)
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Fig 3.2 Distribution of radioactivity along a silica gel coated 
thin layer chromatography plate developed in solvent B 
of urine from a marmoset dosed with sodium 
[14c] benzoate.
(BGr = benzoylglucuronide)
Dose Percentage of radioactive
Age Duration of Radioactivity recovered components in urine present as:-
(years- experiment Dose level per animal over 6 Benzoyl- Hippuric Benzoic
Species months) Sex (h) (mg/kg) (uCi) or 24h glucuronide acid acid
( % ) ...
Rat A F 6 1 1 .67 83 1 . 8 97.4 0.3
(82,84)j (1 .4-2 .0 ) (95.8-97.8) (0 .2- 1 .2 )
Aa F 24 50 1 .0 10 0 1 99 tr




(0 .0- 5 .6 )
Marmoset A M 6 1 1 .67 87 7.9 87.4 5.0
5-9 M 6 1 1.67 64 4.4 8 8 . 0 2.4
A M 24 40 0.50 87 24.5 60.0 14.5
5-9 M 24 40 0.50 45 21 . 5 37.7 3 8 .6
2 - 8 F 24 40 0 . 5 0 66 22.5 18.2 57.7
1 - 8 M 24 40 0 . 5 0 77 58.5 17.1 44.4
A M 24 10 0 1 .08 56 3 0 .8 63.4 2 . 6
3-11 M 24 10 0 1 .08 61 35.0 55.2 7.5
1 - 0 M 24 10 0 1 .08 44 2 9 . 0 65.4 5.6
1 - 6 F 24 10 0 1 .08 55 43.5 50.8 5.7
5-2 M 24 10 0 1 .08 78 47.6 8 . 2 44.2
2 - 8 F 24 10 0 1 .08 74 42.0 10.7 47.0
The results obtained for the rat are expressed as averages with ranges in parentheses. The subscript 
denotes the number of animals used.
The marmoset results are shown for individual animals.
All doses are expressed as mg benzoic acid/kg body weight.
aResults from Bridges et al. (1970).
A-adult animal, age not known; M-male; F-female.
The metabolic fate of sodium [}^cQbenzoate in adult rats and marmosetsTable 5.5
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a substantial proportion of the dose was excreted as benzoyl- 
glucuronide but the percentage excreted as hippuric acid showed 
wide variation. The radioactive component in the urine not 
accounted for as the glucuronic acid or glycine conjugate was 
unchanged benzoic acid.
At a dose level of 100mg/kg body weight a similar situation 
was observed to that at a dose level of 40mg/kg body weight.
Four of the six animals studied excreted only small amounts of 
unchanged benzoate the remainder of the dose being excreted as 
benzoylglucuronide and hippuric acid. In these animals the 
proportion of the dose excreted as benzoylglucuronide was higher 
than that at the lower dose levels. This metabolic profile 
could be referred to as the ’normal’ distribution of metabolites 
expected. Two of the six animals excreted a high percentage of 
the administered benzoate unchanged only relatively small amounts 
of hippuric acid being excreted. The proportion of the radio­
active components in the urine that could be accounted for as 
benzoylglucuronide was not significantly different from that for 
the other four animals. However, if the quantity of benzoyl­
glucuronide excreted in the urine of these six animals is related 
to the dose administered, the four ’normal' animals excreted on 
average 16.3% of the dose as benzoylglucuronide whereas in the 
other two animals this figure was 3 4 .1% indicating that benzoyl­
glucuronide formation may well be compensating in part for the 
low excretion of hippuric acid seen in these two animals.
The low excretion of hippuric acid by some of the animals 
mentioned in Table 3.3 cannot be correlated with either age or 
sex. Furthermore the animals came from two different sets of 
parents and consequently the differences were unlikely to be 
genetic. That previous dosing of these animals had resulted in
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an impairment of their glycine conjugating systems seems 
unlikely. This effect would be expected to be most prominent 
in those animals which had previously been dosed with xenobiotics 
the metabolism of which involved substantial glycine conjugation. 
The two most frequently dosed animals in this respect were two 
male animals (Birmingham Oode Nos 462 and 465) which were dosed
but at two of these dose levels (i.e. 1 and 10 0mg/kg body weight) 
these two animals excreted very little unchanged benzoate while 
at the third dose level studied they excreted less free benzoate 
than the other two animals studied.
Confirmation of the identification of the labelled metabolites 
excreted was furnished by the results contained in Table 3«4 
which show the relative proportions of the radioactive components 
in the P -glucuronidase-treated urine from both adult and 
neonatal rats and marmosets. The result for one adult marmoset, 
which excreted only small quantities of hippuric acid after it 
had been given labelled benzoate at the highest dose level used, 
support the values obtained for the relative proportions of 
labelled components in the untreated urine. Figures 3*3 and
3 . 4  show the change in the radiochemical distribution in the 
urine, as determined in solvents A and B respectively, when the 
urine used to obtain Figs 3*1 and 3.2 was digested with 
¡2 -glucuronidase. When the urine was subjected to j3 -glucuronid­
ase digestion in the presence of D-saccharic acid-1 ,4-lactone the 
radiochemical distribution was the same as that in the untreated 
urine (Figs 3»1 and 3*2).
three times with sodium
Metabolic fate of sodium




Percentage of total metabolites excreted in urine present as:-
Urine + 
BGr
Û -glucuronidas e 
HA BA
Urine or urine + //-glucuronidase + 
D-saccharic acid-1,4-lactone 
BGr HA BA
Rat Adult 10 0 0 . 1 9 1 . 2 7.8 1 .6 95.7 2.7
10 day 'a ' 10 0 3.9 73.8 2 0 . 2 +23.1 76.4 0.5
day
100 0 . 0 79.2 17.6 + 19.7 75.9 0 . 0
10 10 0 1.3 78.5 17.2 17.5 7 8 . 0 0.3
100 1 .4 6 8 .6 23.7 2 5 . 8 6 9 .0 1 . 2
Marmoset Adult 10 0 18.1 65.5 14.5 30.4 6 5 .8 3.7
10 0 9.5 10.5 70.8 3 8 . 0 9.5 43.4
Adult 1 1.4 8 8 . 1 9.9 7.2 88.7 3.8
6 day 10 0 4.4 64.1 31.1 +39-8 60.2 0 . 0
6 day 10 0 5.6 39.1 35.3 +61 .8 38.2 0 . 0
7 day 10 0 8.5 3 2 . 2 59.2 +6 8 . 2 31 .8 0 . 0
5 day 1 1 . 1 89.4 7.9 +8.3 9 0 .8 0.7
6 day 1 0 . 8 93.5 4.2 +5.4 93.1 0 . 0
^Duration of experiment 24h; Duration of experiment 6h.
-L The control results for these animals represent the metabolite distribution in untreated urine. 
HA=Hippuric acid; BA=Benzoic acid; BG=Benzoylglucuronide.
Table 3.4 Effect of /j-glucuronidase on the metabolite distribution of animals dosed with



















VI rr 7 Distribution of radioactivity on a silica yel coated 
thin layer chromatography plate developed in solvent A 
of f i -glucuronidase treated urine from a marmoset 
dosed with sodium P^c] benzoate.
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“thin layer chromatography plate developed in solvent 3 
of /^-glucuronidase treated urine iron a marmoset do.;-ed 













Percentage of radioactive 


































Marmoset 5 6 1 0.22 53 3.5 95.6 0.3
5 6 1 0.22 86 8.3 90.8 0.7
6 6 1 0.22 94 5.4 93.1 0.0
4 6 40 0.06 58 23.3 74.2 1 .0
4 6 40 0.06 38 32.1 66.8 0.0
5 6 40 0.06 33 42.4 55.8 0.8
6 6 100 0.14 10 39.8 60.2 0.0
6 6 100 0.14 40 61 .8 38.2 0.0
7 6 100 0.14 47 68.2 31 .8 0.0
The percentages of metabolites are the averages of those obtained using solvents A and B.
The results for the rats were very similar and are presented as averages, the range of the individual 
values being given in parentheses. The subscript denotes the number of animals used.
Since the neonatal marmosets used were of different ages and from different parents, the results are 
given separately for each animal.
Table 3.5 The metabolic fate of sodium [1 ̂ cjbenzoate in neonatal rats and marmosets
116
117
proportions of benzoylglucuronide, hippuric acid and unchanged 
benzoate excreted when sodium \} benzoate was administered to 
neonatal rats and marmosets at different dose levels. At all 
the dose levels examined, benzoylglucuronide constituted a 
larger proportion of the radioactive components excreted in the 
urine of 9 and 10 day old rats than it did in the urine of adult 
animals. In the neonatal rats the metabolic fate of labelled 
benzoate exhibited a dose dependent pattern not evident in the 
adults, the proportion of the dose excreted conjugated with 
glucuronic acid being much smaller at the lowest dose level than 
at the two higher dose levels examined. The proportion of the 
radioactive components in the urine present as benzoylglucuronide 
were not significantly different at the two higher dose levels 
studied. The proportion of the metabolites excreted in the 
urine at a dose level of 100mg/kg body weight in these neonatal 
animals appeared to be the same whether the urine analysed was 
collected for 6h or 24h after dosing.
The fate of sodium K ]  benzoate in the neonatal marmoset 
was clearly dose dependent and at the 100mg/kg body weight dose 
level the glucosiduronic acid was the main urinary metabolite.
At the lowest dose level studied the metabolic fate of sodium 
\} ̂ c]benzoate in the neonate was very similar to that in the 
adult marmoset.
Plates 2 and 3 are autoradiographs showing the distribution 
of labelled metabolites in the urine of a neonatal marmoset to 
which sodium 0 ^cjbenzoate had been administered at a dose level 
of 40mg/kg body weight. Plates 2 and 3 represent the results 
obtained when the urine was chromatographed on glass, silica gel 
&-coated, thin layer plates in solvents A and B respectively. 








Urine treated Urine treated with 
with /^-glucuronidase in
/^-glucuronidase presence of D-
saccharic acid-1 ,4- 
lactone
Plate 2 Autoradiograph taken from a thin layer chromatogram 
developed in solvent A of the urine from a neonatal marmoset 
which had been dosed with sodium K 1  benzoate. The effect
of —glucuronidase on the distribution is also demonstrated.





Urine Urine treated Urine treated with 
only with /3 -glucuronidase in
^-glucuronidase the presence of D-
saccharic acid-1 ,4~ 
lactone
Plate 3 Autoradiograph taken from a thin layer chromatogram, 
developed in solvent B, of the urine from a neonatal marmoset 
which had been dosed with sodium [»cl benzoate. The effect of 
-glucuronidase on the distribution is also demonstrated.
BA = Benzoic acid, HA = Hippuric acid, BGr = Benzoylglucuronide.
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content of benzoylglucuronide which enabled the effect of 
ft-glucuronidase both in the presence and absence of the inhibitor 
D-saccharic acid-1,4-lactone to be clearly demonstrated.
The effect of the dose level on the metabolic fate of sodium 
K l b e n z o a t e  in the neonate is illustrated in Plate 4 which shows 
an autoradiograph taken from a thin layer chromatography plate 
developed in solvent A to which samples of urine from neonatal 
rats and marmosets, which had been dosed with labelled benzoate 
at levels of both 1 and 40mg/kg body weight, were applied. Two 
identical thin layer plates were prepared simultaneously and the 
metabolites identified by spraying one with reagent I and the 
other with reagent VII. The increase in the proportion of the 
dose excreted conjugated with glucuronic acid at the higher dose 
level is clearly visible for both species.
As shown by the results in Table 3 .4 , -glucuronidase 
treatment of the urine collected from neonatal animals which had 
received sodium K ]  benzoate caused a substantial decrease in 
the benzoylglucuronide content of the urine and in some cases 
complete digestion was achieved, indicating that no other 
metabolite of sodium |j^0]benzoate, such as benzoyltaurine, was 
running at an value similar to that of benzoylglucuronide in 
either solvent A or B.
121
Rat Rat Marmoset Marmoset
(1mg/kg) (40mg/kg) (1mg/kg) (40mg/kg)
Plate 4 Effect of dose level on the metabolic profile of 
sodium [l^cjbenzoate in neonatal rats and marmosets as depicted 
by an autoradiograph taken from a thin layer chromatogram 
developed in solvent A.
BA = Benzoic acid, HA = Hippuric acid, BGr = Benzoylglucuronide. 
Figures in parentheses indicate the dose level in mg/kg body weight.
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Discussion
The results show that the metabolic fate of sodium 
benzoate over the range of dose levels tested is strongly dose 
dependent in the adult marmoset but not in the rat. In the 
marmoset as the dose level is increased, the excretion of 
benzoylglucuronide increases while the proportion of the radio­
active components in the urine present as hippuric acid 
decreases. The amounts of glycine used to support the synthesis 
of the quantity of hippuric acid found to be excreted in the 
urine of the adult animals at different dose levels were 
calculated and are given in Table 3.6. The experiments at the 
lower dose level were carried out over 6h while those at the 
higher dose levels were carried out for 24h which makes it 
difficult to compare the rates of glycine utilisation for the 
synthesis of hippuric acid since the majority of the recovery 
recorded for the 24-h experiments will undoubtedly have been 
attained in a much shorter time period. By using the total 
recoveries obtained for the neonatal rats (Table 3*5) which were 
dosed with sodium D^cjbenzoate at a dose level of 100mg/kg body 
weight and studied over both 6h and 24h it can be calculated that 
the observed 24h excretion probably occurred over a period of 9h. 
The rates of glycine utilisation have therefore been calculated 
assuming that the dose was largely excreted within this period.
In the adult marmoset much less glycine appears to be 
available for conjugation with benzoic acid than in similarly 
dosed rats. The highest rate of glycine utilisation observed 
in the adult marmoset is 2.4mg/kg body weight/h, obtained at the 
highest dose level, whereas that in the rat was 6.6mg/kg body 
weight/h. Even at the highest dose level employed, the rat
1 Duration of Dose level Recovery of dose Percentage of total Rate of glycine
Species Experiment (ms/kg) m metabolites as utilisation
(h) Hippuric acid (mg/kg body wt/h)
Rat 6 1 82 98,0 0.08
6 1 84 96.9 0.08average = 0.08
24 50 100 99 3.38
24 100 95 91.4 5.94
24 100 96 99.8 6.56
24 100 96 93.4 6.10
average = 6.20
Marmoset 6 1 64 87.0 0.06
6 1 87 88.2 0.08
average = 0.07
24 40 87 60.1 1.42
24 40 45 37.7 0.46
24 40 66 18.2 0.33
24 40 77 17.1 0^26
average = 0.64
24 100 56 63.4 2.42
24 100 61 55.2 2.29
24 100 43 65.4 1 .90
24 100 33 50.8 1.15
24 100 78 8.2 0.43
24 100 74 10.7 0 £ ±average = 1.46
Table 3.6 Rates of glycine utilisation for the formation of hippuric acid by adult animals
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excreted administered benzoate almost entirely as hippuric acid 
no limitation in the amount of glycine available being 
encountered at the dose levels examined. Arnstein and Neuberger 
(1 9 5 1 ) reported that the quantity of glycine immediately 
available for conjugation of small doses of benzoate in the rat 
was about 10mg/l00g body weight while Simkin and White (1957a) 
found that the capacity of the rat to provide glycine for the 
conjugation of benzoate was 56pimol/lOOg body weight which 
corresponds to 27mg/kg body weight/h,so that even at the highest 
dose .level of benzoate used in the present study, the amount of 
glycine used was well below the maximum amount available.
Simkin and White (1957a) further reported that the concentration 
of free glycine in rat liver was 1 0 .7>miol/l0 0 g body weight 
whereas the rate of hippuric acid synthesis was 5 6pmol/lOOg body 
weight which suggested that the liver must withdraw free glycine 
from the remaining viscera via the plasma for conjugation 
purposes.
In the marmoset the low rate of glycine utilisation for the 
conjugation of the administered benzoate appears to be 
compensated by the increase in glucosiduronic acid synthesis.
In those marmosets excreting very small amounts of hippuric acid, 
this compensation may not be complete.
The ability of the human liver to conjugate orally 
administered benzoic acid with glycine was formerly used as a 
clinical test of liver function. The test was originally 
reported by Quick (1955a) and later modified by Probstein and Londe 
(1940). Various figures are available as guidelines in this 
test but in general a subject with a normally functioning liver 
was found to excrete 5 *0 g of benzoic acid as hippuric acid 
(4 .4g) in the urine 4h after the ingestion of a 6g dose of
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sodium benzoate. The normal range varies from 85-110# of this 
amount (i.e. from 2.6-3*3g benzoic acid). In a 70kg man the 
dose administered is equivalent to 86mg sodium benzoate/kg body 
weight and the normal range of glycine utilisation is 5«6-7.2mg/ 
kg body weight/h which is considerably greater than that found 
in the marmoset at a similar dose level.
and marmosets at a dose level of 1mg/kg body weight, the rates 
of glycine utilisation for the synthesis of hippuric acid were 
very similar and clearly not rate limiting in either animal.
At this dose level, the rat excreted the administered dose 
almost entirely as hippuric acid, a similar situation to that 
in man as reported by Bridges at al. (1970). However a 
significant quantity of this dose was excreted as the glucosid- 
uronic acid by the marmoset which suggests that in this species 
the glucuronide synthetase system may have an activity greater 
than that in either man or the rat. At this dose level all the 
results were obtained using 6h excretions and consequently they 
all are directly comparable and contain no 'time approximations*.
Hippuric acid is excreted as a normal metabolite by man, 
marmoset and the rat, the average daily excretion being about 
700, 4 and 13mg respectively; these values correspond to an 
average daily output of glycine of 4, 5 and 22mg/kg body weight. 
This normal excretion of hippuric acid has not been considered 
in the discussion of the utilisation of glycine to support the 
synthesis of hippuric acid on administration of benzoate to the 
marmoset and rat reported in the present results. It is 
evident that the difference in the normal daily excretion 
represents a greater utilisation of glycine in the rat than in 
the marmoset and emphasises the superior ability of the rat to
When sodium adult rats
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conjugate benzoic acid with glycine.
The metabolic fate of sodium [} ̂ cjbenzoate in both neonatal 
rats and marmosets is strongly dose dependent. The rates of 
glycine utilisation calculated from the results in Table 3*5 
are given in Table 3«7.
Marmosets aged 4-7 days have a limited capacity to utilise 
glycine for hippuric acid formation which is reached below a 
dose level of benzoic acid of 40mg/kg body weight. At this dose 
level the benzoylglucuronide excreted represents 33$ of the 
metabolites excreted and at the 100mg/kg body weight dose level 
this proportion rises to an average of 57$. Although in the 
adult marmoset the rate of glycine utilisation is low, it is not 
limited at the 40mg/kg body weight dose level since higher rates 
are obtained at the higher dose level. This difference in the 
availability of glycine between neonatal and adult marmosets 
may account for the sharp increase in the proportion of the 
radioactive components excreted in the urine of the neonate 
which are present as benzoylglucuronide when the dose level is 
increased from 40 to 100mg/kg body weight, and the less marked 
increase observed, in general, in the adults. The two adult 
marmosets which excreted very low quantities of a 100mg/kg body 
weight dose of labelled benzoate as hippuric acid excreted more 
of the dose as benzoylglucuronide compared with the ’typical’ 
dosed animals underlining the inverse relationship between the 
availability of glycine for the conjugation of benzoic acid and 
the proportion of the dose excreted conjugated with glucuronic 
acid.
These results indicating the relatively high ability of the 
neonatal marmoset to synthesise glucosiduronic acids may be 
contrasted with the situation in the human neonate which has
Species Age (days) Dose level Recovery of dose Percentage of total Rate of glycine(mg/kg) (*) metabolites as utilisation (mg/kg body wt/h)hippuric acid
Rat 9 1 90 92.3 0.09
9 1 98 92.4 0.09
9 1 99 91 .5 0.09
9 1 91 92.9 0*02average = 0.09
9 40 38 67.3 1.04
9 40 65 74.9 2.00
9 40 110 74.9 3.38
9 40 100 76.0 3.10average = 2.38
10 100 72 74.5 5.48
10 100 72 74.2 5.50
10 100 49 72.8 3*66
10 100 95 67.7 6-56average = 5*30
Marmoset 5 1 53 95.6 0.05
5 1 86 90.8 0.08
6 1 94 93.1 0.0?
average = 0.07
4 40 58 74.2 1.77
4 40 38 66.8 1 .02
5 40 33 55.8 0.76average = 1.18
6 100 10 60.2 0.62
6 100 40 38.2 1.55
7 100 47 31 .8 ii50average = 1.22
Table 3.7 Rates of glycine utilisation for the formation of hippuric acid by neonatal animals
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been shown to conjugate N-acetyl £-aminophenol with glucuronic 
acid at a much slower rate than the adult (Vest, 1958; Vest and 
Streiff, 1959; Vest and Rossier, 1963; Vest, 1965),
At the 40mg/kg body weight dose level the rate of glycine 
utilisation for conjugation of the administered benzoate was 
lower in neonatal rats than in animals of the same age to which 
benzoate was administered at a dose level of 100mg/kg body weight* 
At both dose levels significant amounts of benzoylglucuronide 
were excreted possibly reflecting the relatively high activity 
of the transglucuronylase enzyme in this species which may be an 
example of the Overshoot’ phenomenon (see p.67). Even at the 
lowest dose level when the glycine utilised was far below that 
available, significant amounts of benzoate were excreted 
conjugated with glucuronic acid, the actual amounts excreted by 
both neonatal rats and marmosets being approximately 60pg/kg 
body weight/h.
Baines (1975) reported that neonatal rats excreted two 
unidentified metabolites of sodium [^c]benzoate, administered 
at a dose level of 40mg/kg body weight* These were designated 
’X ’ and ,Y* neither of which appeared to be unchanged benzoate 
nor benzoylglucuronide* The present results show conclusively 
that metabolite ’Y* corresponds to benzoylglucuronide but no 
labelled metabolite corresponding to ’X ’ was detected in the 
urine of the dosed rats examined.
CHAPTER 4
The comparative metabolism of £-aminobenzoic acid
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Chapter 4 - The comparative metabolism of p-aminobenzoic acid 
Introduction
p-Aminobenzoic acid (PAB) is metabolised by acetylation of 
the amino group and conjugation of the carboxyl group with either 
glycine or glucuronic acid. Metabolites in which both bio­
chemically reactive groups are conjugated also occur (Pig 4.1)•
As with benzoic acid PAB undergoes conjugation with ornithine in 
some reptilian species (Smith, 1957).
Many of the investigations of the metabolism of PAB have 
concentrated on its acetylation which has been demonstrated in 
man (Strauss et al., 1941; Smith et al., 1946; Tabor et al., 
1947, 1948, 1951; Vest and Bossier, 1963; Drucker et al., 1964; 
Vest and Salzberg, 1965), rabbit (Harrow ejb al., 1933; Bray et 
al., 1948a; Smith and Williams, 1948; Venkataraman et al., 1950; 
Terp, 1951), rat (Riggs and Christensen, 1951; Riggs and 
Hegsted, 1951), and guinea pig (Terp, 1951), but not in the dog 
(Terp, 1951).
Fewer comprehensive studies of the metabolism of PAB in 
different species have been reported. Tabor et al. (1951) found 
that PAB (6g) administered to man was excreted in urine mainly as 
p-aminohippurate (PAH) and p-aminobenzoylglucuronide (PABG-), with 
small amounts of PAB and acetylated derivatives of PAB, PAH and 
PABGr. Vest and Salzberg (1965) investigating the development 
of the conjugating reactions responsible for the metabolism of 
PAB in humans, showed that an 11 year old child, who had received 
sodium p-aminobenzoate at a dose level of 1 0 0mg/kg body weight, 
excreted 5 0% of the total dose recovered in the urine in 24h in 
the form of PAH; p-acetamidobenzoic acid (PAAB) accounted for a 
further 27%, glucosiduronic acids for 18%, p-acetamidohippuric
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H2N- ^ ^ C°2H
£-/iCetamidohippuric p cid T)“Acetsmiáobenzo¿lglucuronide 
(PAAR) (PAABG)
iC 4.1 The metabolic fate of jD-amiriotenzoie e cid
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acid (PAAH) for 9% and free PAB for 8$. Similar investigations 
carried out in three newborn premature infants of 2 to 6 days of 
age, two newborn full-term infants, two 5 and 8 week old infants 
and three children between the ages of 8 and 10 years, indicated 
that in newborn infants the main conjugate formed was PAAB and 
that in general the proportion of the dose excreted which could 
be accounted for in this form decreased with increasing age, 
whereas the excretion of both PAH and PAB followed an opposite 
trend. The proportion of the excreted dose conjugated with 
glucuronic acid also increased with age while the proportion of 
PAAH decreased. Similar results were also published in a less 
detailed study of the metabolic fate of PAB in the developing 
human by Vest, (1965)* The transition from the pattern of 
metabolism seen in the newborn period to that seen in children 
occurred around the eighth week of life.
Vest and Bossier (1963) had previously shown that the newborn 
infant conjugated PAB with glycine only very slowly and that the 
lack of quickly available glycine was only partly responsible 
for the small amounts of glycine conjugates formed. These 
authors suggested that the formation of acetylated derivations 
by the newborn infant was a compensatory mechanism for the slow 
conjugation with glycine. A similar relationship had previously 
been demonstrated by Biggs and Christensen (1951) in the adult 
rat. With increasing dose levels of administered PAB, the 
proportion of the urinary metabolites that were acetylated 
decreased, whereas the proportion that were conjugated with 
glycine increased; at any one dose level an almost constant 
proportion (91$) of the PAB was conjugated in one position or 
the other. The administration of glycine to these animals 
stimulated acetylation rather than glycine conjugation, an
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observation also made by Venkataraman et al. (1 9 5 0 ) in experi­
ments using the rabbit. Riggs and Hegsted (1951) reported that 
in the rat and rabbit the acetylation of PAB did not exceed 
75-80fo irrespective of the dose level employed.
The development of the glycine N-acyltransferase system in 
the rat and mouse liver has been studied in detail (Brandt, 1964, 
1966; G-orodischer et al., 1971). Using rat liver homogenates 
and mitochondrial preparations, Brandt (1964, 1966) was unable to 
detect the activity of this enzyme, using PAB as substrate, in 
newborn animals; activity was detected when the animals were 
between 6 and 10 days of age, after which it rose to a peak value 
at about 30 days. Similar results were obtained by G-orodischer 
et al. (1 9 7 1 ) using mouse liver preparations, although this 
species differed from the rat in that glycine N-acyltransferase 
activity was present on the first day of life.
This chapter describes an investigation of the comparative 
metabolism of PAB in the adult and neonatal marmoset and rat.
Materials
PAB, PAAB and PAH were all available from the laboratory 
stores. PAAH was synthesised by heating PAH under reflux for 
30min with an acetylating mixture consisting of equal volumes of 
acetic acid and acetic anhydride. The residue obtained on 
evaporation of the reaction mixture under reduced pressure had 
a melting point of 209-213°G> in agreement with that given in 
the literature (Miyatake and Kaya, 1952). On chromatography 
in solvent L on an aluminium-backed 60^254 Product
gave only a single spot when viewed under UV light. Oo- 
chromatography with PAH demonstrated that the R-p value of the 
product was different from that of PAH. The product gave no 




PAB was administered to all animals as a solution of its 
sodium salt in water at a dose level equivalent to 100mg PAB/kg 
body weight. The dose was mixed with Gytacon for administration 
to adult animals or with diluted milk for administration to the 
neonates.
Collection of urine
a) From dosed rats
At each age studied, twelve neonatal rats were dosed and 
divided into three groups of four animals. A control group was 
also studied. Each group was placed on a layer of filter paper 
in a beaker which was housed in an incubator (p.81). Urine was
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collected as previously described at intervals up to 6h after 
the administration of the dose. The urine from each group was 
pooled and made up to 1.Oml with water. The urine from adult 
rats was collected at 6h and 24h after the administration of the 
dose.
b ) From dosed marmosets
After the administration of the dose urine was collected 
for 6h from neonates (p.8 4 ) and at 6h and 24h from adults.
The filter paper on which the neonatal animals were placed 
and the tissues used in collecting urine from the neonatal 
marmosets were extracted with a solution of ammonia (5% w/v) and 
the amount of metabolites in these extracts also determined.
The extraction efficiency of metabolites from the absorbent 
materials was 9 7 '%•
Identification and quantification of metabolites
The colorimetric method of Bratton and Marshall (1939) was 
used to determine the free aromatic amino compounds excreted in 
the urine of dosed animals. Samples of urine which had been 
heated at 100°0 for 1h with 0.2M HC1 to hydrolyse any B- 
acetylamino compounds were also analysed by the same method to 
give the total amount (free + acetylated) of aromatic amino 
compounds present. The difference between the free and ’total' 
amino compounds corresponds to the acetylated material present. 
The absorbance, at 55Qnm, of the colour produced in the Bratton 
and Marshall reaction, was used to determine the amount of 
aromatic amino compounds present by reference to a calibration 
curve prepared from known amounts of PAB.
The separation, identification and quantification of the 
individual metabolites were carried out by the method of Davis
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and Yeary (1977) in which the metabolites were separated by 
chromatography, the zones containing the metabolites eluted and 
the amino compounds present in the eluate determined before and 
after acid hydrolysis using the Bratton and Marshall method. 
Calibration curves for PAB and PAH were not significantly differ­
ent and the PAB calibration curve was used for the determination 
of all the metabolites.
The efficiency of extraction of PAB, PAAB, PAH and PAAH 
from the chromatograms was determined by application of known 
amounts to the plate and measurement of the material recovered 
in the eluate. The recoveries of PAB, PAAB, PAH and PAAH were 
7 8$, 9 0 $, 7 5$ and 80$ respectively.
The Rp values of the reference compounds in solvent L, 
detected by their absorbance in UV light, are given in Table 4.1. 
It may be seen that the Rp values for PAB and PAAB are the same 
and it was found that PAH and PAAH (Rp values 0.55 and 0.65 
respectively) tended to overlap.
Proof of identity of metabolite 4 as PABGr was obtained by 
digesting the urine samples from dosed animals with j] -glucu­
ronidase type H - 1 (Helix pomatia) in an equal volume of 0.4M 
sodium acetate buffer pH 5*0 at 37°CJ for 16h. A control digest 
containing D-saccharic acid-1 ,4-lactone was carried out at the 
same time. The disappearance on j3 -glucuronidase treatment of 
the quenching spot with an Rp value of 0 . 3 0  together with a loss 
of aromatic amino group content in this zone of the plate and a 
corresponding increase in the aromatic amino group content in the 
zone of Rp 0.80 confirmed the identification.
Compound Rr, value in solvent L
Reference compounds
1!... 1 "
£-Aminobenzoic acid (PAB) 0.84
jo-Acetamidobenzoic acid (PAAB) 0.84
£-Acetamidohippuric acid (PAAH) 0 . 6 3
jo-Aminohippuric acid (PAH) 0.55
Urinary metabolites
Metabolite 1 (PAS + PAAB) 0.80
Metabolite 2 (PAAH) 0.60
Metabolite 3 (PAH) 0.52
Metabolite 4 (PABff) 0.30
Chromatography was carried out on aluminium sheets pre-coated with a layer of 
silica gel 6OF2 5 4 (0 *2mm thick).
PABO £-Aminobenzoylglucuronide.
Table 4.1 Chromatographic properties of reference compounds and
metabolites of ]D-*aminobenzoic acid
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Results
Four zones which absorbed UV light were detected on chromato­
grams of samples of the urine of dosed animals. These occurred 
at Rp values 0.80, 0.60, 0 . 5 2  and 0 . 3 0  and are described as 
metabolites 1-4. These quenching areas were not detected in 
urine from control animals.
Metabolite 1 was shown to be a mixture of PAB and PAAB 
since the acid-hydrolysed eluate of this zone showed an increase 
in colour in the Bratton and Marshall test as compared with the 
unhydrolysed eluate.
Metabolites 2 and 3 corresponded to PAAH and PAH respectively. 
The zones containing these two metabolites were not completely 
separated and again the amounts of the individual metabolites 
present were determined by application of the Bratton and 
Marshall test before and after acid hydrolysis of the eluate of 
the two combined zones containing metabolites 2 and 3 .
Eluted metabolite 4 also gave a colour in the Bratton and 
Marshall test showing the presence of an aromatic amino group 
which was not usually increased when the acid-treated eluate was 
examined. This spot was identified as PABGr by the methods 
outlined on p .1 3 5 •
The quantitative results for adult marmosets and rats 
showing the recoveries of the dose, the degree of acetylation of 
the dose and the relative proportions of the metabolites present 
in the urine are given in Table 4.2.
It may be seen that the proportion of the dose excreted in 
the acetylated form was much greater in the marmoset than in the 
rat and that this was due almost entirely to the excretion of a 




Degree of acetylation 
in 6h urine sample
Percentage of total metabolites excreted in 6h 
urine present as
(i) (ii) PABGr PAH PAAH PAB PAAB
Rat 84 23.9 2 0 . 1 6.7 69-4 4.5 0 . 0 1 9 . 2
89 18.6 16.5 7.8 65-9 7.2 2.5 16.4
Marmoset 38 66.9 25.4 7.0 10.4 nd 9.9 72.7
56 59.4 33.3 18.9 4.9 nd 17.2 54.5
77 80.8 6 2 . 2 7.3 11 . 6 5.0 1 .7 75.3
(i) Expressed as a percentage of the dose recovered in the 6h sample.
(ii) Expressed as a percentage of the dose administered.
All animals were dosed with sodium £-aminobenzoate at a level equivalent to 100mg PAB/kg body
weight.
nd not detected.
Table 4.2 The metabolic fate of p-aminobenzoic acid in adult rats and marmosets
139
compared with the rat. PAH was the major metabolite excreted 
by the rat but represented less than an average of 1 0 io of the 
metabolites excreted by the marmoset. About 6$ of the meta­
bolites excreted by the rat corresponded to PAAH but this 
metabolite was only excreted by one of the adult marmosets 
examined. PAB was excreted unchanged by both species but to a 
greater extent in the marmoset than in the rat. PABG- was 
excreted by both species and the determination of the metabolites 
present in the urine of dosed marmosets and rats after treatment 
with P -glucuronidase both in the presence and absence of the 
enzyme inhibitor D-saccharic acid-1,4-lactone is shown in Table 
4.3» In experiments with adult animals, the expected increase 
in PAB on f t -glucuronidase treatment was found in three cases 
but in one of the experiments the increase in PAB was higher than 
expected and cannot be explained.
The quantitative results showing the recovery of the dose, 
the extent of acetylation and the relative amounts of individual 
metabolites excreted by 7 and 11 day old rats and 4 , 5 , 1 0 and 11 
day old marmosets which had been dosed with PAB are given in 
Table 4.4.
It may be seen that in the rats aged 7 days approximately 
equal amounts of PABG, PAAB and PAH were excreted. In rats 
aged 11 days the proportions of these metabolites were markedly 
different; much less PABG- was present and the proportion of PAH 
was slightly greater than that of PAAB. At neither age was 
unchanged PAB excreted.
The recoveries of the doses in marmosets aged 4 or 5 days 
were very low; as in the rat about one third of the metabolites 
excreted were acetylated; in contrast to the rat the relative 
proportion of PAH excreted was small and that of PABG was rather
Percentage of metabolites present in 6h urine present as i-
Species Age






PABGr PAH PAAH PAB PAAB PABGr PAH PAAH PAB PAAB
Rat Adult 0 . 0 51.3 4.8 2 2 . 1 2 0 . 1 6 . 8 6 9 . 0 4.8 0 . 0 19.2
Adult 0 . 0 6 8 . 1 2 . 0 10.4 19.5 7.0 6 6 . 1 7.2 2.5 1 6 . 0
Marmoset Adult 0 . 0 3.7 nd 35.7 60.2 1 5 . 2 5.1 nd 18.6 61 . 0
Adult 0 . 0 8.9 nd 8 . 0 76.3 8.3 9.2 5.0 0.7 7 6 . 1
Marmoset 5 day 0 . 0 7.8 nd 23.3 75.0 14.3 2.9 nd 23.9 59.0
nd = not detected
Table 4.3 Effect of [3 -glucuronidase digestion on the distribution of
metabolites of PAB in adult and neonatal animals
HO
Key T a b l e  4«4
(i) Expressed as a percentage of the dose recovered in 6h.
(ii) Expressed as a percentage of the dose administered.
All animals were dosed with sodium jq-aminobenzoate at a dose level equivalent 
to 100mg PAB/kg body weight.
The rat results are averages of 4 animals.
The marmoset results are reported for individual animals-
(n )K 'This zone contained an acetylated metabolite- 
(b)This zone was totally acetylated.
+Parents 462, 466 j





Degree of acetylation 
in 6h urine sample
Percentage
in
of total metabolites excreted 
6h urine present as:
(i) (ii) PABG PAH PAB PAAB
Rat 7 31 35.4 11 . 0 28.8 35.7 0 . 0 35.5
27 35.8 7.3 (a)36.5 3 0 . 1 0 . 0 33.4
56 3 0 . 8 16.9 35.4 3 2 . 6 0 . 0 3 2 . 0
11 9 33.9 2 . 0 3.6 56.7 0 . 0 39.8
2 2 41 .0 6.4 8.4 46.7 0 . 0 44.8
17 37.4 4.0 8.5 48.7 0 . 0 42.8
Marmoset 4+ 1 0 37.5 3.8 9.8 9.8 43.6 37.0
4++ 10 39.1 3.9 5.6 9.4 21 . 9 54.3
5+ 1 0 33.4 3.3 2 2 . 6 7.4 34.4 35.5
5++ 1 0 4 8 . 1 4.8 1 0 . 3 3.3 3 0 . 2 57.4
1 0+++ 51 6 8 . 6 35.0 1 2 . 6 3.9 3.1 80.9
1 1+++
6 2 71.5 44.3 6 . 6 3.3 6 . 0 84.4
Table 4.4 M e t a b o l i c  f a t e  o f  p - a m i n o b e n z o i c  a c i d  i n  n e o n a t a l  r a t s  a n d  m a r m o s e t s
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less than in the rat aged 7 days. These marmosets excreted 
approximately one third of the dose as unchanged PAB. Marmosets 
aged 10 and 11 days excreted the dose more rapidly. Unchanged 
PAB constituted not more than 6fo of the excreted products and 
PAH less than 5$. The relative amount of PABGr was not signifi­
cantly different from that excreted by the younger animals but 
the relative proportion of PAAB was higher being above 80$ of 
the metabolites excreted.
Incubation of a sample of the urine from a 5 day old 
marmoset, which had been dosed with PAB, with /?-glucuronidase 
both with and without D-saccharic acid-1 ,4 -lactone, was carried 
out and the relative amounts of the metabolites present in the 
urine are given in Table 4.3* The results show that the glucu- 
ronide was hydrolysed without any increase in the relative amount 
of PAB but with an increase in PAAB suggesting that the double 
conjugate N-acetyl ;p-aminobenzoylglucuronide constituted the 
glucuronic acid conjugate in this marmoset. This was also 
suggested from the results shown in Table 4.4 for this animal in 




The results show that in the adult marmoset a greater 
proportion of administered PAB is acetylated than in the rat.
The major metabolite in the rat is the glycine conjugate PAH.
In both species PABG- is excreted.
The development of the conjugating systems responsible for 
the metabolism of PAB as determined by the study of the metabolic 
fate of administered PAB in animals of different ages is 
completely different in the rat and marmoset. In the rat 
conjugation of PAB with glycine becomes increasingly important 
and appears to approach adult levels when the animals are 11 days 
old. The conjugation of PAB with glucuronic acid becomes less 
important falling to adult levels by 11 days of age. No marked 
change in the proportion of the dose acetylated occurs between 
7 and 11 days but the extent of acetylation is greater in young 
than in adult rats.
The metabolic fate of PAB is similar in both 4 and 5 day 
old marmosets but different from that in 10 and 11 day old 
marmosets by which time the metabolic profile of PAB closely 
resembles that in the adult animals. In the neonatal period 
between 5 and 10 days post partum, the acetylation of PAB becomes 
increasingly important whereas there is little change in the 
relative activities of the other conjugating systems. With this 
increase in the proportion of the dose excreted as PAAB the 
amount of unchanged PAB excreted falls.
Table 4.4 shows that the metabolic fate of PAB was 
investigated in two 4 day old and two 5 day old marmosets one of
each pair being of different parentage. The offspring from 
parents No. 462 and No. 466 were always smaller than those from
4
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the other two sets of parents (see Pig 2.1) and at the age of 
5 days their weight was, on average, only 65$> of that of 5 day 
old offspring from the other parents. These smaller animals 
when compared with the larger offspring from parents No. 417 and 
No. 418 excreted less of the administered PAB in the acetylated 
form and more in the unchanged form reflecting the developmental 
pattern outlined above.
The overall results for the metabolic fate of PAB in the 
neonatal rat and marmoset suggest that whereas in the young rat 
the metabolic fate of PAB is determined by the developmental 
changes in the relative activities of the enzyme systems 
responsible for the conjugation of PAB with glycine, glucuronic 
acid and acetate, in the young marmoset only the development of 
the acetylation system appears to govern the metabolic fate of 
administered PAB.
Using PAB as substrate, Brandt (1964, 1966) showed that 
glycine N-acyltransferase activity was present in the livers of 
rats at about 6 days of age and continually increased thereafter 
until the rats were about 30 days of age. The in vivo results 
reported here for the conjugation of administered PAB with 
glycine support these early in vitro experiments. As with 
administered benzoic acid (see chapter 3) glucosiduronic acid 
formation from PAB is much more important in the neonatal rat 
than it is in the adult, which may be the result of the ’over­
shoot’ phenomenon mentioned earlier (p.67). Glucuronidation 
accounts for a greater proportion of the dose in 7 day old rats 
than in those aged 11 days suggesting that the relative activity 
of the enzyme systems catalysing the conjugation of PAB with 
glucuronic acid and glycine changes during this period. In view 
of the ability of the young rat to synthesise hippuric acid from
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administered benzoate as described in the last chapter it is 
unlikely that the availability of glycine is rate limiting in 
the metabolism of PAB at the dose level used. The small 
proportion of the dose of PAB conjugated with glycine in the 
young rat as compared with the formation of hippuric acid from 
benzoate may be due to the lower affinity of the glycine 11- 
acyltransferase for PAB as compared with its affinity for 
benzoic acid or different enzymes may be involved. A further 
explanation might be the competition of the alternative 
acetylation pathway for PAB.
In chapter 3 it was reported that in neonatal marmosets 
the rate of glycine utilisation in the formation of hippuric 
acid became rate limiting when benzoic acid was administered at 
or below a dose level of 40mg/kg body weight. While such a 
limitation may partly determine the metabolic fate of PAB»an 
alternative pathway of metabolism, 11-acetylation, is available 
and appears to be active in 4 and 5 day old marmosets and to 
reach adult levels of activity by 10 days of age. The high 
activity of the acetylation system in the young marmoset is 
emphasised by the observation that a 5 day old marmoset studied 
excreted no PABG, only the acetylated double conjugate H-acetyl 
£-aminobenzoylglucuronide.
Vest (1965) and Vest and Salzberg (1965) reported that the 
development of the conjugating systems responsible for the 
metabolism of PAB in the human were manifested by an increase in 
the formation of both PAH and PABG and a decrease in PAAB form­
ation. A detailed study of the results obtained by Vest and 
Salzberg shows that the decrease in the proportion of the 
metabolites excreted as PAAB was not completely compensated for 
by the formation of PAH and PABG- and that between the ages of 8
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weeks and 8.5 years the substantial decrease in the excretion of 
PAAB was accompanied by an increase in the proportion of the dose 
that was excreted unchanged. This suggests that it is not so 
much an increase in the activity of the PAH- and PABGr-synthetase 
systems that is responsible for the developmental changes 
observed in the metabolic fate of PAB in humans, but a decrease 
in the activity of the N-acetylase system. However, whatever 
changes in enzyme activity are involved, the metabolic fate of 
PAB in both the rat and man follows a similar developmental 
pattern, with the exception of a possible ’overshoot* in the 
activity of the PAB-UDPG-T system in the very young rat.
The change in the metabolic profile of PAB with age is very 
different in the marmoset from that in man. The most marked 
difference is the increase in the ability to acetylate PAB which 
clearly increases with age whereas in man the proportion of 
administered PAB which is acetylated decreases with age.
CHAPTER 5
The activity of hepatic and renal bilirubin-UDPGrT
in the marmoset
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Chapter 5 - The activity of hepatic and renal bilirubin-UDPGrT
in the marmoset
Introduction
The results described in chapters 3 and 4 showed that both 
neonatal rats and marmosets excreted a higher proportion of 
administered benzoic acid and PAB as their glucosiduronic acids 
than did their adult counterparts. Furthermore, glucuronidation 
appeared to be a more important biotransformation reaction in 
marmosets than it was in rats. In view of these findings, 
experiments were carried out to determine the activity of UDPGrT 
in the liver and kidney of the marmoset and to compare it with 





UDPGA (ammonium salt), bilirubin (from bovine gall stones) 
and bovine serum albumin were purchased from Sigma Chemical Co. 
Ltd. Ethylanthranilate was purchased from Eastman Organic 
Chemicals (Rochester E.Y.) and methyl n-propyl ketone from BDH 
Chemicals Ltd., Poole.
All the other materials used in this study were available 
from the laboratory stores.
Methods
Animals
As the number of marmosets in the colony was small and each 
animal valuable no marmoset was deliberately killed to provide 
tissue for the determination of bilirubin-UEPG-T activity.
Assays were carried out using the tissues of animals which had 
died from natural causes or which were killed after sustaining 
physical injury. The marmosets in this colony nearly always gave 
birth to triplets one of which was abandoned either at birth or 
after a few days. Meonates abandoned at birth were invariably 
discarded overnight so that these animals had been dead for some 
hours before the tissues were obtained. The animals which 
were rejected after a few days were ill-treated by the mother 
and when this was detected the young animal was taken and killed. 
Two young males injured each other fighting and had to be killed. 
All animals were killed by exposure to CO2 , their liver and 
kidneys removed and stored at -20°C until the assays could be 
carried out.
Por each determination of the enzymic activity of the
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tissues of a marmoset,rats of the same sex and comparable 
maturity were killed by exposure to CO2 and the bilirubin-UDPGrT 
activity of their tissues determined at the same time. In some 
cases this was not possible and then fresh tissue from an adult 
rat was included as a check that the assay was satisfactory.
Preparation of homogenates
Homogenates of liver and kidney (10$ w/v) were prepared 
using ice-cold 0.25M sucrose in 0.001M EDTA (pH 7.4) by rapid 
homogenisation using a teflon head. An equal volume of a 0.4$ 
(w/v) solution of Lubrol in 0.25M sucrose was then added. The 
rate of bilirubin conjugation with glucuronic acid by an aliquot 
(0.2ml) of this homogenate was then assayed by the method of 
Van Roy and Heirwegh (1968), using an incubation period of 
30min. A control digest to which no UDPGA or MgCO^ was added 
was also incubated.
Measurement of the rate of bilirubin conjugation
In the method employed conjugated bilirubin was converted 
to an azo pigment the absorbance of which was read against a 
solvent blank at 530nm using a Unicam SP1800 spectrophotometer. 
Subtraction of the absorbance of the control from that of the 
test gave a value equivalent to the amount of conjugated bilirubin 
formed by 10mg of tissue in 30min.
Protein determinations were carried out on the homogenates by 
the method of Lowry et al. (1951).
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Results
The activities of hepatic bilirubin-lIDPGrT found in the 
abandoned neonatal marmosets ranged from 0.7 - 12.4Jig bilirubin 
conjugated/h/mg protein and exhibited no obvious trend with age. 
The wide variability in these results was probably due to the 
condition of the tissues used in the assays. Beyond showing 
that the enzyme was present at birth these results are not 
considered of value and are not included in Table 5*1»
The results obtained using tissues dissected from animals 
immediately after they were killed are summarised in Table 5*1»
It can be seen that the specific activity of hepatic bilirubin- 
UDPG-T does not vary significantly over the range 24 days to 
adult in the rat. The results for the corresponding hepatic 
enzyme activity in the marmoset were lower than in the rat being 
on average 79% of the value found for the rat liver.
The specific activity of renal bilirubin-UBPG-T in the marmo­
set was found to be 14% of that in the liver while that of the 
rat was 21% of the level in the liver. The results indicate 
that in both species the activity of this enzyme developed more 
slowly in the kidney than it did in the liver.
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Species Sex Age Organ
Activity of bilirubin-UDPG-T 
expressed in terms of 
Ug bilirubin con.iugated/h ¡-
£ tissue organ mg protein
Rat M A L 3500 51850 21 .9
M A L 2350 35110 12.5
F A 1 2930 3 0 5 9 0 15.3
F 8w 1 3434 23540 17.5
M 7w L 2723 26524 14.7
M 24d L 2620 7070 15.3
Marmoset M 29w L 1435 15510 10.2
M 29w L 932 10870 6.3
F 8w L 2205 9116 1 3 . 2
M 4w L 3480 9990 21 .6
U 5d L 1480 1990 9.9
Rat M A K 858 2673 5.5
M A K 474 1330 3.0
F A K 488 1247 2.8
F 8w K 266 381 1 .8
M 7w K 784 1570 5.5
M 24d K 74 56 0 . 6
Marmoset M 29w K 326 525 2.7
M 29 w K 518 1010 4.3
F 8w K 59 50 0.4
M 4w K 44 210 0.4
U 5a K 59 10 0.5
M - male F - female U - sex undetermined
A - adult w - weeks d - days
L - liver K - kidney
Table 5.1 Activities of hepatic and renal
bilirubin-UDPG-T in rats and marmosets of various ages.
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Discussion
It is probable that the levels of bilirubin-UDPG-T activity 
found in the marmoset represent minimum values. The animals 
used were all in a relatively poor condition with the exception 
of the four-week old animal which was killed immediately after 
it was found with an almost severed hand but was otherwise 
healthy; this animal had the highest level of bilirubin-UDPG-T 
activity found in the liver of all the marmosets examined.
'Black and Billing (1969) reported that the average rate of 
conjugation of bilirubin in the human liver was 1100 + 28Qug 
conjugated/g liver/h which is similar to that rate obtained in 
this study using the 29-week old marmosets. The results 
obtained for healthy rats of different ages were higher than 
those obtained for the marmoset but it may be tentatively 
concluded that the bill rub in-UDPG-T activity is of the same order 
in the marmoset as it is in the rat.
CHAPTER 6
The comparative metabolism of sulphadiagine
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Chapter 6 - The comparative metabolism of sulphadiazine 
Introduction
Sulphadiazine (2-sulphanilamidopyrimidine) (I) is a member 
of the sulphonamide group of antibacterial drugs. It is known 
that in order to maintain therapeutic concentrations in the blood,
(i)
sulphonamides must usually be administered to a patient several
times a day. However sulphadiazine is readily absorbed but not
rapidly excreted resulting in the maintenance of high blood levels
of the drug for a considerable time after a single dose (Sadusk
and Tredway, 1941). Consequently the maintenance of therapeutic
blood levels of sulphadiazine can be achieved by less frequent
administration of ’booster-doses’ than are required for other
sulphonamides. Recently studies have been carried out to test
the suitability of sulphadiazine in combination with trimethoprim
. »>in the treatment of urinary tract infections (Mannisto et al.,
1975; Tuomisto et al.. 1977; Seppanen and Vilen, 1978).
Sulphadiazine may be expected to undergo four main metabolic 
transformations consisting of H -acetylation, -glucuronidation, 
-sulphation, and H -glucuronidation (see p.56). However since
iN -glucuronide formation, a reaction characteristic of primate 
species only, occurs with a limited number of sulphanilamido- 
pyrimidines, it may not take place with sulphadiazine (Bridges et
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al., 1 966,1969a,b; Walker and Williams, 1972).
Welch et al. (1945) in a study of the comparative metabolism 
of sulphamethazine, sulphamerazine and sulphadiazine in human 
volunteers reported that of these three drugs sulphadiazine was 
the least acetylated. This result was confirmed by G-illigan 
(1945) who studied the metabolic fate of a number of sulphonamides 
in patients undergoing sulphonamide therapy. In those patients 
treated with sulphadiazine there was no appreciable increase in 
either the sulphate ester or the glucuronide excretion over 
control levels. No hydroxylated metabolites of sulphadiazine 
were excreted by these patients. Similar results to these for 
man were obtained for the rabbit (Smith and Williams, 1948a). By 
administering N^-acetylsulphadiazine to rabbits Smith and Williams 
(1948a)were able to show that the relatively low excretion of 
sulphadiazine as its N^-acetyl derivative as compared with other 
sulphonamides, was not due to an active deacetylase system.
However Shaffer and Bieter (1950) demonstrated the presence of an 
active N-deacetylase system in the kidney of the chick.
In 1965, Uno et al.reported the presence of unchanged 
sulphadiazine, sulphadiazine N^-glucuronide, sulphadiazine 
N^-sulphate, H^-acetylsulphadiazine and sulphanilamide in the 
urine of humans after the oral administration of sulphadiazine. 
Later Uno and Sekine (1966) determined these metabolites in the 
48h urine of humans dosed with sulphadiazine (2g) and found 45$ 
of the dose was excreted unchanged, 56.5?« in the acetylat-ed form, 
0.7$ as the N^-sulphate, 0.5$ as the N^-glucuronide and 0.5$ as 
sulphanilamide. Madsen (1966) reported similar results for the 
excretion of the unchanged and acetylated drug but found that 4$ 
of the dose excreted was conjugated with glucuronic acid. These 
reports indicate that in man, sulphadiazine is metabolised mainly
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to its N^-acetyl derivative, the other possible conjugates 
appearing in the urine in only trace amounts.
Atef and Nielsen (1975) investigated the metabolism of 
sulphadiazine in goats and found that like man, these animals 
excreted a large proportion of the dose in the unchanged form, 
but that unlike man little N^-acetylsulphadiazine was excreted 
in the urine. The major metabolite of sulphadiazine detected 
in the urine of this species was the hydroxylated product 
2-sulphanilamido-4-hydroxypyrimidine. Bray et al. (1951b)had 
previously reported the presence of small quantities of an 
oxidation product of sulphadiazine in the urine of rabbits to 
which sulphadiazine had been administered. This metabolite 
appeared to be oxidised in the 5-position of the benzene ring and 
not in the pyrimidine ring as reported for the goat. Nielsen 
(I975a> b) reported that sulphadimidine (4,6-dimethyl-2- 
sulphanilamidopyrimidine) was metabolised in goats and cows 
mainly by oxidative reactions which together with the results 
mentioned above for sulphadiazine suggest that the oxidation of 
sulphonamides is an important metabolic reaction in ruminants 
only.
This chapter describes investigations into the metabolic fate 
of both labelled and unlabelled sulphadiazine in the adult 
marmoset, rat and rabbit.
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Materials
Lr oj Sulphadiazine (2.3niCi; 29.8piCi/mg) was obtained from
the Radiochemical Centre Ltd., the reference date from which all
short half-life (87.1 days) of sulphur-35, the labelled sulpha­
diazine was diluted in small batches with an appropriate quantity 
of unlabelled sulphadiazine (Sigma Chemical Co. Ltd., Surrey) 
shortly before use so that doses of suitable specific activity 
could be administered. The procedure for diluting the labelled 
sulphadiazine involved dissolving the required quantities of both 
labelled and unlabelled sulphadiazine in a mixture of aqueous 
ammonia (sp. gr. 0.88) and ethanol (1:10 v/v) and mixing the 
solution thoroughly for 10min. The solvents were then removed 
at 40°C under reduced pressure and the product dried in a vacuum 
desiccator.
its molecular weight, but instead the fragmentation pattern is
the molecule. Similar fragmentation patterns with the expulsion 
of SO2 have previously been described for sulphadiazine (Atef and 
Nielsen, 1975) and for sulphonylureas (Budzikiewicz et al., 1967). 
Mass measurement of the peak at m/e 186 gave a value of 186.0891 + 
0.005 whereas that for C1Q H1Q N^ (M+-S02) requires 186.0905.
accounted for by the proposed breakdown of sulphanilamide 
(Budzikiewicz et al., 1967) (Big 6.2). The peaks at m/e 172 and
thdecay was calculated being 6 " September 1976. Because of the
The mass spectrum of the diluted shown
1in Figure 6.1. It exhibits no top mass ion (M ) peak at 250,
dominated by two ion peaks at m/e 185 and 186. The peak at 
m/e 186 corresponds to M+-64 representing the loss of S02 from
Other peaks in the fragmentation pattern of the diluted 
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Fi^ 6.1 Mass spectrum of [-^s] sulphadiazine following
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FiS 6.2 The proposed mass spectral breakdown of Sulphanilamide (from Budzikiewicz et al. (1967)).
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156 are not seen with sulphadiazine since the sulphur atom has 
been lost from the molecule.
N^-Acetylsulphadiazine was prepared by the acetylation of 
sulphadiazine. Sulphadiazine was dissolved in a solution 
consisting of equal volumes of acetic acid and acetic anhydride. 
The mixture was heated under reflux for 50min, the solvents 
removed under reduced pressure at 40°C and the product re- 
crystallised from aqueous ethanol (Atef and Nielsen, 1975)» The 
final product had m.p. 258-260°G which was in close agreement with 
that 262-265°0 reported by Atef and Nielsen (1975)» The mass 
spectrum of the product (Pig 6.5) showed small peaks at m/e 185 
and 186 characteristic of sulphadiazine as well as those at m/ e  
108 and 92. The spectrum was dominated by peaks at ra/e 227 and 
228 which correspond to ni/e 185 and 186 + 42 respectively and are 
indicative of mono-acetylation.
A further sample of N^-acetylsulphadiazine was isolated 
from the ethereal extract of the acidified 24h urine of a rabbit 
which had been dosed with sulphadiazine (2g) as described by 
Smith and Williams (1948a). The material obtained by evaporation 
of the extract was recrystallised from aqueous ethanol. The 
product had m.p. 225-250°0 which was lower than the melting point 
of 245°C reported by Smith and Williams (1948a). Its mass 
spectrum (Pig 6.4) was the same as that for the synthetic material 
(Pig 6.5) although the peaks at ia/e 185 and 186 were more 
pronounced in the isolated sample suggesting the presence of some 
free sulphadiazine. This was also indicated by the results 
obtained from the HPLG analysis of the material (Table 6 .4 ) and 
may explain the lower melting point observed compared with that 



















pig 6.4 The mass spectrum of l/'-acet\-lsulphadiazine isolated from the urine of rabbits which had
been dosed with sulphadiazine (2^).
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Williams (1948a)for their isolated compound.
Sulphadiazine N^-sulphate. The potassium salt of this compound
was prepared according to the method described by Bridges et al. 
(1968) for the preparation of sulphadimethoxine N^-sulphate.
The product was impure and contained unchanged sulphadiazine.
On paper chromatography in solvent G- a spot at Rp 0.22 was seen 
which gave a positive reaction with detecting reagent VI and a 
slow reaction (2min) with reagent VIII.
Sulphadiazine E^-glucuronide was prepared according to the method 
of Uno et al. (1967) as modified by Atef and Nielsen (1975).
Again the product was impure but contained a component having an 
Rp value of 0.03 in solvent E (Table 6.2) and 0.19 in solvent G- 
(Table 6 .3 ) as determined by its reaction with detecting reagent 
VIII.
Sulphanilic acid was purchased from Sigma Chemical Co. Ltd.
When chromatographed on paper by the ascending technique in solvent 
G, the sulphanilic acid was seen to contain in addition to the 
main component (Rp 0.35, Table 6.5) a second component (Rp 0.47, 
Table 6.5). After repeated recrystallisation from water both 
components were still present. It is probable that the second 
component is the ortho isomer of sulphanilic acid. A mass 
spectral analysis of the recrystallised compound (Fig 6.5) gave 
the molecular ion peak at m/e 173. The fragmentation pattern 
obtained contained peaks at m/e 156, 108, 92, 80 and 65 corres­




The enzyme preparations used were all obtained from Sigma 
Chemical Co. ltd., Surrey.




Sulphadiazine was administered to all animals at a dose level 
of 100mg/kg body weight as a suspension in Cytacon.
Chromatography
Paper chromatography was carried out by both ascending and 
descending techniques. Chromatography on glass plates coated 
with a layer of silica gel G- (0.3mm thick) was used for the 
detection of glucuronic acid and its conjugates.
High pressure liquid chromatography (EPIC)
This was carried out as described in the general methods 
(p.88). A solvent of constant composition, consisting of 
methanol (40°/°) and 1.0% acetic acid (60%) was used to elute the 
metabolites from the column. The metabolites were detected by 
their absorbance at 260nm. Confirmation of the identification
of metabolites was obtained by co-chromatography with reference
{
compounds where these were available.
Separation of metabolites
Metabolites were separated from the 24h urine of dosed 
marmosets by ascending paper chromatography in solvent G-. The 
urine was first digested with urease to remove urea which had a
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similar By value to one of the metabolites of sulphadiazine 
(Table 6.3)* Digestion with urease type III (from Jackbeans) 
was carried out at 30°C. The pH of the digest was maintained at 
7.0 by the addition of 2M EG1 at intervals. The treated urine 
was applied as a streak to a 9” wide chromatogram which was 
developed in solvent G-. A sample strip was cut from the dried 
chromatogram and sprayed with reagent VIII. The zones corres­
ponding to the located metabolites (Ĝ  and G^) were cut out and 
eluted with methanol. Metabolite G-̂ (Table 6.3) contained two 
overlapping components one of which, the lower R^ component (Gr-ĵ ), 
gave an immediate colour with reagent VIII while the second 
component (G-̂ a) which had the higher R^ value, developed the colour 
in about 12h. The two metabolites were eluted separately. The 
extracts were evaporated under reduced pressure at room temperature 
and the residues containing the partially purified metabolites 
were used for their identification. Control 24h urine samples, 
from animals which had received Gytacon only, were treated in the 
same way, and extracts prepared from the zones with R^ values 
corresponding to those of the different extracts prepared from 
the urine of dosed animals.
Determination of unchanged sulphadiazine and its metabolites 
excreted in urine.
Aromatic amino and N-acetylamino compounds
These were determined by the method of Bratton and Marshall 
(1939) as previously described (p.134). Calibration curves were 
prepared with sulphadiazine and the absorbance was determined at 
550nm. Similar determinations were carried out on the urine 
collected from undosed animals and from animals which had 
received Oytacon only.
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In experiments using L55sJ sulphadiazine the recovery of the
dose in urine was measured by liquid scintillation counting as 
previously described (p.89). 'The individual radioactive 
components in the urine were separated by ascending paper 
chromatography in solvents E and Gr and the distribution of 
radioactivity along the chromatograms measured as previously 
described (p.90) using 1cm sections. The average recovery of 
the radioactivity applied to the chromatograms was 937°•
Determination of dose in faeces
The 24h faeces of dosed animals were lyophilized and ground 
to a fine powder which was extracted with 0.2M HOI. Aliquots
of the extract were used for measurement of radioactivity and of 
material containing aromatic amino compounds. The recovery of 
sulphadiazine added to a sample of dried faeces was 98$ as 
determined by the method of Bratton and Marshall (1939).
Blood levels of sulphadiazine and its metabolites
The levels of radioactivity in blood samples taken from
sulphadiazine were determined by the method previously described 
(p.90).
marmosets at intervals after the oral administration
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Results
The Rp values of the reference compounds and of the three 
main urinary constituents excreted by dosed animals and not seen 
in normal urine are summarised in Table 6.1. In some systems 
sulphadiazine and E^-acetylsulphadiazine overlapped on the 
chromatograms but the two compounds were distinguished because 
the sulphadiazine gave an immediate reaction with reagent VIII 
while the U^-acetyl derivative reacted slowly, the colour 
developing in about 12h. Better separations of sulphadiazine 
and its metabolites were achieved by ascending chromatography in 
solvents E and Grj Up values of minor metabolites in addition to 
those shown in Table 6.1 are given in Tables 6.2 and 6.3 respect­
ively. Chromatography, in these two solvents, of a sample of 
urine from animals to which Cytacon alone had been administered 
and from undosed animals, indicated that the metabolites detected 
by reagent VIII in the urine of dosed animals were not due to the 
dosing vehicle.
Identification of unchanged sulphadiazine and its metabolites in 
the urine of dosed animals.
Sulphadiazine
Unchanged sulphadiazine was detected in the urine of all 
dosed animals by ascending paper chromatography (Metabolite 1, 
Table 6.1; E2, Table 6.2; GKj , Table 6.3)« A sample of the
material separated from the urine of a dosed marmoset (p.165; 
extract G-^) had the same retention time as sulphadiazine on 
HPLC (Table 6.4). The aromatic amine content of this extract 
increased slightly on acid hydrolysis as determined by the method 
of Bratton and Marshall (1939) which indicated that it was
Rr, value in the solvent listed
Compound Fa g£ if; if, ¡¿L
Urinary metabolites
1 0.26 0.77 0.77 0.79 0.09 0.09 0.77 0.81
2 0.45 nd 0.82 nd 0.17 0.17 • 0.82 nd
3 nd 0.62 0.63 0.62 nd nd nd nd
Reference compounds
Sulphadiazine 0.28 0.79 0.77 0.79 0.07 0.09 0.78 0.80
N -Acetylsulphadiazine 0.45 ne 0.82 0.79 0.16 0.17 0.83 0.84
All chromatograms were developed on Whatman 3MM paper either by the descending (a) or ascending (b) 
technique.
All reference compounds and metabolites were detected using reagent VIII* Metabolites 1 and 3 
and sulphadiazine gave an immediate purple colour with this reagent, white metabolite 2 and 
-acetylsulphadiazine developed the colour after about 12h.
nd - not determined ne - not examined
Table 6,1 Chromatographic properties of reference compounds and major 
metabolites of sulphadiazine
Time to Reaction Species in urine
Colour with develop with from which metabolite
Compound R« value reagent VIII colour reagent I was detected
Metabolite
l1 1
Ei 0.45 pu 8-24h - M, Ra, Rb
h2 0.26 pu imm - M, Ra, Rb
0.16 pi.fl imm M, Ra, Rb
E4 0.10 pi.fl imm - M, Ra
E5 0.05 pi. f 1 imm - M, Ra, Rb
Reference compounds
N^-Acetylsulphadiazine 0.45 pu 8-24h - -
Sulphadiazine 0.28 pu imm - -
Sulphadiazine N^-glucuronide 0.05 pi.fl imm bl/br —
Colour codes: pu, purple; pi.fl, pink fluorescence (seen under UV light); bl/br, blue brown, 
imm - immediate colour development.
Species: M, marmoset; Ra, rat; Rb, rabbit.
Table 6.2 Detailed chromatographic properties of urinary metabolites and reference compounds 























0.77-0.82 pu imm"1’ red bl _ or M, Ra, Rb
0.63 pu imm - - - - - M, Ra
ff3 0.27 pi imm - - - - ye M
a4 0.23 pi.fl 2min - - bl - - Ra, Rb
% 0.19 pi.fl 1min - - - - - M, Ra
Reference compounds
N -Acetylsulphadiazine 0.82 pu 8-24h - red bl - or
Sulphadiazine 0.77 pu imm - red bl - or
Sulphadiazine sulphate 0.22 pi 2min - ne ne ye ne
Sulphadiazine N^-glucuronide 0.18 pi.fl imm bl/br ne ne - ne
Normal metabolite urea 0.53 pi imm - - - - -
Colour codes: pu, purple; pi, pink; pi.fl, pink fluorescence (seen under UV light); bl/br, blue-brown 
bl, blue; or, orange; ye, yellow. _u
imm, immediate colour development. +This spot developed an immediate purple colour on spraying with 
reagent VIII. After 12h a purple cap appeared, 
ne, not examined.
Species: M, marmoset; Ra, rat; Rb, rabbit.
Table 6.3 Detailed chromatographic properties of urinary metabolites and reference compounds as




Main peak (s) Subsidiary peak (s)
Reference Compounds
Sulphadiazine 2.00 -
N^-Acetylsulphadiazine (a) 2.55 -
N^-Acetylsulphadiazine (b) 2.60 2.00
Extracts
CO- 1 .551 a
0&ib 1 .55 -
ca2 1 .50 1 .70
G1a 2.65 1 .55
G1b 2.00 2.65, 1.55
g2 1.55 1.70, 1.85, 2.00
0- + M^-acetylsulphadiazine 2.60 1.55, 2.00
^ib + N4-acetyisuiphadiazine 2.05, 2.65 -
O-jl̂ + sulphadiazine 2.05 2.65, 1.55
(a) synthetic compound
(b) isolated from rabbit urine
GG-2 etc - extract from control urine with Up value equivalent 
to that of metabolite e'*:c*
Table 6.4 EPLC analysis of methanolic extracts of urinary 
metabolites isolated from pacer chromatograms 
developed in solvent 0.
)
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slightly contaminated with N^-acetylsulphadiazine (Metabolite 
Grio). A similar contamination was also suggested by the HPLO 
result. The mass spectrum of the isolated metabolite was 
identical with that of authentic sulphadiazine (Fig 6.1).
E^-Acetylsulphadiazine
This metabolite was identified on chromatograms by its ftp 
value and by the colour given with reagent VIII which developed 
slowly (Metabolite 2, Table 6.1; , Table 6.2; Ĝ  , Table 6.3)«
A sample of this metabolite separated by preparative paper 
chromatography (p.165; extract Gh ) had the same retention time 
on KPLC as a synthetic sample of N^-acetylsulphadiazine (Table 
6.4)« Analysis of the extract by the Bratton and Marshall (1939)
method, before and after acid hydrolysis,showed that the separated 
metabolite contained 16% free amino compound.
Sulphadiazine N^-glucuronide was identified in the urine of dosed 
animals by its value in solvents E and Gr. (Metabolite E^,
Table 6.2; Gr̂ , Table 6.3) > using detecting reagent VIII. Since 
N^-glucuronide conjugates of sulphonamides can form spontaneously 
in the urine (Bridges et al., 1968) this metabolite may be an 
artifact.
■iSulphadiazine N -glucuronide
ASulphadiazine E -glucuronide (metabolite G-2, Table 6.3) was 
tentatively identified in the urine of dosed animals by comparison 
of chromatograms of samples of urine before and after digestion 
with ft -glucuronidase (Table 6.5) when metabolite was almost 
completely destroyed and an aromatic amino compound, Rp 0.36 was 
produced. Two types of -glucuronidase digestion were used in
Rp in solvent 0- as determined by reagent VIII





0.64 0 . 6 2 ^ 0.66(d)
nd nd nd
h 0.21 0.23 0.23
a5 0.19 0.19 nd
breakdown product(s)^e' - 0.36 0 . 3 6 h ; 0. 42
Reference compounds
N^-Acetylsulphadia zine 0.80 —• —
Sulphadiazine 0.76 — —
Sulphadiazine N^-glucuronide 
Sulphamlic acid' '
0.19 — - --I,
0.35, 0.47 — —
^ ' /2-glucuronidase type L—1 ; ^0<i Sodium acetate buffer 0.2M, pH 3*8; Barely detectable
Faint colour; ^G; Both spots developed purple colour immediately on spraying;
^  Main metabolite.
The effect of -glucuronidase digestion on the chromatographic pattern of





(i) f t -glucuronidase type H-1 (from Helix pomatia) was
used to digest samples of urine mixed with an equal volume of 
0.4M sodium acetate buffer pH 5.0
used to digest samples of urine in an equal volume of 0.2M sodium 
acetate buffer pH 5*8.
Both types of digest were incubated at 57°C for 12-24h.
Control digests prepared as above but with the addition of 
D-saccharic acid-1,4-lactone were incubated at the same time.
Samples of the metabolite tentatively identified as sulpha- 
diazine N -glucuronide by the above procedure were separated by- 
preparative paper chromatography and further examined to determine 
the extent of acetylation and the glucuronic acid content.
There was no increase in the aromatic amine content of the extract 
on acid hydrolysis as determined by the Bratton and Marshall (1959) 
test, indicating that metabolite G^ >7as n0  ̂acetylated. A further 
sample of the metabolite when subjected to the carbazole test for 
glucosiduronic acids (p. 92), gave a faint pink colour which was 
not detected with the corresponding extract from normal urine.
None of the other extracts gave this positive reaction. Samples 
of all the methanolic extracts were evaporated, the residue 
dissolved in 0.2M sodium acetate buffer pH 5.0 (0.5^1) and 
subjected to digestion with /?-glucuronidase (type H-1) for 12h 
at 57°0. Samples of the digests, together with samples of 
authentic glucuronic acid, sulphadiazine and sulphanilic acid, 
were chromatographed on thin layer plates in solvent G and the 
components detected using reagents I and VIII. The results are 
shown in Table 6.6. Only metabolite G^ broke down, under 
/3 -glucuronidase digestion to yield glucuronic acid;









Sample Sp colour Sf colour
CG,1 a — —
+ E 0.85 bl/t —* —■
Cff16 - - - -
+ E 0.80 bl/t — —
c g2 - - - -
+ E 0.84 bl/t —
ff1a — — 0.88 pi/pu
+ E 0.86 bl/t 0.87 pi/pu
ff1lD — — 0.82 pi/pu
+ E 0.86 bl/t 0.85 pi/pu






■jaglucuronic acid 0.45 bl - -
S + buffer blank 0.80 bl/t - -
Sulphadiazine - - 0.85 pu
Sulphanilic acid - - 0.85 pi/pu
E - P -glucuronidase enzyme type H-1
Colour codes:- bl/t, blue tinge; bl, blue; pu, purple; pi/pu, 
light purple colour (pinkish)
+Chromatographed in a buffer/enzyme mixture
CG-2 etc:- extract from control urine with an ftp value equivalent 
to that of metabolite G-2 etc.
Table 6.6 Thin layer chromatographic analysis in solvent G- of
the effects of /̂ -glucuronidase on extracts isolated 
from marmoset urine after paper chromatography in solvent G-.
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occur with the corresponding extract from control urine. (The 
faint colour seen with reagent I at 0.83 ± 0.02 was also seen 
in control digests of enzyme and buffer only). Metabolite G^ 
appears to break down under f l -glucuronidase treatment to yield 
sulphanilic acid (see later) which has an Rp value similar to 
that of metabolite G^ in this chromatographic system. This 
explains why on treatment of metabolite with f t -glucuronidase 
no change ŵ as observed in the position of the aromatic amino 
compounds on the chromatogram.
Sulphadiazine Ĥ r-sulphate was detected on chromatograms by its 
reaction with detecting reagent VIII (metabolite G-̂ , Table 6.3)» 
The presence of sulphadiazine N^-sulphate in the urine of
dosed animals was confirmed by comparing the distribution of 
labelled metabolites along chromatograms of the urine before and 
after it had been digested with an arylsulphatase preparation 
(from Helix pomatia). The digestion was carried out at 37°0 
for 12h with an equal volume of 0.075M sodium acetate buffer 
pH 5.5 to which was added D-saccharic acid-1,4-lactone to inhibit 
the endogenous j i -glucuronidase activity present in the urine 
(see later) and the ^-glucuronidase activity which was present 
in the arylsulphatase preparation. The results in Table 6.3 
show that when the a urine sample from a dosed animal was 
chromatographed in solvent G-, the area occupied by sulphadiazine 
N^-sulphate also gave a positive reaction with detecting reagents 
IV and XII for the detection of phenolic compounds. These 
results cannot however be used as evidence for the presence of a 
phenolic metabolite of sulphadiazine since these detecting 
reagents also gave a positive reaction with both sulphadiazine and 
n^-acetylsulphadiazine.
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The species in which unchanged sulphadiazine and its 
metabolites were detected are shown in Tables 6.2 and 6.3»
Determination of sulphadiazine and its metabolites excreted in the 
urine of dosed marmosets, rats and rabbits.
The quantitative results obtained for the recovery of the 
dose and the degree of acetylation of sulphadiazine in the three 
species are summarised in Table 6.7. The radiochemical recover­
ies after the administration of sulphadiazine to the animals
are also included in this table and show in general, within 
experimental error, good agreement with those recoveries obtained 
by the method of Bratton and Marshall (1939)•
The urinary distribution of the radioactivity between the 
sulphadiazine excreted unchanged and its metabolites was deter­
mined as previously described (p.90). Figures 6.6 and 6.7 are 
examples of the histograms obtained using solvents E and Q- 
respectively. The percentage of radioactive components excreted 
that were accounted for as H^-acetylsulphadiazine (metabolite E-j) 
as determined in solvent E by this method are included in Table 
6.7 and show excellent agreement with the results obtained by the 
method of Bratton and Marshall (1939) for the proportion of 
N^-acetylsulphadiazine present in the urine. Chromatography in
isolvent E of the extract corresponding to sulphadiazine N - 
glucuronide (metabolite G^) isolated from marmoset urine, showed 
that in this solvent metabolite had a similar Rp value to that 
of authentic sulphadiazine so that it will be present in metabolite
■̂2 *
The proportion of the total urinary metabolites excreted in
24h urine samples after the administration of
to the different species as determined in solvents E and G- are
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Recovery of dose Percentage of radioactive components
(cr/\ ( c ) excreted in acetviated form____ UP.) Of dose (a) Of dose (a) Of dose (b)
Species (a) m i administered excreted excreted
Rat 61 6.8 12.1
76 - 9.3 13-1 —
93 - 18.8 25.9 —
78 - 10.2 20.5 —
92 82 6.0 11 .7 ne
87 82 10.9 16.4 ne
87 77 10.1 18.4 ne
80 80 6.8 11 .8 ne
92 78 7.5 13.3 15.5
82 83 10.7 14.5 14.461 61 9.9 17.7 17.8
84 82 11 .2 17.2 18.7
81 77 11.5 16.7 17.3
average 81 78 10.0 16.1 16.7
Marmoset 32 _ 11 .3 37.3
32 - 7.3 31 .0 —
26 - 6.8 30.2 —
29 - 4.1 21 .8 —
47 46 3.9 27.7 ne
44 40 5.5 27.8 ne
62 61 14.7 26.7 29.3
53 53 21 .6 50.1 35.8
59 76 17.3 34.0 40.072 70 16.1 30.1 31 .6
80 ne 23.7 29.6 33.4
average 48.7 58 12.0 31 .5 34.0
Rabbit 79 71 26.8 (50.1) 56.9 58.2
88 67 51.0 (56.9) 63.8 66.4
84 69 38.9 (53-5) 60.4 62.3
(a) Determined by method of Bratton and Marshall (1939)
(b) Determined by liquid scintillation counting
(c) Total urinary and faecal recoveries were determined for a 
24h period after dosing in the marmoset, and a 48h period 
in the rat and rabbit.
ne - not examined
Figures in parentheses indicate the 48h excretion figures for 
the rabbits studied.
Table 6.7 Degree of acetylation of sulphadiazine in 24h 
urine samples of the marmoset, rat and rabbit.
Fig 6
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Pig 6.7 Distribution of radioactivity rlong a pr.per chromatogram developed in solvent G- of
u r i r 'n  "rorr ' marmoset dosed  - i t h  [ ' ;^S] c u l p h a d i a z i n e .
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shown in Tables 6.8 and 6.9 respectively. The code numbers used 
in these tables for the different metabolites are the same as 
those in Tables 6.2 and 6.3« In Tables 6.8 and 6.9 the animals 
are listed in the same order so that comparisons may be made 
between the distribution of metabolites as determined for any one 
animal in solvents E and 0. Metabolite G-̂ was a mixture of 
unchanged sulphadiazine and i\r̂ -acetylsulphadiazine, whereas 
metabolite E-j contained the E^-acetyl derivative only. The 
amount of free sulphadiazine excreted was given by G^-B^ and 
these values are also given in Table 6.9.
Using solvent G, which gave the best resolution of the 
metabolites, it can be seen that the minor metabolites G^, G^ 
(sulphadiazine U^-sulphate) and G^ (sulphadiazine N^-glucuronide) 
contribute not more than 5f° of the total radioactive components 
in the urine. Metabolite G^ was detected more readily in the 
urine of dosed marmosets whereas metabolite G^ was more prominent 
in the urine of dosed rats and rabbits. Since both these 
metabolites were never detected in the same sample of urine, their 
similar Rp values suggest that they both may correspond to 
sulphadiazine U^-sulphate. Metabolite G^ although giving a
weak reaction with detecting reagent VIII appeared not to be 
labelled which can only be explained if the sulphadiazine mole­
cule is undergoing cleavage between the two ring systems. A 
small peak of radioactivity was detected just above the origin 
when urine from dosed animals was chromatographed in solvent G. 
This metabolite (G^, Table 6.9) gave no obvious reaction with 
detecting reagent VIII.
Chromatograms developed in solvent E, although providing a 
good separation of sulphadiazine and N^-acetylsulphadiazine did 
not give a very good resolution of the minor metabolites in the
Key Table 6.8
Metabolite codes (eg ) refer to the metabolites in Table 6.2.
Figures in parentheses denote the Rp value used to identify the 
metabolites.
a Radiochemical recovery of dose (see Table 6.7).
The Rp value of these radioactive peaks corresponded to neither metabolite 
E^ or E^ exactly.
c The Rp value of this radioactive peak corresponded to neither metabolite 
E^ or E^ exactly.
nd not detected




Species B1 (0.45) (0.26) E-, (0.16) E. (0.10) %  (0-03)
Rat 78 15.5 75.3 nd
- 4
nd 9.3
82 18.7 53.9 nd 11.5b 11.5
77 17.3 55.1 nd 7.9b 8.5
83 14.4 75.6 2.2 nd 3.9
61 17.8 67.2 4.1 nd 5.2
Average 76 16.7 65-4 1 .3 3.9 7.7
Marmoset 70 31 .6 54.6 nd 9.4 4.0
53 35.8 51.4 nd 11.6° nd
61 29.3 54.4 nd nd 9.6
76 40.0 38.7 nd 12.3 5.0
80 33.4 51 .6 nd 6.8 2.7
Average 68 34.0 50.1 - 8.0 4.3
Rabbit 71 58.2 35.1 nd nd 6.8
67 66.4 25.7 nd nd 4.1
Average 69 62.3 •30.4 - - 5.5
Table 6.8 The relative proportions of the radioactive components present in the 24h urine excreted
by animals dosed with [-̂ sl sulphadiazine as determined in solvent E.
Key Table 6 . 9
Metabolite codes (eg ) refer to the metabolites in Table 6 .3 . Figures 
in parentheses denote the values used to identify the metabolites.
a Not detected by reagent VIII and therefore is not included in Table 6 ,3 .
0 Obtained by subtracting the proportion of metabolite B-j (Table 6.8) 
from that of metabolite Gh.
c The urine from these animals was not analysed in solvent E (Table 6.8).
Average of 5 animals only, 
nd not detected.
Radioactivity of metabolites GL-G-g expressed as a percentage of the
total radioactivity present _ U i l  w  1 1  o i l  1 ^  vl/ L I  *1
Species G. (0.80) Go (0.63) G, (0.27) G, (0.23) Go (0. 131 Ge (0.00)a sulphadiazine D
Rat
■ 1 1,1 —1 Lr
93.2 ’ 5.3 nd
4 j  
nd nd 1 .5 77.7
78.7 11.0 ' 3.0 nd nd 2.1 60.0
71 .8 14.5 nd 2.7 1 .7 2.1 54.5
91 .4 4.0 nd 1 .2 nd 1 .0 77.0
85.8 7.1 nd 1 .8 nd 1 .6 68.0
78.8° 10.8 3.6 nd nd 1 .8 -
79.3° 8.6 4.1 nd nd 1 .3 -
Average 82.7 8.8 1 .5 0.8 - 1 .6 67.4d
Marmoset 69.2 23.9 nd 1 .3 nd 0.8 37.6
75.4 18.6 2.9 nd nd nd 39.6
65.9 21 .5 3.3 nd nd 2.1 36 • 6
72.6 19.8 4.4 nd nd nd 3 2 . 6
64.5 28.3 1 .3 2.2 nd 0.8 31 .1
Average 69.5 22.4 2.4 0.7 - 0.7 35.5
Rabbit 84.3 nd 4.1 nd nd 6.9 26.1
83.9 nd nd 4.6 nd 4*6 17.5
Average 84.1 - 2.1 2.3 - 5.8 21 .8
Table 6.9 The relative proportions of the radioactive components present in the 24h urine excretec.




Figures 6.8, 6.9> 6.10 and 6.11 show the effect of -  
glucuronidase (type H-1) on the distribution of labelled metabol­
ites as shorn by chromatography in solvent G-. The urine samples 
used in these experiments were from the same 24h sample used to 
obtain Figures 6.6 and 6.7. When the urine -was incubated with 
an equal volume of 0.4M sodium acetate buffer pH 5*0 containing 
D-saccharic acid-1,4-lactone, either alone or with the enzyme, no 
change in the distribution of labelled metabolites was observed 
as compared with the untreated urine. When the inhibitor was 
omitted from the incubation, the concentration of metabolite 
was severely diminished whether or not the enzyme was added.
Under these conditions the decrease in the amount of metabolite 
was not accompanied by a corresponding increase in sulpha- 
diazine but instead two labelled break down products were formed, 
the main one having an Rv value of 0.33 as determined by radio­
chemical counting (see Figs 6.10 and 6.11). Similar results 
were obtained for the effect of f}  -glucuronidase type L-1 at pH 
3.8 on the distribution of metabolites of sulphadiazine as 
detected by reagent VIII (Table 6.5). In both cases the main 
break down product had an Rp value equivalent to the major 
component observed in the authentic sulphanilic acid sample 
(Table 6.5).
That the breakdown of metabolite on incubation of the 
urine sample with buffer alone was inhibited by D-saccharic acid- 
1, 4-lactone suggests that the urine of marmosets contains an 
active /] -glucuronidase.
When sulphanilic acid was administered to the animal, the 
urine from which had been used to obtain Figures 6.6 - 6.11, at 
a dose level of 100mg/kg body weight no metabolite corresponding
20001
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yig 6.8 Distribution of radioactivity alone a paper chromatogram developed in solvent 0 of




in the presence of E-sncch*’ric acid-1 ,4-lactone.
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a paper chromatogram developed in solvent 
a marmoset dosed with [35 3] sulphadiazine.
0 of
188




11 Distribution of radioactivity along a paper chromatogram developed in solvent G- of 
/? -glucuronidrse treated urine (in the presence of D-saccharic a.cid-1 ,4-lactone) 
from a marmoset dosed with P^s] sulphadi~zine.
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to &2 was detected by reagent VIII.
Figure 6.12 shows the distribution of labelled metabolites 
in the urine used to obtain Figure 6.7 after it had been incubated 
with arylsulphatase as previously described (p-177). Metabolite 
Gr̂ disappeared on digestion with the enzyme confirming earlier 
chromatographic evidence that this metabolite was sulphadiazine 
sulphate.
Blood levels of l> s] sulphadiazine and its metabolites
Figure 6.13 shows the variation with time of the level of 
radioactive components in the blood of two marmosets after the 
oral administration of O^s] sulphadiazine at time 0. The peak of 
radioactivity occurred at different times after the administration 
of the dose to the animals. The peak level of radioactivity was 
maintained near the maximum value for several hours after which 










Distribution of radioactivity along a paper chromatogram developed in solvent 0- of 










F i g  6 . 1 3 The levels of radioactive components in the blood of 
intervals following the oral administration
two marmosets at various 





The metabolism of sulphadiazine in the marmoset, rat and 
rabbit proceeds mainly by N-acetylation. Compared with the 
marmoset and rat, the degree of acetylation of orally administered 
sulphadiazine is high in the rabbit as reported in the literature. 
The rabbit has been shown to excrete high proportions of 
administered sulphanilamide and various sulphonamides, including 
sulphadiazine as N -3-cetyl derivatives (Smith and Williams, 1948a; 
Bray et al., 1951b; Bridges and Williams, 1963; Bridges et al.. 
1966, 1968, 1969b; Uno et al., 1967; Adamson et al., 1970a;
Walker and Williams, 1972). In the marmoset the degree of 
acetylation of sulphadiazine is significantly higher than it is 
in the rat.
The degree of acetylation of sulphonamide derivatives in 
different species varies with the structure of the sulphonamide 
(Bridges et al., 1969a)» The degree of acetylation of several 
methoxy derivatives of 6-sulphanilamidopyrimidines is almost as 
high in the rhesus monkey as it is in the rabbit (Bridges et, al., 
1969a; Walker and Williams, 1972) whereas that of sulphadimethox- 
ine is considerably lower in the rhesus monkey than in the rabbit 
(Bridges et al., 1968, 1969b; Adamson et al., 1970a).
Adamson et al. (1970a)studied the metabolic fate of sulpha- 
dimethoxine in many primate species (p.56) including two New World 
species. The proportion of the total metabolites excreted in 24h 
by the squirrel monkey and capuchin monkey, after the administra­
tion of a 100mg/kg body weight dose, as the N^-acetyl derivative 
were 37$ and 2$ respectively. The results obtained in this work 
suggest that the degree of acetylation of sulphadiazine in the 
marmoset is similar to that of sulphadimethoxine in the squirrel
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monkey.
Uno and Sekine (1966) reported that 96.5% of administered 
sulphadiazine (2g) was excreted in the acetylated form in the 
urine of humans over 48h, This was equivalent to 45% of the 
total metabolites excreted in this period. Although the dose 
level used in this study was less than that used with the marmo­
set, there are clearly similarities between the degree of 
sulphadiazine acetylation in the marmoset and man.
The proportion of administered sulphadiazine found to be 
excreted unchanged in the present investigation was highest in the 
rat and lowest in the rabbit. A major metabolite, 0-2» was 
excreted by both rats and marmosets but not by rabbits to which 
sulphadiazine had been administered. This metabolite accounted 
for a greater proportion of the total metabolites excreted by 
the marmoset than by the rat.
Although the identity of metabolite ^as n0^ keen 
definitely established it is probably a conjugate of glucuronic 
acid in which the aglycone contains a free amino group. Since 
hydroxylation of sulphadiazine has been reported (Bray et al., 
1951b; Atef and Nielsen, 1975) it is possible that metabolite G2 
could be either an 0- or an N -glucuronide. Digestion of this
metabolite with either type 1-1 or H-1 ¡rf -glucuronidase appeared 
to release sulphanilic acid, but this compound is unlikely to be 
the aglycone since it was not found to be metabolised to metabolite 
&2 by the marmoset. Bridges et al. (1965) reported that
glucuronidase (type 1-1) to sulphadimethoxine and glucuronic vacid, 
whereas acid hydrolysis of the conjugate yielded sulphanilic acid, 
barbituric acid and glucuronic acid showing that it is possible 
for sulphanilic acid to be formed as a result of a non-enzymic
sulphadimethoxine N -glucuronide was slowly broken down
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hydrolysis of the 17 -glucuronide of a sulphonamide.
Since the break down of metabolite G^ by f t  -glucuronidase 
was inhibited by D-saccharic acid-1,4-lactone there must be a 
specific binding of the enzyme to the molecule and therefore the 
release of sulphanilic acid is much more likely when the 
glucuronic acid moiety is attached in the 17 -position than if it 
were attached through a ring hydroxyl group.
That IT -glucuronide formation only occurs with a limited
number of sulphanilamidopyrimidines has already been mentioned
(p.154). The conclusions drawn by Walker and Williams (1972) as
to the structural requirements for 17 -glucuronidation suggest that
sulphadiazine would not undergo such a reaction. Bridges et. al.
(1966, 1969a),Adamson et al. (1970a)and Walker and Williams (1972)
reported that in general where 17 -glucuronide formation did occur
with a particular sulphanilamidopyrimidine,it did so to a major
extent only in man and rhesus monkey, to a minor extent in the
rat and did not occur in the rabbit. Assuming that the tentative
-1identification of metabolite as an hT -glucuronide is correct 
the results obtained in the present study are in accord with these
■ireports for the rat and rabbit; the W -glucuronide of sulpha­
diazine was a significant metabolite excreted by the marmoset.
iIf metabolite &2 is sulphadiazine 17 -glucuronide its low excretion 
in the urine of dosed rats may not be a true indication of the 
capability of this species to form it since its high molecular 
weight (427) would permit its excretion in the bile as in the 
case of sulphadimethoxine (Adamson et al., 1970a).
Uno and Sekine (1966) did not report the presence of 
sulphadiazine N -glucuronide as a metabolite of sulphadiazine in 
man, while Gilligan (1945) had previously reported that the 
administration of sulphadiazine to humans caused no increase in
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the excretion of total glucuronic acid above control levels.
A comparison of these results with those reported here, may 
suggest that there are major differences in the metabolic fate of 
sulphadiazine between man and the marmoset.
The excretion of sulphadiazine N^-sulphate as a minor 
metabolite of sulphadiazine in the marmoset has been shown in this 
work and this result is similar to that obtained by Uno and Sekine 
(1 9 6 6 ) for the excretion of sulphadiazine sulphate in the 
urine of humans to whom sulphadiazine had been administered.
A detailed analysis of the radiochemical distribution along 
chromatograms of urine from dosed animals, developed in solvent 
G-j indicates the presence of a minor metabolite (G-g, Table 6.9) 
which was not detected by reagent VIII. The absence of such a 
reaction may be due to the low concentration of this metabolite 
in the urine.
Peak blood levels of sulphadiazine and its metabolites
were observed in the marmosets studied at 2 .5h and 5 *Oh after 
dosing. After this peak the levels of radioactivity fell off 
to near-zero by 24h. Goodwin et al. (194-2) showed that the 
blood levels of both free sulphadiazine and total sulphadiazine 
reached a plateau 6h after the administration of a single 5g oral 
dose to human subjects. This plateau level was maintained for 
a period of 6h after which there was a gradual decrease in the 
blood levels until near-zero levels were achieved 3 days after 
dosing. Welch et al.(1943) reported that when sulphadiazine 
was administered to human subjects at a dose level of 5 0mg/kg 
body weight peak blood levels of both free and total drug were 
reached 4h after dosing,after which the levels fell off to reach 
near-zero between 3 and 4 days. The rates of absorption of 
sulphadiazine from the gastrointestinal tract appear therefore to
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be similar in man and the marmoset, but the rate of elimination 
of the dose from the blood appears to be much faster in the 
marmoset than it is in man.
CHAPTER 7
Acetylation of sul'phadimidine by the marmoset
C h a p t e r  7 -  A c e t y l a t i o n  o f  s u l p h a d i m i d i n e  by  t h e  m a r m o s e t
Introduction
The rate of inactivation of certain amino group-containing 
compounds is an individual characteristic, highly variable from 
person to person and known to be under genetic control. The 
inter-individual differences are due to the activities of hepatic 
K-acetyltransferase, the enzyme responsible for the acetylation of 
amino groups. Acetylator polymorphisms were originally discovered 
in man as a result of studies of the metabolism of isoniazid in 
both healthy volunteers and in patients suffering from tuberculosis. 
Slow inactivation of isoniazid by means of acetylation is a 
Mendelian autosomal recessive character, while rapid inactivation 
is an autosomal dominant character (Knight et al., 1959; Evans 
et_ al_., 1960; Sunahara et al., 1961). The frequency of the 
acetylator phenotypes exhibits large inter-ethnic variability 
(Armstrong and Peart, 1960; Dufour et al., 1964; Scott et al., 
1969; Raoetal., 1970; Lunde et al., 1977).
Much of the early work on acetylation polymorphisms was 
carried out using isoniazid. However Evans and White (1964) and 
Peters et al., (1965) showed that similar polymorphisms were also 
apparent in the acetylation of the sulphonamide, sulphadimidine 
(sulphamethazine). The ease of phenotyping individuals using 
a single test dose of sulphadimidine (Evans, 1969; Eze and Evans, 
1972) has resulted in the replacement of isoniazid by this compound 
as the most widely used drug for the determination of acetylator 
phenotypes.
Several other amino compounds also exhibit an acetylation 
polymorphism in man, including dapsone (G-elber et al. , 1971) 
sulphapyridine (Schroder and Evans, 1972) and procainamide (Gibson
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et al., 1975; Uarlsson and Molin, 1975). The rabbit has also 
been shown to exhibit acetylation polymorphisms with respect to 
sulphadiazine (Frymoyer and Jacox, 1963a,b) and sulphadimidine 
(Hearse and Weber, 1975)» Using rabbits which had been pheno- 
typed with sulphadimidine, Hearse and Weber (1973) demonstrated 
the possible existence of more than one N-acetyltransferase. One
type of this H-acetyltransferase appeared to be present in the 
liver and gut and was responsible for the polymorphism trait 
exhibited in vivo, while a second U-acetyltransferase, found in 
extra-hepatic tissues, exhibited no polymorphic characteristics.
In primate species there exist wide inter-individual differ­
ences in the extent of acetylation of isoniazid but only in the 
mangabey and African green monkey have there been any indications 
suggesting the existence of a polymorphism in acetylation (Gfoedde 
et al., 1964; Peters et al., 1965).
Using sulphadimidine, the acetylator phenotype of an 
individual can be determined by measuring the degree of acetylation 
of sulphadimidine in the urine or plasma of the subject. Evans 
(1969) observed that the percentage of H^-acetylsulphadimidine in 
serum appeared to be a better phenotype discriminant than the same 
constituent in urine. Hoo et al. (1977) also reported that a 
distinct difference between fast and slow acetylators of 
sulphadimidine could be demonstrated by measuring the proportion 
of acetylated drug in a blood sample taken 2h after dosing but that 
considerable overlap existed with urine samples. However Rao et 
al. (1970) concluded that when either sulphadimidine or isoniazid 
was used to determine the acetylator phenotype of patients, the 
urine test was preferable to the blood test, while more recently 
Tulseth and Landmark (1977) reported that it was possible to 
distinguish fast and slow acetylators by measuring the percentage
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of N^-acetylsulphadimidine in a single serum or urine sample. 
Furthermore these authors also reported that the amount of 
sulphadimidine administered in the test was not critical and that 
differences between slow and fast acetylators could be demonstrated 
in plasma samples taken at any time between 0.5 and 24h after the 
administration of the compound, and in urine samples up to 8h 
after dosing.
This chapter gives an account of the acetylation of 
sulphadimidine by the marmoset. The members of two families of 
these animals were examined.
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Materials and Methods 
Materials
Sulphadimidine tablets were obtained from the Area 
Pharmaceutical Service, United Birmingham Hospitals. Bach tablet 
weighed 600mg and contained 500mg of sulphadimidine. Pour tablets 
were crushed up to form an evenly mixed powder for dosing.
All the other chemicals used in this study were available 
from the laboratory stores.
Methods
Administration of dose
The tablet preparation was administered to each marmoset in 
the colony as a suspension in Oytacon at a dose level of 60mg/kg 
body weight, equivalent to 50mg sulphadimidine/kg body weight.
After determining the quantity of the doses which remained in the 
syringes after dosing, the average dose of sulphadimidine 
administered to each animal was found to be 45mg/kg body weight.
Collection of urine
Urine samples were collected at 2, 4, 6 and 24h after the 
administration of the dose.
Collection of blood samples
Triplicate samples of blood were collected approximately 4h 
after the administration of the dose as described previously (p 90) 
and placed onto pieces of filter paper according to the method of 
Weber and Brenner (1974)»
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Determination of the degree of acetylation in urine and blood 
samples
(a) Urine The percentage of free and acetylated drug excreted 
in each urine sample was determined by the Bratton and Marshall 
(1939) method, as previously described (p 134). A calibration 
curve constructed from known quantities of sulphadimidine was used.
By repeating the experiments on four animals the reproducibility 
of the results was established.
(b) Blood The percentage of sulphadimidine that was present 
in the plasma in the acetylated form was determined by the method 
of Weber and Brenner (1974-)»
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Results
Figure 7.1 shows a typical excretion curve obtained for 
free, total and hence acetylated metabolites of sulphadimidine 
in the urine of a dosed marmoset. In the first 2h after the 
administration of the dose, a slight lag phase was seen in the 
excretion of sulphadimidine and its N^-acetyl derivative and so 
the 2h urine sample was not used in determining the acetylator 
status of the animals.
Tables 7.1 and 7.2 are summaries of the data obtained for the 
proportion of the dose excreted as N^-acetylsulphadimidine and the 
rates of excretion of the acetylated derivative in the urine of 
marmosets from family I (parents Nos 417 and 418) and family II 
(parents Nos 463 and 465) respectively (see Fig 2.1). The rates 
of excretion of N^-acetylsulphadimidine were calculated for the 
period 2-6h after dosing from the cumulative curves for the 
excretion of N^-acetylsulphadimidine. The rates of excretion of 
p4_acetylsulphadimidine were taken as being equivalent to the rate 
of acetylation of the drug. Table 7.2 also contains the results 
obtained using marmoset No 462, a feral male, which had not started 
breeding at the time of this study.
The proportions of the dosed sulphadimidine present as 
N^-acetylsulphadimidine in the urine samples collected at 4h and 
6h after the administration of the dose were very similar in all 
the animals studied. The average results for the proportion of 
the dose excreted as N^'-acetylsulphadimidine in the 4h and 6h 
urine samples, together with the rate of acetylation of sulpha­
dimidine are slightly higher for family I than for family II but 
the difference is not statistically significant. When averaging 
the rates of acetylation per animal for either family, the results 
obtained using animals Nos 764» 765» 783 a^d 784 were not included

Marmoset Sex Age
Recovery of dose 
(°/o) between 2 and 
6b after dosing
Degree of acetylation (#)









4 and 6b 
acetylation mg/animal/b mg/kg/b
417 F A 27 68.4 69.0 68.7 0.72 2.38
418 M A 12 78.0 79.2 78.6 0.38 1 .25
492 M 2-9 33 70.7 71 .4 71.1 0.91 3.00
493 M 2-9 12+ 71 .8 - 71 .8 0.91 3.00
466 F 3-2 25 72.3 74.2 73.3 1 .06 3.50
532 F 2-8 14 72.7 80.6 76.7 0.76 2.51
582 F 1-8 32 74.2 76.0 75.1 0.94 3.10
626 F 1-5 20 70.3 74.1 72.2 0.81 2.67
689 M 1-0 20 66.9 69.3 68.1 0.73 2.41
690 M 1-0 16 78.2 79.2 78.7 0.63 2.08
783 M 0-3 36 72.0 75.8 73.9 0.48 2.88
784 M 0-3 25 71 .4 74.2 72.8 0.35 2.10
Average 72.2 74.8 n73*4 0.79 2.57
Ages are expressed in years-montbs 
A - adult, exact age not known 
- no urine sample available
^Recovery of dose contained in 2-4b urine sample only 
M - male F - female
Table 7.1 Acetylation of sifLphadimidine in family I (parents Nos 417 and 418)
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Marmoset Sex Age
Recovery of dose 






of acetylation ( % )
in 6h average of 
urine 4 and 6h 
sample acetylation
Rate of excretion of 
R^-acetylsulphadimidine
mg/animal/h mg/kg/li
463 F A 31
C\J• 59.4 60.3 0.75 2.48
465 M 3-3 19 69 • 6 57.8 63.7 0.48 1 .58
607 M 1-8 28 62.9 65.0 63.9 0.45 1.49
608 M 1-8 31 60.8 60.9 60.9 0.70 2.31
652 F 1-3 23 70.5 68.1 69.2 0.91 3.00
653 F 1-3 21 67.6 74.1 70.8 0.85 2.80
708 M 1-0 12 67.2 65.9 66.6 0.44 1 .58
709 M 1-0 14+ - 63.9 63.9 0 .5 4 1 .94
764 M 0-4 30 67.4 73.4 70.4 0.42 2.52
765 M 0-4 25 64 »0 61 .8 62.9 0.32 • V£> rv)
Average 65.7 65.0 65.3 0 .64 2.16
462 M A 17 68.9 69.7 69.3
Ages are expressed in years-months 
A - adult, exact age not known 
- no urine sample available
'^Recovery of dose contained in 4-6h urine sample only 
M - male F - female
Table 7.2 Acetylation of sulphadimidine in family II (parents Nos 463 and 465)
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since these animals were very young and received less than half 
the dose administered to adult animals. However the results 
obtained using these animals were included when averaging the rates 
of acetylation expressed per kg body weight since on a mg/kg body 
weight basis the dose administered to these young animals was the 
same as that given to the adults.
fable 7.3 shows the average rates of acetylation of 
sulphadimidine in male and female animals both from the separate 
families and from both families combined. In all cases the 
average rate of acetylation of sulphadimidine is higher in female 
animals than in males but the values are not significantly 
different, the difference in the average values being less than 
the sum of their standard deviations.
The d e g re e  o f  a c e t y l a t i o n  o f  s u lp h a d im id in e  i n  t h e  b lood  o f  
t h r e e  a n im a ls  was d e te rm in e d  and th e  r e s u l t s  a r e  g iv e n  i n  T ab le  
7 . 4 . Blood sam ples were ta k e n  from  th e s e  a n im a ls  a t  t h e  same 
tim e a s  th e y  were b e in g  used  f o r  t h e  e x c r e t i o n  s t u d i e s  and so t h e  
d eg re e  o f  a c e t y l a t i o n  i n  th e  b lo o d  and u r i n e  o f  t h e s e  a n im a ls  may 
be compared. I t  may be seen  t h a t  th e  p e rc e n ta g e  o f  th e  t o t a l  
d rug  p r e s e n t  i n  th e  a c e t y l a t e d  form  i s  lo w e r  th a n  t h a t  i n  th e  
c o r re sp o n d in g  u r i n e  i n d i c a t i n g  t h a t  th e  a c e t y l a t e d  d rug  i s  
p r e f e r e n t i a l l y  e x c r e t e d .
Average acetylation rates (mg/kg/h.) + S.D.
Family Females Males
I 2.83 ± 0.46 2.39 + 0.64
II 2.76 + 0.26 1.91 ± 0.39
X + IX 2.80 + 0.38 2.15 ± 0.57
Ijibl e 7.3 Average acetylation rates of sulnhadimidine in male and female marmosets
Time of sampling after Percentage of metabolites
dose administration present in acetylated
Marmoset h min form
493 3 - 5 0 35.5
532 oi 37.9
582 -P̂ 1 O o 25.5




Although the rates of acetylation of sulphadimicLine found for 
all the animals examined ranged from 1.25- 3•50mg/kg/h the values 
did not fall into distinct groups; the percentage of the dose 
excreted as the acetyl derivative varied from 6 0 . 3 %  to 7 Q . 7 ? ° and 
again no dividing line in these values was discernible. It is 
unlikely therefore that acetylation dimorphism is present in these 
animals. The extension of this conclusion to this species of 
marmoset in general can only be tentative for two reasons
(i) The number of animals used in this study was only small.
(ii) Although two families were used, one parent of family II (i.e. 
No 465) was an offspring of family I (see Pig 2.1) and hence the 
families were genetically related.
If a polymorphism does exist in marmosets, regarding the 
acetylation of sulphadimidine then the high degree of acetylation 
observed in the marmosets studied, together with the consistency 
of these results, suggest that the minimum genetical requirements
for both sets of parents would be for one parent to be homozygous
dominant and the other heterozygous. If the gene responsible for 
a high degree of sulphadimidine acetylation is not dominant over 
that for a low degree of acetylation then both sets of parents
examined would appear to be homozygous with respect to the gene for
high acetylation since no results were obtained which could be 
attributed to an intermediate degree in the acetylation of 
sulphadimidine.
Table 7.5 is a summary of some of the results obtained by 
other workers for the bi-modal distribution of sulphadimidine 
acetylation in man. The results, taken from the different 
reports, are similar and a comparison with the results obtained 
here for the marmoset suggest the acetylation of sulphadimidine
Percentage of urinary metabolites 
present in acetylated form
Dose level Slow Past
(mg/kg body weight) acetylators acetylators Reference
40+ 40 - 55 65 - 85 Evans and White (1964)
47 (160+ ) 30 - 60 7 0 - 9 5  )
Evans (1969) - 2 groups
40 40 - 70 8 0 - 1 0 0  )
44 40 - 60 65 - 95 Rao et al. (1970)
40 40 - 55 75 - 90 Eze and Evans (1972)
47 29 - 53 69 - 93 Tulseth and Landmark (1977)
+Dose level expressed per kg active body mass.
Table 7.5 Published data for the bi-modal distribution of sulphadimidine acetylation in humans
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occurs to a similar degree in these animals as it does in those 
humans who are classified as fast acetylators. The results 
obtained by Rao et al. (1970) may be considered guidelines for the 
phenotyping of individuals for the acetylation of isoniazid.
Hence if more than 70% of the metabolites of sulphadimidine present 
in the urine 6h after the administration of a dose of 44rng 
sulphadimidine/kg body weight are accounted for as N -acetylsulpha- 
dimidine then the subject may be classified not only as a fast 
acetylator of sulphadimidine but also as a fast inactivator of 
isoniazid.
Prom the results of Schroder and Evans (1972) it is possible 
to calculate that the rate of acetylation of sulphadimidine in 
man after a 10mg/kg body weight dose is 0.63mg/kg/h in slow 
acetylators and 1.39mg/kg/h in fast acetylators. An investigation 
into the rate of acetylation of orally administered sulphadimidine 
in a class experiment involving 27 students in this department, 
showed that at a dose level of approximately 15mg/kg body weight 
the rates of acetylation varied from 0.11 to 1*57mg/kg/h, the 
majority of the subjects (60%) acetylating the drug at a rate of 
between 0.14 and 0.53mg/kg/h. While these results are not 
entirely reliable they support the conclusion that the rates of 
acetylation of sulphadimidine in the marmoset, expressed per kg 
body weight as given in Tables 7.1 and 7.2,are considerably higher 
than the rate of acetylation reported for man.
The proportion of sulphadimidine present as the N^-acetyl 
derivative in the blood of dosed marmosets is much lower than that 
in the corresponding urine. Similar results have been reported 
for man (Evans, 1969; Rao et, al., 1970; Bze and Evans, 1972).
If more than 25% of the plasma metabolites of administered 
sulphadimidine (44mg/kg body weight) are present as H^-acetyl-
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sulphadimidine 6h after the administration of the dose, then the 
human individual is classified as a fast acetylator (Rao et al., 
1970). The results reported here for the degree of acetylation 
of sulphadimidine in the plasma of marmosets indicates that these 
animals acetylated the drug to a similar degree as humans 
classified as fast acetylators, which is in agreement with the 
urinary results obtained.
CHAPTER 8
The comparative metabolism of aspirin
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C h a p te r  8 -  The c o m p a ra t iv e  m etabo lism  o f  a s p i r i n  
I n t r o d u c t i o n
Aspirin (acetylsalicylic acid; I), a powerful analgesic 
and antipyretic has probably been the most widely used drug for 
many years. Acetylsalicylic acid is easily hydrolysed in
solution especially at pH values above 7, and in the animal body 
is readily converted to salicylic acid (Hill, 1902; Lester erfc al., 
1946; Smith et al., 1947; Williams, 1959; Leonard, 1962; Smith 
and Smith, 1966; Rowland et al., 1967; Davison, 1971). The 
work of Mandel et al. (1954) and Leonard (1962) showed that the 
drug was absorbed in its unhydrolysed form from the gastro­
intestinal tract and that hydrolysis occurred after absorption, 
but Rowland et al. (1967) concluded that appreciable hydrolysis 
occurred in the gastrointestinal fluids and/or in the gut wall.
Because of the susceptibility of acetylsalicylic acid to 
hydrolysis, the metabolism and excretion of this compound becomes 
almost equivalent to that of salicylic acid (II); conjugation 
with glycine to form salicyluric acid and with glucuronic acid 
to form acyl and phenolic glucuronides occurs (Quick, 1935b;
Alpen et al., 1951; Robinson and Williams, 1956). A small 
fraction of salicylic acid is further hydroxylated to gentisic
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acid (2,5-dihydroxybenzoic acid) while the excretion of small 
amounts of the oxidation products 2,3-dihydroxy and 
2,3>5-trihydroxybenzoic acids has also been reported (Bray et al., 
1950b; Dumazart and Ouachi, 1954).
Despite the widespread use of aspirin there is relatively
little published data on its metabolic fate in different animal
species, and those reports that have been published are mainly
concerned with the metabolic fate of salicylic acid. In a
study using [carboxyl-^o] salicylic acid, Alpen et al. (1951)
reported that in man between 10 and 85$ of a dose of salicylic
acid (1g) was excreted unchanged, 0 - 5 0 %  as salicyluric acid, 1 %
or less as gentisic acid, 12-30$ as an ether glucuronide and 0-10$
as an ester glucuronide. In general a low excretion of free
salicylic acid was accompanied by a high excretion of salicyluric
acid. Hoffman and Nobe (1950) demonstrated the importance of
urinary pH on the renal excretion of salicylic acid derivatives
during acetylsalicylic acid therapy, but the wide variations in
the proportions of the various metabolites excreted by the
different subjects reported by Alpen et al. (1951) could not be
correlated with urinary pH. More recently Levy et al. (1972)
showed that an average of 50$ of administered salicylate (3g)
was excreted as salicyluric acid in the urine of four healthy
human subjects, 14$ of the dose was excreted as unchanged
a
salicylate, 2 0 %  as salicylphenylglucuronide, 10$ as salicylacyl- 
bglucuronide and 3%  as gentisic acid. The wide inter-individual 
variations in the results observed by Alpen at al. (1951) were 
not encountered by Levy et al. (1972), suggesting that the use 
by these earlier authors of patients suffering from malignant 
growths may have been responsible for the variations observed.
Alpen at al. (1951) also showed that in the dog, 50$ of a
“Uo-Oarboxyphenylglucuronide “ o-Hydroxybenzoylglucuronide
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dose of salicylic acid (1g) was excreted unchanged, 25% conjugated 
with glucuronic acid, 10% conjugated with glycine and 4-5% was 
excreted as gentisic acid. In this species only the ether-type 
glucosiduronic acid was excreted. In the rat, the same 
metabolites were formed as those described above for man and the 
dog (Williams, 1959)*
Bray et al. (1948b) reported that in the rabbit a large 
proportion (85%) of administered salicylic acid was excreted as 
ether-soluble acid which contained very little salicyluric acid, 
3-4% was excreted as salicylacylglucuronide, 5-14% as 
salicylphenylglucuronide and 4-5% as gentisic acid. Roseman 
and Dorfman (1951) administered sodium gentisate to man and mouse 
and found that the dose was excreted unconjugated in the urine 
of man but that in the mouse up to 50% of the dose may be further 
metabolised.
Although the hydrolysis of aspirin in the body occurs 
relatively quickly, appreciable levels of an oral dose to man 
can be detected in plasma up to 2h after its administration 
(Lester et_ al., 1946; Mandel ert al., 1954; Leonard, 1962;
Rowland et al., 1967). Cummings and King (1966) using a thin 
layer chromatographic procedure showed that an average of 1.5% 
of a 12mg/kg body weight oral dose of acetylsalicylic acid in 
human male subjects was excreted unchanged in the urine within 
1.5h of dosing, but that after this time very little unchanged 
acetylsalicylic acid was excreted. This was the first report 
of the urinary excretion of unchanged acetyisalicylic acid.
This chapter gives an account of an investigation of the 
metabolic fate of acetylsalicylic acid in the marmoset which is 
compared with that in the rat. The excretion of unchanged 




was obtained from the Radiochemical Centre Ltd. and diluted with 
unlabelled acetylsalicylic acid (British Drug Houses Ltd., Poole) 
by removing the contents of the ampoule with small volumes of 
hot benzene (3ml) and transferring the solution to a small round 
flask. Unlabelled acetylsalicylic acid (250mg) was then added 
and the contents heated under reflux. Sufficient benzene was 
added dropwise until all the residue had dissolved. The 
crystals which separated on cooling were filtered, washed with 
cold benzene (2ml) and petroleum ether (b.pt range 60-80°C; 10ml)
then dried under vacuum. The specific activity of the acetyl-
r e c o v e ry  o f  th e  nom inal a c t i v i t y  s u p p l i e d  o f  7Qfo.
When chrom atographed  on g l a s s  p l a t e s  c o a te d  w i th  a t h i n  
l a y e r  o f  s i l i c a  g e l  G- i n  s o lv e n t  B and on a lum in ium  s h e e t s  p r e ­
c o a ted  w ith  a l a y e r  o f  s i l i c a  g e l  601*2 5 4 s0 -̂v en^ 0 (p 85 ) th e  
p ro d u c t  was shown to  be r a d io c h e m ic a l ly  p u re  a s  d e te rm in e d  by 
l i q u i d  s c i n t i l l a t i o n  c o u n tin g  and rad io ch ro m a to g ram  s c a n n in g .  
However an a u to r a d io g r a p h  p r e p a r e d  from  an alum in ium  p r e - c o a t e d  
p l a t e ,  deve loped  a s  above, i n d i c a t e d  th e  p r e s e n c e  o f  a sm a ll  
amount o f  [ c a r b o x y l - * ' s a l i c y l i c  a c id  i n  th e  sam ple ( P l a t e  5)*
A further sample of acetyl [carboxyl-salicylic acid which 
had been diluted by the method described above was also available 
in the laboratory. The specific activity of this sample was 
0.12p.Ci/mg and its radiochemical purity was 99.8$ as determined 
by the above methods. The different specific activities
obtained was 8.89p.0i/mg giving a
permitted the administration of suitable quantities of radio­
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activity to the animals at the different dose levels of 
acetylsalicylic acid employed.
[carboxyl-14c] salicylic acid was prepared by alkaline 
hydrolysis of acetyl [carboxyl-1 ̂ Cjsalicylic acid and was used as 
a reference compound in the preparation of chromatograms from 
which autoradiographs were made.
Methods
Administration of dose
Acetyl K ]  salicylic acid was administered to rats and 
marmosets at dose levels of 100 and 13mg/kg body weight. At 
the higher dose level the dose was administered as its sodium 
salt with either milk or Oytacon as the dosing vehicle (p 81). 
The labelled dose was suitably diluted with unlabelled aspirin 
so that the radioactivity administered at this dose level was 
4.5,p.Oi/kg body -weight. At the lower dose level acetyl K ] -  
salicylic acid of high specific activity (0.89p.Ci/mg) was 
administered as a suspension in Oytacon.
Human volunteers took three tablets of soluble aspirin 
(Queen Elizabeth Hospital Pharmacy) each containing 300mg of 
acetylsalicylate, approximately equivalent to a dose of 13mg/kg 
body weight.
Collection of urine
Eor investigations in which acetyl K ]  salicylic acid was 
administered to rats auid marmosets at the higher dose level 
urine samples were collected 24h after dosing. In experiments 
where the lower dose level was employed urine was collected from 
the dosed animals after a period of 6h and then after 24h.
In the study of the excretion of unchanged acetylsalicylic
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acid by the marmoset and man, urine samples were collected 1.5h, 
3.Oh and 4.5h after the administration of the dose.
Chromât ography
Chromatography was carried out using the following methods:- 
(i) glass plates coated with a thin layer of silica gel G- were 
developed in solvents B and M; (ii) descending paper chromato­
graphy in solvents E and N; (iii) aluminium sheets pre-coated 
with silica gel 60^254 so-*-ven“!: 0 as described by Cummings and
King (1966). The metabolites were identified by comparison with 
reference compounds. In methods (i) and (ii) the compounds 
were detected by their radioactivity and/or by their reaction 
with the detecting reagents listed in Table 8.1. In method (iii) 
the metabolites and reference compounds were detected by their 
radioactivity and/or their absorption in UY light.
G-lucosiduronic acids, resulting from the administered dose 
were located on non-fluorescent chromatograms by the reaction 
with detecting reagent I. The presence of these labelled 
metabolites was confirmed by digesting the urine from dosed 
animals with -glucuronidase (type H -I or L - I )  as previously 
described (p 175) and observing the change in the radiochemical 
distribution on the chromatograms as compared with that observed 
for the untreated urine.
To distinguish between labelled salicylacyl and labelled 
salicylphenyl glucuronides on chromatograms a sample of urine,
K ] salicylic 
o,
collected from a marmoset which had received acetyl 
acid, was adjusted to pH 10-11 with 0.1M EFaOH and kept at 50^0 for 
45min. Under these conditions salicylacyl but not salicylphenyl 
glucuronide would be expected to hydrolyse. Chromatography of
samples of the urine before and after this mild alkaline
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hydrolysis showed which glucuronide had been destroyed.
Recovery of dose
(a) In urine
The urinary recovery of administered acetyl K l  salicylic 
acid was determined by liquid scintillation counting (p 89)*
(b) In faeces
The quantity of radioactive components excreted in the 
faeces of dosed animals was determined by the combustion method 
(p 90).
Detection and determination of unchanged acetylsalicylic acid in 
the urine of dosed marmosets and humans
The excretion of unchanged acetylsalicylic acid in the 
urine of dosed marmosets and humans was investigated.
A 010 method based upon that described by Ranee et al. (1975) 
for the detection of aspirin in plasma was explored using a 5%  
07-101 column coating, but although salicylic acid was detected 
in the urine extracts, unchanged aspirin was not. The following 
KPLC method was therefore developed.
After administration of acetylsalicylic acid (13mg/kg body 
weight) to the marmoset, urine samples were collected at intervals 
up to 4«5h after the dose was given; each sample was diluted to 
20ml with water, acidified to pH 1.0 and extracted manually with 
ether (3 x 40ml). The combined extracts from each sample were 
evaporated to dryness under reduced pressure at room temperature 
and the residue dissolved in methanol (0.5ml). The methanoiic 
extract was quickly filtered through a Fluoropore filter 
(Millipore Gorp., Mass.) of pore size 0.5pm and an aliquot of 
the filtrate applied to the HPLQ column (p 88). A solvent
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gradient was used to elute the metabolites as shown in Fig 8.1. 
The metabolites were detected by their absorption at 260nm.
The identification of the acetylsalicylic acid, peak was based 
upon a comparison of the retention time with that of a reference 
sample of aspirin and was confirmed by co-chromatography. The 
amounts of aspirin present in the samples were determined by 
measuring the areas under the peaks and comparing them with the 
areas produced by known amounts of aspirin. By this method the 
recovery of acetihLsalicylic acid added to normal marmoset urine 
was 82^.
Urine samples collected from dosed humans were similarly 
extracted and the amount of unchanged aspirin determined.
Distribution of labelled metabolites in the urine of dosed rats 
and marmosets
This was carried out by the method of chromatography and 
liquid scintillation counting of the fragmented chromatograms 
(p 90). Most of the quantitative work, particularly at the 
high dose level,was carried out using descending paper chromato­
graphy in solvents E and N. In all cases parallel chromatograms 
were developed so that the labelled metabolites could be 
identified using detecting reagents I, II and III.
When the lower dose was administered to marmosets and rats 
the urine was collected 6h after the dose was given. Samples 
of the urine were chromatographed bn aluminium sheets pre-coated 
with silica gel in solvent 0, and the distribution of
radioactivity determined by radiochromatogram scanning and liquid 
scintillation counting of the scraped-off coating from 0.5cm 
sections of the plates. With these chromatograms the metabolites 
were located by their quenching of UV light before the plates




Determination of sulphate excretion
The inorganic and organic sulphate content of the 24h urine 
excreted by rats before and after they had been dosed with aspirin 
was determined by the method of Morrison (1973)»
Blood levels of acetyl M  salicylic acid and its metabolites
The levels of radioactivity in blood samples taken from 
marmosets at intervals after the oral administration of 
acetyl [ « a  salicylic acid were determined as described 
previously (p 90).
Samples of the blood were applied to aluminium sheets pre­
coated with a thin layer of silica gel , which were





The chromatographic properties of the reference compounds 
and of the main urinary metabolites excreted by dosed animals and 
not seen in normal urine are summarised in Table 8.1.
Aspirin and salicylic acid were only clearly separated by 
chromatography on the aluminium-backed plates in solvent 0. 
Unchanged aspirin was not detected in samples of the urine of 
dosed animals using this system. Salicylic, salicyluric and 
gentisic acids were clearly separated by this procedure and gave 
characteristic colours when viewed under UV light. Plate 5 is 
an autoradiograph of a chromatogram, developed in solvent 0 of 
samples of urine from three marmosets which had been dosed with
Metabolite 1 (Table 8.1) detected in the urine of all dosed 
animals was identified as salicylic acid by its Rp values and by 
the reaction given with the detecting agents shown in Table 8.1. 
Similarly metabolite 2, excreted by dosed rats and marmosets was 
identified as salicyluric acid and metabolite 3 (detected by 
reagent II in urine of two dosed rats) as gentisic acid.
Metabolites 4 and 5 detected in the urine excreted by dosed rats 
and marmosets gave a positive reaction with the naphthoresorcinol 
reagent (reagent I) indicating that they were glucosiduronic 
acids. Their further examination is described later.
2,3“ i 2,4- and 2,6-dihydroxybenzoic acids were not detected 
by reagent V in the urine of either marmosets or rats which had 
been dosed with acetylsalicylic acid. When parallel chromatograms 
were developed in solvents B and U, one containing reference 



















Acetylsalicylic acid d 0.82 0.67 0.65 nd yellow ne 0.85 d/b
Salicyclic acid 0.86 0.65 0.65 0.90 yellow blue ne 0.89 l/b
G-entisic acid 0.32 0.38 0.43 0.80 - beige blue beige 0.77 i/b
Salicyluric acid 0.2 6 0.28 0.22 0.82 - red purple ne 0.58 violet
2,5-dihydroxybenzoic acid ne ne 0.50 0.80 - ne ne grey ne -
2,4-dihydroxybenzoic acid ne ne 0.39 0.80 - ne ne orange ne -
2,6-dihydroxybenzoic acid ne ne 0.70 0.60 - ne ne yellow ne -
Urinary metabolites
Metabolite 1 0.86 0.72 0.63 0.85® - yellow blue ne 0.89 l/b
2 0.21 0.26 0.24 0.85 - red purple ne 0.57 violet
3 nd 0.36 0.44 nd - beige blue nd nd -
4 nd 0.08 0.05 0.24 61 - - ne 0.00 d/b
5 - - - 0.10 61 - - ne
a Chromatography carried out on glass thin layer plates
b Chromatography carried out by descending technique on paper
c Chromatography carried out on aluminium backed fluorescent thin layer plates 
d Acetylsalicylic acid does not react with the phenolic sprays in its unhydrolysed form
e Can be distinguished by the mixtures of colours given with reagent II
l/b - light blue, d/b - dark blue nd - not detected, ne - not examined.
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Plate 5 Autoradiograph taken from an aluminium-backed thin 
layer chromatogram developed in solvent 0, showing the radio­
metabolite distribution in the urine of three marmosets (Gode 
numbers as shown) which had been dosed with acetyl K ]  salicylic 
acid.
SA = Salicylic acid, ASA = acetylsalicylic acid,
SU = salicyluric acid, GA’s = glucosiduronic acids.
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or rats which had been dosed with acetyl L14cJ salicylic acid, no 
radioactive metabolite was detected in the urine of the dosed 
animals which corresponded to any of the reference compounds.
Determination of the relative amounts of radioactive metabolites 
in the urine of dosed animals
Figures 8.2 and 8.3 are typical histograms showing the 
radiochemical distribution along paper chromatograms of samples 
of urine from a dosed marmoset, developed in solvents E and N 
respectively. In solvent S, radiochemical peaks were apparent 
corresponding to salicylic acid, salicyluric acid and metabolite 
4 (Table 8.1) a glucosiduronic acid. In some experiments a 
small peak corresponding to gentisic acid was seen. In some 
cases the peak attributed to salicyluric acid appeared to consist 
of two separate components, especially when the lower dose level 
was employed where the specific activity of the administered 
compound was relatively high.
In solvent iT, four labelled metabolites were detected. 
Salicylic and salicyluric acids were not separated and 
constituted the large radiochemical peak at high Rp value. Two 
peaks of low R-p values were evident and correspond to metabolites 
4 and 5 (Table 8.1). A fourth radioactive area was also 
detected; this was diffuse and had an average Rp value of 0.57 
(metabolite X; Table 8.3). It was not detected by either 
detecting reagents I, II, III or Y. In a few experiments this 
peak appeared to consist of two components. The further 
examination of this material is described later.
In Tables 8.2 and 8.3 the recoveries of the doses are given 
and the relative proportions of the metabolites expressed as 




Distribution of radioactivity along n chromatogram developed in solvent B of 24h urine 










dose in 6h 
or 24h sample
Percentage of radioactive components present in urine as
Salicylic acid Salicyluric acid G-entisic acid
(Metabolite 1) (Metabolite 2) (Metabolite 3) Metabolite 4
Rat (1 ) 100 0-24h 7 9 (9 0 ) 6 2 . 7 23.1 1 .8 6 . 02) 100 0-24h 81 (91) 73.1 21 .9 1 .0 6 . 0
(3) 100 0-24h 83 (90) 73.2 12.0 9.0 5.7
(4) 100 0-24h 77 (88) 63-5 1 1 .4 4.8 20.3
Average 68.1 17.1 4.2 9.5
Rat (5) 13 0-6h 55 (93) 65.8 30.4 1 .3 2.5(6) 13 0-6h 54 (79) 54.8 39.7 1 .7 3.8
Average 6 0 . 3 35.1 1 .5 3.2
Marmoset (1)100 0-24h 49 (60) 55.3 25.6 2.1 10.3(2)100 0-24h 22 (46) 5 3 . 6 19.6 1 .2 12.2
(3)100 0-24h 45 (63) 67.3 14.1 nd 18.6
(4)100 0-24h 55 (72) 72.0 7.2 nd 15.1
Average 62.1 16.6 0.8 14.1
Marmoset (5) 13 0-6h 62 (81) 57.1 25.3 nd 14.5
(6) 13 0-6h 62 (68) 88.2 6.7 nd 6.2
(7) 13 0-6h 78 (85) 47.3 28.3 5.0 19.3
Average 64.2 20.1 1 .7 13.3
Metabolite numbers as listed in Table 8.1 
nd - not detected
+Figures in parentheses denote total recovery of dose over 24h (marmoset) and 48h (rat) including 
excretion in faeces as determined by combustion.
Table 8.2 The relative proportions of metabolites excreted expressed as a percentage of the total 
radioactivity in the urine as determined after chromatography in solvent E
Dose Urine Recovery of+ Percentage of radioactive components present in urine as
level sample dose in 6h SA+SU+GA Unidentified (x)
(mg/hg) analysed or 24h sample (Metabolites = 0.57 Metabolite 4 Metabolite 5
1+2+3)
Rat (1) 1 0 0 0-24h 79 (9 0 ) 77.7 15.1 6.1 nd
(2) 100 0-24h 81 92 79.2 1 3 . 6 2.8 4.0
(3) 100 0-24h 83 (90) 72.5 18.2 2.8 6.2
(4) 100 0-24h 77 (88) 78.4 15.8 nd 7.8
Average 77.0 15.7 2.9 4.5
Rat (5) 1 3 0-6h 55 (93) 85.4 17.7 1 .0 0.9
(6) 13 0-6h 54 (79) 79.1 17.8 2.0 1 .2
Average 82.3 17.8 1 .5 1 .1
Marmoset 0 ) 100 0-24h 49 (60) 46.2 34.1 1 1 .9 5.0
(2 ) 100 0-24h 22 (46) 52.8 19.2 7.3 11 .0
(3) 100 0 -2411 45 (63) 76.8 15.0 nd 8.3
(4) 100 0-24h 55 (72) 74.7 14.3 8.6 nd
Average 62.6 20.7 9.3 8.1
Marmoset (5) 13 0-6h 62 (81 ) 59.0 26.3 13.7 1 .0
(6) 13 0-6h 62 (68) 90.8 4.2 5.0 nd
(7) 13 0-6h 78 (85) 57.2 27.1 4.6 nd
Average 6 9 . 0 19.2 7.8 0.3
Metabolite codes as listed in Table 8.1
nd - not detected; SA - Salicylic acid, GA - G-entisic acid, SU - Salicyluric acid
j Figures in parentheses are total recoveries over 24-h (marmoset) and 48h (rat) including faecal excretion 
as determined by combustion.
Table 8,5 The relative proportions of metabolites excreted expressed as a percentage of the total
radioactivity in the urine as determined by chromatography in solvent N
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dosed rats and marmosets as determined in solvent systems B and N.
The results obtained using solvent B indicated that at the 
higher dose level the conversion of salicylic acid to gentisic 
acid occurred to a greater extent in the rat than in the marmoset, 
while the formation of the metabolite of low Rp value, tentatively 
identified as a glucosiduronic acid^was more evident in the 
marmoset. In both species the formation of the metabolite(s) 
with an Up value equivalent to that of salicyluric acid occurred 
to a similar extent at the higher dose level but the relative 
proportion of this metabolite(s) in the urine was greater in 
the rat than in the marmoset after the administration of the dose 
at the lower level. At the lower dose level the average 
excretion of gentisic acid by rats and marmosets were similar.
As with the higher dose level, the formation of the metabolites 
of lower Rp value was more evident in the marmoset than in 
similarly dosed rats.
The quantitative results obtained using solvent N (Table 
8.3) show that the formation of the unidentified metabolite 
mentioned above (metabolite X) was more evident in the marmoset 
than in the rat. The two minor metabolites 4 and 5 (Table 8.1) 
were clearly visible in this solvent.
The effect of incubation with /3 -glucuronidase on the distribution 
of radioactive components in the urine
The distribution of the labelled components in the urine of 
dosed rats and marmosets after treatment with f t -glucuronidase 
type L-I and H-I is given in Table 8 .4 . In solvent B, metabolite 
4 (Table 8,1, 8.2) was little affected by this treatment, whereas 
metabolite 2, initially identified as salicyluric acid was almost 
completely destroyed. In all the digestions carried out, the
Percentage of radioactive components present in urine after j ? -glucuronidase++treatment
Animal Metabolite 1 (E) Metabolite 2 (E) Metabolite 3 (E) Metabolite 4 (B)
Rat (1)+ 75.8 (62.7) 5.3 (23-1) 9.4 (1.8) 7 . 3  (6 .0 )
(6) 88.7 (54.8) nd (39.7) 1.5 (1.7) 9 . 6  (3 .8 )
Marmoset 0 ) 79.0 (55.3) 7.8 (25.6) 1.8 (2.1 ) 9 . 2  (1 0 .3 )
Metabolite 1 00 Metabolite X (N) Metabolite 4 0 0 Metabolite 5 (N)
Rat (1 ) 90.6 (77.7) 4.1 (15.1) 2 . 1  (6 .1 ) nd (nd)
(2) 98.5 (79.2) nd (13.6) 1 . 5  (2 .8 ) nd (4.0)
Marmoset 0 ) 81.1 (46.2) 1 3 . 8  (3 4 .1 ) 3 . 0  (1 1 .9 ) nd (5.0)
+Animal numbers correspond to those in 'Tables 8.2 and 8.3
"^Preparation H-I or L-I
(E) - As determined in solvent E
(N) - As determined in solvent N .
Percentages in parentheses denote the values observed before digestion with Jo -glucuronidase 
nd - Not detected.
Table 8.4 Effect of A -glucuronidase on the metabolite distribution in the urine of dosed rats 
and. marmosets as determined in solvents E and N
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reduction in the labelled components was balanced by an increase 
in salicylic acid, except in the case of one rat, where an 
increase in gentisic acid concentration was observed suggesting 
the presence of a glucuronide conjugate of gentisic acid. These 
results strongly support the previous suggestion that two labelled 
components constituted the peak of radioactivity in solvent E, 
attributed initially to salicyluric acid, and further suggest that 
the second component of this peak was a glucosiduronic acid. A 
sample of authentic salicyluric acid was dissolved in 0.2M sodium 
acetate buffer pH 3*8 and subjected to digestion with f t -glucuron­
idase type L-I at 37°0 for periods of up to 48h. By using the 
GrIO method described previously (p 219) it was shown that such 
treatment did not result in the formation of salicylic acid 
(retention time 12min).
The results in Table 8.4 for solvent N indicated that 
metabolite 5 (Tables 8.1 and 8.3) was a glucosiduronic acid but 
that metabolite 4 which was only partially digested by the 
f t -glucuronidase preparation may have been a sulphate ester which 
was partially hydrolysed by the sulphatase impurities in the . 
f t  -glucuronidase used. No increase in the excretion of sulphate 
esters on the administration of aspirin to rats was detected 
(Table 8.5) but metabolite 4 (Table 8.3) was present in only 
small amounts which the method of Morrison (1973) may not be 
sufficiently sensitive to detect.
The unidentified metabolite X of Rp value 0.57 in solvent N 
(Table 8.3) was broken down significantly by f t  -glucuronidase 
treatment which suggested it was a glucosiduronic acid. After 
mild alkaline hydrolysis of the urine collected from a marmoset 
which had been dosed with acetyl [he] salicylic acid, an analysis 
of the radiochemical distribution along chromatograms developed
Animal Form of sulphate excreted
Sulphat e (mg) 
Control day 1
excreted either free or in conjuged form 
Control day 2 Dosed day 1 Dosed day 2
Rat (1 ) Total 65.0 62.6 55.9 49.3
Inorganic 51 .0 60.8 51 .7 45.7
Ethereal 13.7 1 .8 4.1 3.6
Rat (2) Total 68.1 47.2 65*4 57.5
Inorganic 62.1 48.0 61.3 55.2
Ethereal 6.1 — 4.1 2.3
Rat (3) Total 58.2 60.2 50.8 49.9
Inorganic 52.4 60.3 47.2 45.8
Ethereal 5.7 — 3.6 4.1
- no increase observed.
Table 8.5 Effect of the administration of acetylsalicylic acid (1OOrng/kg body weight)




in solvent N by radiochromatogram scanning and fragmentation 
analysis (p 90) showed that the diffuse peak corresponding to 
metabolite X was entirely destroyed. Metabolite 5 was unaffected 
and the proportion of metabolite 4 was much reduced. It is 
therefore probable that metabolite 5 was salicylphenylglucuronide 
and metabolite X was salicylacylglucuronide. In both species 
studied the proportion of the metabolites excreted in the urine 
that were present as salicylphenylglucuronide increased 
significantly on increasing the dose level from 13 to 100mg/kg 
body weight, whereas the proportion of salicylacylglucuronide was 
unaffected. In no instance did metabolite X give a positive 
reaction with detecting reagent I for glucosiduronic acids.
The chromatographic properties of this metabolite were such that 
the peak of radioactivity observed in solvent N was always 
diffuse, being on average 8cm in length and consequently the 
concentration of the metabolite per unit area of chromatogram may 
well have been too low to give a positive reaction with detecting- 
reagent I .
Figure 8.4 shows a typical radiochromatogram scan when the 
urine from a dosed marmoset was chromatographed on aluminium 
backed thin layer chromatography plates in solvent 0 while Fig
8.5 shows a typical histogram obtained when the radioactivity 
contained in 0.5cm sections of the silica was determined by 
liquid scintillation counting. Only three quenching spots were 
seen on the chromatograms when they were viewed under light of 
wavelength 254nm; they corresponded to salicylic acid, 
salicyluric acid and the glucosiduronic acids (see Table 8.1 and 
Plate 5). Proof of the identity of the glucuronic acid 
conjugates was obtained by digesting the urine with 
f t  -glucuronidase (type H-I) when the quenching spot on the origin
Distribution of radioactivity along an aluminium thin layer
chromatography plate coated with silica gel 60FQ!-/1 and developed
0 ,- n  ̂2 ■
1̂ OJacetylsalicylic acid dosed (13mg/kg body 












Fig 8.5 Distribution of radioactivity along a chromatogram 
of urine from a marmoset dosed with acetyl P4c] salicylic acid.
The chromatographic system employed consisted of an aluminium 
plate pre-coated with a thin layer of silica gel developed
in solvent 0.
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of the plate disappeared. The relative proportions of the 
various urinary metabolites of acetyl N  salicylic acid in rats 
and marmosets as determined by liquid scintillation counting of 
the fragmented chromatograms are given in Table 8.6 (where 
applicable the same animal numbers are used as those in Tables 
8.2 and 8.3)»
All the results, except one, listed in Table 8.6 were 
obtained from analysis of urine collected 6h after dosing. One 
set of results however was obtained by the analysis of the 6-24h 
urine sample and indicates that the excretion of glucosiduronic 
acids was more significant in the period immediately after dosing.
Excretion of unchanged aspirin
Table 8.7 shows the retention times of acetylsalicylic acid 
and its metabolites as determined by co-chromatographic HPLO 
while Table 8.8 contains the percentages of a dose of acetyl­
salicylic acid that were excreted unchanged in the urine of 
marmosets and man as determined by the HPLO method. The results 
show that at a dose level of approximately 13mg/kg body weight, 
the percentage of the administered dose that was excreted 
unchanged was similar in both man and marmoset and that in general 
the main urinary excretion of this compound occurred within 1.5h 
of dosing. The results obtained for the marmoset at different 
dose levels of acetylsalicylic acid indicate that a greater 
proportion of the dose was excreted unchanged at the higher dose 
level.
Blood levels of acetyl [14c] salicylic acid and its metabolites
Figure 8.6 shows the variation with time in the level of 











in urine present as 
G-lucosiduronic acids
Rat (5) 0-6h 55 (93) 56.9 23.4 18.8
(6) 0-6h 54 (79) 43.3 29.1 25.4
(7) 0-6h 52 (95) 81 .9 5.4 12.5
(8) 0-6h 61 (97) 73.6 12.3 13.6
Average 63-9 17.6 17.6
Marmoset (5) 0 - 6 h 62 (81 ) 30.8 16.2 51 .5
(6) 0-6h 62 (68) 64*6 2.5 32.6
(6) 6-24h 3 74.6 1 .9 23.4
(7) 0-6h 78 (85) 60.7 11 .3 28.0
Average 52.0 10.0 37.4
'^Figures in parentheses are total recoveries over 24h (marmoset) and 48h (rat) including the faecal 
excretion as determined by combustion.
T able  8 .6  The r e l a t i v e  p r o p o r t i o n s  o f  m e t a b o l i t e s  e x c r e te d  e x p re s s e d  a s  a p e r c e n ta g e  o f  t h e  t o t a l  
r a d i o a c t i v i t y  i n  th e  u r i n e  a s  d e te rm in e d  by ch rom atography  on alum in ium  backed  t h i n  
l a y e r  f l u o r e s c e n t  ch rom atography  p l a t e s  developed, i n  s o lv e n t  0 .
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Table 6.7 Retention times of metabolites of acetylsalicylic




Percentage acetylsalicylic acid 
excreted unchanged in urine 
sample listed
1 . 5h 5.Oh 4.5h
Marmoset F 15.0 tr 0 0
M 15.0 1 .1 tr 0
M 77.0 5.4 1 .2 0
Human F 7.0 2.1 nd nd
F 15.0 1 .4 0.2 0
M 15.0 0.5 0.7 0.2
F 16.0 5.4 CM•o 0
Human4* M 12.0 0-2.6 0 nd
M - Male F - Female
tr - trace nd - not determined
+Results obtained by Cummings and King (1966) using six male 
subjects.









Time pfter administration (h)
.6 Variation in the blood level of radioactive components with time, in two marmosets 
following the administration of acetyl [1 ̂ c] salicylic acid ( 13mg/kg body weight).
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after the administration of acetyl L14cJ salicylic acid. In both 
experiments the first blood sample was taken after the peak in 
the level of the radioactive components in the blood had 
occurred and indicate that a rapid absorption of the dose from 
the gastrointestinal tract occurred in the marmoset.
Examination of the autoradiographs prepared from the 
chromatograms of the blood samples taken from marmosets at 1.Oh, 
2.29iand 5.5h after the administration of the dose revealed the 




The metabolic products excreted in the urine after the 
administration of acetylsalicylic acid are similar in the marmoset 
and rat. There are however variations in the relative 
proportions of the different metabolites excreted; glucosiduronic 
acid formation occurs to a greater extent in the marmoset than in 
the rat while the reverse appears to be true for glycine 
conjugation at the lower dose level. The proportion of 
administered acetylsalicylic acid that is excreted as salicyluric 
acid is variable in both species studied. A similar situation 
has already been reported for the marmoset, but not the rat, 
using benzoic acid as the dose (Chapter 3)* It is interesting 
that the marmoset which excreted very little of the administered 
aspirin as salicyluric acid (M6) was the animal which excreted 
only 8.2% of the total metabolites of a 100mg/kg body weight dose 
of benzoate as hippuric acid (Chapter 3)* Over the 24h period 
after the administration of acetylsalicylic acid the quantity of 
glycine utilized by this animal for the synthesis of salicyluric 
acid was only 0.1mg/kg body weight. In a similar time period 
this animal when challenged with a 100mg/kg body weight dose of 
0 ̂ q]benzoate utilized 3»9mg of glycine/kg body weight in the 
synthesis of hippuric acid which suggests that the low proportion 
of administered acetyl [14c| salicylic acid excreted conjugated 
with glycine is probably due to some factor other than a 
deficiency in the supply of glycine available for conjugation.
Both the rat and marmoset excrete administered acetylsalicylic 
acid as salicylacyl and salicylphenyl glucuronides. In both 
species salicylacylglucuronide constitutes the major x^oportion 
of the total glucosiduronic acids excreted. The proportion of 
the total metabolites accounted for by this component appears not
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to vary with the dose level employed although the proportion of 
salicylphenylglucuronide excreted in the urine appears to be 
slightly dose dependent. Alpen et al. (1951) reported that in 
the dog salicylphenylglucuronide was the only glucosiduronic acid 
formed from administered salicylate while the excretion of 
administered salicylate as salicylphenylglucuronide has been 
shown to be more important than salicylacylglucuronide in the 
rabbit (Bray et al., 1948b) and in man (Levy et al., 1972).
The present results suggest that in the rat and marmoset more 
acyl than phenyl glucuronide is formed, emphasising the high 
ability of the marmoset to form ester glucosiduronic acids.
Both the rat and marmoset excreted a minor metabolite 
tentatively identified as a sulphate ester. The concentration 
of this metabolite in the urine was low and no increase in the 
excretion of sulphate esters after the administration of 
unlabelled acetylsalicylic acid to the rat was found; no ester 
sulphate formation was reported for the rabbit (Bray et al.,
1948b) which had been dosed with salicylic acid.
The only other minor metabolite detected in the urine of 
rats and marmosets which had been dosed with acetyl K ]  salicylic 
acid was gentisic acid. In the marmoset this metabolite 
appeared to be excreted unconjugated while in the rat evidence 
was obtained that some conjugation of gentisic acid with 
glucuronic acid occurred. In the marmoset the proportion of 
the administered dose that was excreted as gentisic acid was 
only small; similar results have been reported for man (Alpen 
et al., 1951; Levy et al., 1972). Sodium gentisate, on 
administration to man, is excreted unchanged and not conjugated 
with any endogenous molecule (Roseman and Dorfman, 1951).
After the administration of acetylsalicylic acid at a dose
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level of 43nig/kg body weight to man, Levy et al. (1972) reported 
that salicyluric acid accounted for 5 0 %  of the metabolites 
excreted which is considerably higher than that found in the 
present study for the metabolic fate of acetyl K ]  salicylic acid 
in rats and marmosets at dose levels of either 13 or 100mg/kg 
body weight. Furthermore the proportions of metabolites 
excreted that were accounted for as salicyluric acid after the 
administration of acetyl [14a] salicylic acid to the rat and 
marmoset did not appear to be significantly affected by the dose 
level and clearly the availability of glycine was not the 
limiting factor in the synthesis of salicyluric acid. ■ Davison 
(1971) reported that glycine administration in man did not modify 
salicyluric acid excretion after the administration of salicylic 
acid, but did cause an increase in hippurate formation following 
benzoate administration. The limitation was not in the supply 
of glycine but in another factor. It was suggested by this 
author that different enzymes may be operative in the synthesis 
of hippurate and salicylurate, or that the affinities of the two 
substrates for the conjugating enzyme may vary markedly. A 
low excretion of salicyluric acid has also been reported for the 
rabbit (Bray et al., 1948b) following the administration of 
salicylic acid. The results indicate that the formation of 
salicyluric acid from administered salicylate may be a more 
important biotransformation reaction in man than in either New 
World primates or non-primate species.
The pH of the marmoset urine both before and after the 
administration of sodium acetylsalicylate at a dose level 
100mg acetylsalicylate/kg body weight or as the free acid at a 
level of 1 3mg/kg body weight varied between 6.9 and 7.1« This 
is higher than the average pH of human urine (6.0) and may
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explain to some extent why the proportions of the administered 
dose of aspirin excreted as salicylic acid is higher in the 
marmoset than in man (see Hoffmann and Kobe, 1950).
The proportion of a 13mg/kg body weight dose of acetylsalicylic 
acid that is excreted unchanged within a short period after dosing 
is similar in the marmoset and man. The results obtained for 
man in the present study indicate that female subjects excrete 
a higher proportion of the administered acetylsalicylic acid 
unchanged than do males which may possibly be correlated with 
the reported lower levels of plasma aspirin esterase found in 
females as compared with males (Menguy et al., 1972).
In the marmoset, peak plasma levels of radioactivity are 
attained, within one hour of the oral administration of acetyl
salicylic acid (13mg/kg body weight). Peak plasma levels 
of both unchanged acetylsalicylic acid and salicylate have been 
found to occur within 40min of the administration of acetyl­
salicylic acid (0.65g) to human subjects (Rowland et al., 1967). 
Leonard (1962) obtained similar results when the dose was 
administered as its sodium salt, but this author also showed that 
when the dose was administered- as the free acid the peak level 
of total plasma salicylate was not reached within a period of 
one hour after the dose was given. The administration of 
acetylsalicylic acid as its sodium salt had previously been shown 
to increase its rate of absorption from the human gut as determined 
by the time taken for peak plasma levels of salicylate to be 
reached (Lester _et al., 1946). In the present study the dose 
was administered as the free acid to the marmoset, and at a dose 
level which was higher than that used by either Leonard (1962) 
or Rowland et al. (1967) suggesting that the short time taken to 
reach peak plasma levels in the marmoset indicates a rapid rate
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of absorption of acetylsalicylic acid from the gut. That the 
peak plasma levels of radioactivity attained in the marmoset are 
not maintained for any length of time indicates a rapid rate of 
metabolism of a„spirin in this species.
CHAPTER 9
The comparative metabolism of quinic acid
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Chapter, 9 - The comparative metabolism of quinic acid 
Introduction
The increased excretion of hippuric acid by man after the 
ingestion of quinic acid (1,3,4,5-tetrahydroxycyclohexanecarboxylic 
acid; I), a compound occurring in tea, coffee, fruits and 
vegetables was first reported by Lautemann (1863). This early
observation has since been confirmed by several authors (Quick, 
1931; Beer et al., 1951; Bernhard et al., 1955; Gotran et al., 
1960; Adamson et al., 1970b).
Beer et al. (1951) reported that little or no aromatization 
of orally administered quinic acid occurred in rabbits and rats 
and that subcutaneously administered quinic acid was not 
aromatized by the cat or guinea pig. Bernhard et al. (1955) 
and Ootran et al. (I960) however, found that a substantial 
proportion of orally administered quinic acid was aromatized in 
the guinea pig which suggested a possible role of the gut flora 
in the aromatization process.
A comprehensive study of the aromatization of quinic acid 
in various animal species, including man, was reported by 
Adamson et al. (1970b). These authors found that orally 
administered quinic acid was extensively aromatized (20-70% of 
the dose) in man, rhesus monkey, baboon and green monkey but that
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little aromatization occurred (0-11% of the dose) in the squirrel, 
spider and capuchin monkeys, bush baby, slow loris and treeshrew. 
In the dog, cat, ferret, rabbit, rat, mouse, guinea pig, hamster, 
lemming, fruit bat, hedgehog and pigeon oral quinic acid was not 
significantly aromatized (0-5% of the dose). Further studies 
showed that injected quinic acid was not converted to hippuric 
acid by the rhesus monkey but was largely excreted unchanged; 
pre-treatment with neomycin to suppress the gut flora consider­
ably suppressed the aromatization of oral quinic acid (Adamson 
et al., 1970b). These results clearly indicated that an 
essential step in the aromatization of quinic acid was effected 
by the gut flora of man and Old World monkeys, but not by the 
gut flora of hew World monkeys, Prosimians and non-primate 
species. Furthermore, the same authors demonstrated that orally 
administered shikimic acid (trihydroxycyclohex-1-enecarboxylic 
acid) was metabolised to hippuric acid by the rhesus monkey but 
not by the rat.
The results reported by Adamson et al. (1970b) for the 
degree of aromatization of quinic acid by the rat do not agree 
with those previously reported by Asatoor (1965) who found that 
orally administered quinic acid was aromatized by the rat, but 
as with the results obtained by Adamson et al. (1970b) using 
the rhesus monkey, the aromatization was suppressed in neomycin 
pre-treated animals.
The mechanism by which orally administered quinic acid is 
converted to hippuric acid has been the subject of many 
investigations. Davis and Weiss (1955) showed that coliform 
bacteria could aromatize quinic acid, whereas Mitoma et, al. (1958) 
found no aromatization of quinic acid by human or guinea pig 
liver homogenates. These authors also found that guinea pig
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liver homogenates were capable of carrying out the aromatization 
of cyclohexanecarboxylic acid. These results suggested that 
either administered quinic acid was aromatized to benzoic acid 
by the gut flora and then conjugated with glycine in the liver 
to form hippuric acid, or that the formation of benzoic acid 
occurred by the aromatization of cyclohexanecarboxylic acid in 
the liver. Some support for the former theory came from work 
by Asatoor (1965) and Indahl and Scheline (1975) which showed 
that the incubation of quinic acid with rat gastrointestinal 
micro-organisms resulted in the formation of benzoic acid under 
both aerobic and anaerobic conditions.
Early work on the metabolism of cyclohexanecarboxylic acid 
(Beer et al., 1951; Bubior and Bloch, 1966) showed that this 
compound was aromatized by mammalian species and more recent 
reports have shown that hippuric acid is a major metabolite of 
cyclohexanecarboxylic acid in the rat. Brewster ejfc al. (1977a) 
demonstrated that intraduodenally administered sodium cyclo­
hexyl carboxylate was metabolised to hippurate, hexahydrohippurate, 
5,4,5,6-tetrahydrohippurate and benzoyl and cyclohexylcarbonyl 
/?-glucuronides in the rat, while using a liver perfusion 
technique Brewster et al. (1977b) were able to show that the 
formation of the various hippuric acids occurred in the liver 
of this species.
The observation that the oral administration of shikimate 
to the rhesus monkey resulted in the increased excretion of 
hippuric acid (Adamson et al., 1970b) suggested that shikimic 
acid may lie on the pathway of the conversion of quinic acid to 
hippuric acid. Brewster et al. (1976) investigated the metabolic 
fate of shikimic acid in the rat and showed that cyclohexane­
carboxylic acid was the major product following the anaerobic
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metabolism of shikimic acid by rat gastrointestinal micro­
organisms. Furthermore the observation that the metabolism of 
shikimate in the rat was suppressed by pre-treatment with neomycin 
and that shikimic acid was not metabolised by animal tissues 
(Brewster et al., 1578) suggested that the conversion of shikimic 
acid to cyclohexanecarboxylic acid by the gut flora was an 
important step in the overall metabolism of shikimic acid and 
closely related quinic acids. Brewster et al. (1978) have shown 
that the metabolites of shikimic acid excreted by the rat are the 
same as those excreted after the administration of cyclohexane­
carboxylic acid (Brewster et al., 1977a) further implicating the 
role of cyclohexanecarboxylic acid as an intermediate in the 
metabolism of shikimic acid.
Based on the evidence so far accumulated a series of bio­
transformations can be postulated for the conversion of orally 
administered quinic acid to hippuric acid involving an initial 
reduction (possibly via shikimate) to cyclohexanecarboxylic acid 
by the gastrointestinal micro-organisms and the aromatization of 
this intermediate to benzoic acid in the liver (Fig 9*1)* The 
formation of hexahydrohippurate and 3>4,5,6-tetrahydrohippurate 
either after the intraduodenal administration of cyclohexane­
carboxylic acid or during perfusion of the liver with this 
compound (Brewster et al.t 1977a,b) suggests that the various 
co-enzyme A intermediates involved in the hepatic aromatization 
of cyclohexanecarboxylic acid are able to undergo conjugation 
with glycine, a reaction which prevents any further aromatization 
of the ring system.
In this chapter an investigation of the ability of adult 
marmosets to convert orally administered quinic acid and sodium 
cyclohexylcarboxylate to hippuric acid is described.
Key: I Quiñic acid
II = Shikimic acid 
III = Dihydroshikimic acid 
17 = Oyclohexanecarboxylic acid
7 = Hexahydrohippuric acid
71 = 3,4,5,6-tetrahydrohippuric acid
711 = Hippuric acid
Metabolites 7 —^711 are excreted in the urine
Fig 9.1 Postulated pathway for the conversion of
orally administered quinic acid to 







Quinic acid was purchased from Sigma Chemical Co. Ltd., 
Surrey. Cyclohexanecarboxylic acid was obtained from Aldrich 
Chemical Co. Ltd., Gillingham, Kent and was redistilled twice 
before use. The acid (l.28g) was converted to its sodium salt 
by solution in 2M NaOH (5ml).
All other chemicals used in this study were freely available 
from the laboratory stores.
Methods
Administration of corn-pounds
Quinic acid was administered orally to marmosets at a dose 
level of 300mg/kg body weight as a suspension in diluted Cytacon.
Sodium cyclohexylcarboxylate was administered to marmosets 
at a dose level equivalent to 130mg free acid/kg body weight as 
a solution in diluted Cytacon.
Collection of urine
After the administration of Cytacon only, a 24h normal urine 
sample was collected from every animal used in the course of this 
study. After this, period the animals were removed from the all­
glass metabolism cages and allowed 24h to recover before being 
dosed with the test compound. Urine was then collected for a 
further 24h period.
Concentration of urine samples
The 24h urine samples were lyophilized and the residue 
extracted with a known volume of methanol (5-10ml). The extracts
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were then centrifuged using stoppered tubes and the hippuric acid 
content of the supernatant determined as outlined below.
Estimation of hipouric acid
Using an Agla syringe duplicate volumes of the methanolic 
extracts were applied to a large (46cm wide) sheet of chromato­
graphy paper. Duplicate aliquots of a standard methanolic 
solution of hippuric acid (2mg/ml) were also applied to the 
paper to provide a calibration curve over the range 20-80>ig 
hippuric acid. The chromatogram was developed in solvent E by 
the descending technique and the hippuric acid located using 
detecting reagent VII. The bright orange spots corresponding 
to hippuric acid were cut out and eluted with methanol (4ml) for 
15min in stoppered tubes in the dark. The optical density of 
each eluate was measured at 460nm using a Unicam SP1800 spectro­
photometer and the quantity of hippuric acid in the urinary 
extracts determined from the calibration curve.
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Results
The results in Table 9«1 show the quantity of hippuric acid 
excreted by four marmosets following the administration of 
quinic acid. Only two of the animals studied showed any 
increased excretion of hippuric acid when quinic acid was 
administered, and in both cases the observed increase was small.
Table 9*2 shows the effect of the administration of sodium 
cyclohexylcarboxylate upon hippuric acid excretion in the 
marmoset. It may be seen that two of the four animals studied 
converted a substantial proportion of the administered dose to 
hippuric acid while with the other two animals no increased 
hippuric acid output was observed.
Marmoset
Hippuric acid
After administration of 
dosing vehicle only
excretion (rng/day)
After administration of 
quinic acid (100mg)
Degree of aromatization 
of dose administered)
689 4.4 6 • 1 1 .8
532 4 • 6 8.4 4.1
690 3.2 3.0 0.0
582 4.3 3.5 0.0
Table 9.1 Effect of the administration of quinic acid on the urinary hippuric acid-
excretion in adult marmosets
Marmoset
Hippuric acid
After administration of 
dosing vehicle only
excretion (mg/day)
After administration of 
sodium cyclohexylcarboxylate 
(equivalent to 43mg free acid)
Degree of aromatization 
(fo of dose administered)
462 3.9 1 .0 0.0
764 4.3 30.8 44.1
765 2.9 1 .2 0.0
784 8.8 46.3 62.4
Table 9.2 Effect of the administration of sodium cyclohexylcarboxylate on the urinary
hippuric acid excretion in adult marmosets
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Discussion
The low capacity of the marmoset to aromatize orally- 
administered quinic acid is a characteristic of New World monkeys 
and in this respect this species fits into the general taxonomic 
trend reported by Adamson et al. (1970b).
The conversion of sodium cyclohexylcarboxylate to hippuric 
acid has been demonstrated in two marmosets although two other 
marmosets did not carry out this process. This was a 
surprising result since in all the studies the experimental 
conditions were kept constant. Unfortunately it was not 
possible to carry out further work using marmosets at this time 
and so the indication obtained that the marmoset shares with 
other animal species the ability to aromatize cyclohexanecarboxylic 
acid could not be confirmed.
CHAPTER 10
Mercapturic acid formation in the marmoset
258
Chapter 10 - Mercapturic acid formation in the marmoset 
Introduction
The formation of meroapturic acids in the marmoset has not 
been reported and it was of interest to establish to what extent 
this pathway of xenobiotic metabolism occurred in this species.
Mercapturic acid formation is initially a Phase II reaction 
involving the conjugation of a xenobiotic with glutathione to 
give an S-substituted glutathione derivative. The two terminal 
amino acids are then successively removed from the conjugate, 
firstly glutamic acid and then glycine, the reactions being 
catalysed by the enzymes ^-glutamyltranspeptidase and 
cysteinylglycinase respectively. The conjugate remaining, an 
S-substituted cysteine, then undergoes N-acetylation to yield 
the mercapturic acid.
The S-substituted cysteines may be metabolised with the 
formation of products other than mercapturic acids. The possible 
reactions were summarised by James and Needham (1975) in an 
investigation of the metabolism of S-pentylcysteine. The main 
reactions in addition to acetylation involved oxidative 
deamination with the formation of S-pentylthiolactic and 
S-pentylthiopyruvic acids. With this particular substituted 
cysteine hydroxylation of the pentyl residue may occur although 
this is more evident in the metabolism of 1-bromopentane the 
precursor of pentylcysteine (Grasse and James, 1972) and the 
terminal methyl group may be oxidised to a carboxylic acid group 
(James and Needham, 1973)» Mercapturic acids may also be 
excreted as the corresponding sulphoxides.
The initial reaction with glutathione may often be detected 
by a decrease in the level of hepatic glutathione (Barnes ,et al.
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1959). Thus the administration of methyl iodide to the rat 
leads to a marked decrease in hepatic glutathione and a high 
proportion of the dose is converted to the S-methylglutathione 
derivative which is excreted in the bile (Johnson, 1966). 
Reabsorption occurs and methylcysteine is eventually formed.
This compound undergoes several biotransformations and the amount 
of methylmercapturic acid excreted represents less than 0.5f° 
of the dose (Barnsley and Young, 1965). Thus the excretion of 
even small amounts of mercapturic acid may indicate that a 
considerable proportion of the dose has entered the glutathione 
detoxication pathway.
Considerable species differences exist in the extent of 
mercapturic acid formation. Thus in the rat large proportions 
of doses of different precursors are excreted as mercapturic 
acids (Bray at al., 1958). In the rabbit a considerable 
proportion of the dose of some precursors is represented by 
deaminated products of the substituted cysteine the amount of 
mercapturic acid excreted being correspondingly less (James and 
Needham, 1975). The guinea pig is notable for its apparent 
inability to excrete more than a small proportion (usually less 
than 10fo of the dose) of known mercapturic acid precursors as 
mercapturic acids (see p 52). This has been attributed to a 
poor ability to acetylate the S-substituted cysteines but it seems 
likely that this is not the whole explanation as recent work 
using benzyl chloride in this laboratory (James S.P. unpublished 
results) has shown that the small amounts of benzylmercapturie 
acid excreted are accompanied by larger amounts of the correspond­
ing sulphoxide.
Mercapturic acid formation is considered to be of relatively 
little importance in man (e.g. Dutton, 1978)» investigations
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have been carried out in man possibly due to the toxic properties 
of many mercapturic acid precursors. However the protective 
role of glutathione in the prevention of hepatic necrosis 
following the administration of phenacetin and paracetamol has 
already been discussed (p 42). Wainer and Lorincz (1963) 
reported that mercapturic acid formation from orally administered 
bromobenzene was very low in infants while French et al. 
(unpublished observations: see Smith and Williams, 1974) have 
reported that 19f° of administered chlorobenzene was excreted as 
p-chlorophenylmercapturic acid by human subjects.
Considerable interest in the ’glutathione pathway' arises 
from the finding that some environmental hydrocarbons are 
metabolised to epoxides which may be converted to diols by the 
action of epoxide hydrase or conjugated with glutathione in a 
reaction catalysed by glutathione-S-epoxide transferase (Boyland 
and Williams, 1965)«
This chapter describes an investigation of the formation 
of mercapturic acids by marmosets dosed with K ]  benzyl chloride 
or 1,2-epoxybutane and of the acetylation of S-pentylcysteine.
The metabolic fate of 0 benzyl chloride was also studied in 
the rat for comparison with the marmoset.
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Materials and Methods 
Materials
[ t i ethy 1  ene-^cj benzyl chloride (500^i0i; 87^iCi/mg) was 
purchased from the Radiochemical Centre Ltd. end diluted with 
unlabelled benzyl chloride (ig) at 0°C. The specific activity 
of the diluted material was 0.79>iCi/ing. S-Benzyl-L-cysteine 
(benzylcysteine), H-acetyl-S-benzylcysteine (benzylmercapturic 
acid) and M-acetyl-S-benzylcysteine sulphoxide (benzylmercapturic 
acid sulphoxide) were all available in the laboratory.
1,2-Epoxybutane was purchased from Eluorochem ltd., G-lossop, 
Derbyshire. N-Acetyl-S-L2-hydroxybutyl]-L-cysteine (2- 
hydroxybutylmercapturic acid), di cyclohexyl amine salt was 
available in the laboratory. It had been synthesised by the 
method described by James and White (1967) for the preparation of 
N-acetyl-S- p-hydroxyphenethyl-L-cysteine.
S-Pentyl-L-cysteine (pentylcysteine), E-acetyl-S-pentyl-L- 
cysteine (pentylmercapturic acid) .and N-acetyl-S-pentyl-L-cysteine 




[14c]Benzyl chloride was administered to rats and marmosets 
at a dose level of 30mg/kg body weight. The rats were given 
the dose mixed with Cytacon by the method previously described 
(p 81 ). The pungent smell of this compound led to dosing 
difficulties with the marmoset and as a result the usual dosing- 
technique was modified. The method found most successful was 
carried out by allowing the marmoset to drink diluted Cytacon
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from a syringe as previously described (p 81) and then injecting 
the dose to the rear of the throat using a Pasteur pipette.
The quantity of M  benzyl chloride remaining in the pipette 
was estimated by liquid scintillation counting.
1,2-Epoxybutane was administered to marmosets at a dose 
level of 100mg/kg body weight by the method described above for
[14o]benzyl chloride. In this case the residual dose was not 
determined.
Pentylcysteine was administered to marmosets at a dose level 
of 115mg/kg body weight as a suspension in Gytacon.
Collection of urine samples
Urine samples were collected at 24 and 48h after the doses 
were given. Ho normal sulphur-containing metabolites correspond­
ing to the metabolites of the doses were present in control urine 
samples.
Chromatography
Paper chromatography was carried out by the descending 
technique in solvents E and P. In the studies of the metabolism 
of [^cjbenzyl chloride and the acetylation of pentylcysteine, 
chromatograms were developed in solvents E and P for periods of 
12 and 24-30h respectively. In the investigations with
1,2-epoxybutane, chromatograms were developed in solvent E for 10h.
Quantitative methods 
Recovery of dose
The quantity of radioactive components excreted in the urine 
of animals dosed with D M  benzyl chloride was determined by- 
liquid scintillation counting (p 89)« The radiochemical content
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of freeze dried faecal samples was determined by the combustion 
method (p 90).
Quantification of metabolites
The relative proportions of labelled metabolites excreted 
in the urine of animals dosed with benzyl chloride were
determined by liquid scintillation counting following chromato­
graphy in solvents E and P (p 90). The chromatograms were cut 
up into strips of width 0.5cm starting 1.0cm below the origin and 
proceeding to the end of the chromatogram.
Determination of unlabelled mercapturic acids b.v planimetry
The percentages of doses of 1,2-epoxybutane and pentylcysteine 
excreted as the corresponding mercapturic acids were estimated 
by the method of planimetry (Bray et al., 1964) after separation 
by paper chromatography. Calibration curves were constructed 
using the appropriate mercapturic acid. Aliquots of the standard 
solutions (the dicyclohexylamine salt of 2-hydroxybutylrnercapturic 
acid or pentylmercapturic acid) were applied to the chromatograms 
and suitable quantities of urine from a marmoset which had been 
dosed with Cytacon only were then applied to the spots of the 
reference compounds. The chromatograms were developed in either 
solvent E or P and the areas corresponding to the mercapturic acid 
visualised with the chloroplatinate reagent, detecting reagent 
IX. The areas of the spots were measured with a planimeter and 
the concentration of the mercapturic acid in the urine sample 
determined by comparison with the standard curve.
Determination of -pentylcysteine
The method used was described by G-rasse (1971) and was based
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upon the method of Suga et al. (1967). After the administration 
of pentylcysteine to the marmoset, the residual dose was 
estimated by transferring the contents of the syringe and specimen 
tube into which the dose was weighed, to a volumetric flask (5ml 
capacity) using aqueous ammonia (10% v/v) and the contents diluted 
to the mark. Aliquots of this solution were then applied to a 
thin layer silica gel G- plate (p 85). A standard curve was 
prepared ranging from 25-IOOp.g of pentylcysteine by the 
application of aliquots of a solution of pentylcysteine (5mg/ml) 
in aqueous ammonia (10̂ > v/v). After developing in solvent 1 the 
chromatogram was sprayed with a solution of 0.5% ninhydrin in 
acetone/butan-1-ol (1:1 v/v). After heating at 1 20°C for 5mln 
the areas corresponding to pentylcysteine were scraped off the 
plate and transferred to stoppered test tubes each containing 
cupric sulphate (8mg). Aqueous ethanol (80^ v/v; 4ml) -was then 
added and after mixing, the tubes were left to extract in the 
dark for 30min. The absorbance of the extract was determined 
at 540nm using a Unicam SP1800 spectrophotometer, and the 
amount of pentylcysteine in the unknown solutions determined 




The R-p values obtained for the urinary metabolites of
benzyl chloride, together with those of reference compounds 
as determined by their reactions with different detecting 
reagents, are given in Table 10.1. With those chromatograms 
developed in solvent P, no solvent front remained on the paper 
and so all Rp values were calculated relative to benzy liner cap turic 
acid which was taken as 1.0. The presence of benzylcysteine 
and benzylmercapturic acid sulphoxide in the urine of dosed 
animals could only be determined following co-chromatography with 
authentic samples and radiochromatogram scanning since their 
concentration in the urine appeared to be too low for detection 
by the detecting reagents used. Solvent S failed to resolve 
hippuric acid and benzylmercapturic acid sulphoxide and did not 
give an absolute resolution of benzylcysteine and benzylmercapturic 
acid in many instances. For this reason solvent P was used for 
the majority of the quantitative estimations carried out.
Figure 10.1 shows a typical histogram obtained when the radio­
activity contained in 0.5cm sections of paper chromatograms 
developed in solvent P was determined by liquid scintillation 
counting.
Tables 10.2 and 10.5 show the percentages of the metabolites
of N benzyl chloride present in the urine of dosed rats and 
marmosets as determined in solvents E and P respectively. Table
10.5 also indicates the percentage of the administered dose 
which was recovered in the urine of rats and marmosets during 
the first 24h period after dosing. Very little of the dose 
(less than 1 fo) was recovered from either species in the second 
24-h period or in the faeces. Figures 10.1 and 10.2 show typical 
histograms from which the figures in Tables 10.2 and 10.5 were
Rp value in solvent Reaction with detecting reagent listed
Compound E jlL VII IX XI
Reference compounds
Benzylmercapturic acid 0.65 1 .0 - pale spot yellow -
Benzylcysteine 0.55 0.71 - pale spot pale cream blue/grey
Benzylmercapturic acid 
sulphoxide 0.45 0.23 - yellowa nd -
Hippuric acid 0.50 0.31 orange — — —
Urinary metabolites
Benzylmercapturic acid 0.66 1 .0 - pale spot yellow -
Benzylcysteine^ 0.53 0.65 - pale spot pale cream blue/grey
Benzylmercapturic acid , 
sulphoxide0 0.40 0.24 - yellowa nd -
Hippuric acid 0.47 0.30 orange — — —
+Rate of movement of spots relative to that of mercapturic acid which is taken as 1.0
Q'Developed colour after 6h
identified in urine by co-chromatography with unlabelled reference compound and radiochromatogram 
scanning
nd - not detected.
Table 10.1 Chromatographic properties of reference compounds and urinary metabolites of
H, benzyl chloride
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ir A.HC - len^ylrnercapturic e.cid sulphoxide
Animal
Recovery of dose 




Radioactivity of metabolites expressed as a percentage of the total 
radioactive components present
Benzylmercapturic Benzylcysteine Hippuric acid + Unidentified 
acid Benzylmercapturic (R-, = 0.35)
acid sulphoxide L
71.4 nd 27.8 0.8
68.4 nd 30.4 0.2
nd - not detected
Table 10.2 Relative proportions of the radioactive metabolites present 
in 24h urine excreted by rats dosed with K ]  benzyl chloride
as determined in solvent E
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R at+ 1 72 45.4 nd2 82 55.1 nd
Average 77 48.5 nd
Marmoset
Wo 652 52 36.3 tr
689 71 35.6 nd
690 52 25.4 0.8
784 48 55.7 tr
Average 56 55.5 0.2
same number code used as in Table 10.2 
tr - trace 
nd - not detected
BMASO - Benzylmercapturic acid sulphoxide









68.6 1 .2 25-5 5.7 1 .2
64.7 1 .2 24.5 5.4 1 .1
66.7 1 .2 25-9 5.6 1 .2
69.9 7.6 nd 16.2 6 • 4
50.2 5.5 24.4 12.4 1 .2
48.9 50.5 nd 10.5 2.8
74.4 9.8 4.8 9.1 1 .9
60.9 15.5 7.5 12.1 5.1
(V)Ch
VX)
Table 10.3 The relative proportions of radioactive metabolites present in 24b urine excreted by
animals dosed with [¡^OJbenzyl chloride as determined in solvent P
n rat dosed with methylene . P^c] benzyl chloride.
BKASO = Benzylmercnpturic acid sulphoxide
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obtained. A labelled metabolite having an value of 1.2 
relative to benzylmercapturic acid, was detected in the urine of 
one marmoset which had been dosed with K ]  benzyl chloride.
This metabolite was not detected by any of the detecting agents 
listed in Table 8.1 and was probably a deaminated product since 
such metabolites of benzylcysteine have been described (Shen and 
Lewis, 1946) and it was found that S-substituted thiolactic and 
thiopyruvic acids ran faster than the corresponding mercapturic 
acid in this chromatographic system (James and Needham, 1973)«
The Rp values obtained for hippuric acid and benzylmercapturic 
acid sulphoxide excreted in the urine of the two rats studied, as 
determined in solvent P, did not correspond exactly with those 
listed in Table 10.1 although the Rp values relative to each 
other were similar to those for the reference compounds. The 
total proportion of the metabolites excreted accounted for by 
these two metabolites as determined in solvent P3 corresponded to 
the figure obtained for the combined proportion of hippuric acid 
and benzylmercapturic acid sulphoxide as determined in solvent E 
(Table 10.2) thus confirming their identification.
A similar situation occurred when samples of urine from 
„ ™ , , t 8 „0 , 652 »»a 690, which had received K ] b e » e y l  ehlerxde. 
were chromatographed in solvent P except that in these cases only 
one of these two metabolites was detected by radiochemical 
techniques. The Rp value of this metabolite was similar to that 
of benzylmercapturic acid sulphoxide observed in the rat urine 
indicating that these two marmosets were excreting benzyl­
mercapturic acid sulphoxide and not hippuric acid. Two 
dimensional paper co-chromatography using solvent P in the first 
dimension and solvent E in the second, followed by radiochromato­
gram scanning, failed to detect labelled hippuric acid in the
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urine. Determination of the 24h excretion of hippuric acid by 
marmoset No. 652 before and after the administration of
hippurate occurred. Furthermore, when a sample of the urine of 
the dosed animal was heated with HC1 (final concentration 6M) 
under reflux for oh, subsequent extraction of the hydrolysate 
with ether and evaporation of the extract at room temperature and 
atmospheric pressure gave a residue which was not radioactive. 
Under these conditions any labelled benzoic acid formed from 
labelled hippuric acid should have been present in the extract. 
The residue from the ethereal extract and a sample of the aqueous 
solution were both examined by chromatography in solvent P. The 
aqueous solution contained increased amounts of benzylcysteine 
which was not extracted from the strongly acidic solution.
The results in Table 10.2 indicate the presence of a minor 
metabolite in the urine of dosed rats which had an R™ value of 
0.55. This metabolite was tentatively identified as benzyl- 
glucuronide by comparison with a sample of benzylglucuronide 
which had been isolated, by chromatography, from the urine of
level of 100mg/kg body weight (Baines et al., 1978). An 
unidentified metabolite of low R™ value in solvent P was alsoi!
detected in the urine of both rats and marmosets which had been
The amount of 2-hydroxybutylmercapturic acid excreted by 
each of two marmosets which had been dosed with 1,2-epoxybutane 
represented 1.1 io of the dose. The results are minimum values 
since not all the dose was received by the marmosets, but the
volatility of 1,2-epoxybutane (b.pt 65°0) will probably result in
benzyl chloride showed that no increased excretion of
neonatal rats to which
dosed with jj^c) "benzyl chloride.
remaining undosed material was not determined. Furthermore the
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a significant amount of the administered dose being exhaled.
The chromatographic properties of the metabolites of 
pentylcysteine excreted in the urine of dosed marmosets as 
determined in solvents S and P using three detecting reagents 
are summarised in Table 10.4- The results show that orally 
administered pentylcysteine was mainly excreted as pentyl- 
mercapturic acid by the marmoset but that traces of pentyl- 
mercapturic acid sulphoxide were also formed; no unchanged 
pentylcysteine appeared to be excreted by either animal studied. 
No metabolites with a greater mobility on chromatography in 
solvent P than pentylmercapturic acid were detected so that 
deamination of pentylcysteine does not occur to any significant 
extent. At a dose level of 11 5mg/kg body weight two marmosets 
excreted 44.7$ and 33*7$ of the dose as pentylmercapturic acid.
R-p value in solvent Reaction with detecting agent listed
Compound P+ II X XI
Reference compounds
Pentylmercapturic acid 0.73 1 .00 pale spot yellow -
Pentylcysteine 0.69 0.92 pale spot yellow grey
Pentylmercapturic acid 
sulphoxide 0.59 0.35 pale spota - -
Urinary metabolites
Pentylmercapturic acid 0.72 1 .00 pale spot yellow -
Pentylmercapturic acid 
sulphoxide 0.59 0.39 pale spotca - -
+Rate of movement of spots relative to that of meroapturic acid which is taken as 1.0 
developed colour after 6h.
fable 10.4 Chromatographic properties of reference compounds and urinary metabolites of




The results show that the marmoset is able to synthesise 
mercapturic acids from two types of mercapturic acid precursors, 
benzyl chloride and 1,2-epoxybutane and that it readily 
acetylates pentylcysteine.
In both the marmoset and the rat the main urinary metabolite 
of K ]  benzyl chloride, administered at a dose level of 50mg/kg 
body weight, is benzylmercapturic acid which accounts for an 
average of 53.3% of the administered dose in the marmoset and 
48.5% in the rat. The percentage of the total urinary metabolites 
of benzyl chloride that are accounted for by benzylmercapturic 
acid are however similar in both species. Barnes et al. (1959) 
reported that at a dose level of 200mg/kg bod,y weight, only 27% 
of administered benzyl chloride was excreted as benzylmercapturic 
acid by the rat, indicating that the degree of conversion of 
administered benzyl chloride to its corresponding mercapturic 
acid may be dose dependent. The conversion of benzyl chloride 
to benzylmercapturic acid sulphoxide appears to be a more 
important metabolic biotransformation in the marmoset than it is 
in the rat.
The excretion of benzylcysteine after the administration of 
benzyl chloride is more evident in the marmoset than it is in the 
rat and one marmoset examined excreted considerable quantities 
of this metabolite. The deamination of benzylcysteine appears 
to be a minor metabolic reaction in the marmoset but was not 
detected in the rat. The conversion of benzyl chloride to 
hippuric acid is variable in the marmoset and in three of the 
animals examined the formation of hippuric acid accounted for 
less than 5% of the labelled metabolites excreted. In the 
marmoset which did carry out this synthesis from benzyl chloride,
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the amount of hippuric acid formed was similar to that synthesised 
by similarly dosed rats. Benzoylglucuronide was tentatively 
identified as a minor metabolite of benzyl chloride in the rat 
but was not detected in the urine of dosed marmosets.
With 1,2-epoxybutane at a dose level of 100mg/kg body weight, 
mercapturic acid formation by the marmoset accounts for only 1.1 % 
of the administered dose, James et al. (1968) reported that at 
a dose level of 180mg/kg body weight the rat excreted 11% of the 
administered epoxide as 2-hydroxybutylmercapturic acid whereas the 
rabbit at a dose level of 137mg/kg body weight excreted of the 
dose in this form.
Pentylcysteine is readily acetylated to pentylmercapturic acid 
by the marmoset and some pentylmercapturic acid sulphoxide is 
also formed by this species. The percentage acetylation of the 
dose may be compared with those percentages found for other 
species which are summarised in Table 10.5 from the results 
reported by James and Needham (1975)* The degree of acetylation 
of pentylcysteine by the marmoset is similar to that in the rat.
No evidence for the deamination of pentylcysteine by the marmoset 
was obtained in the present study and in this respect the 
marmoset resembles the rat but differs from the rabbit and mouse 
(James and Needham, 1973)»
A comparison of the capabilities of the marmoset and man to 
convert various mercapturic acid precursors to their corresponding 
mercapturic acids is difficult since little work has been carried 
out on mercapturic acid formation in man. As mentioned earlier 
(pages 59 and 260) man converts a significant proportion (19%) of 
chlorobenzene to p-chlorophenylmercapturic acid (French et al. 
unpublished observations) but as pointed out by Smith and Williams 





Percentage of dose excreted 
as pentylmercapturic acid












Range of results are in parentheses; the number of animals 
used is indicated by the superior figures.
+Data from James and Needham (1973) except that for the 
marmoset which is the result from the present work.
The degree of acetylation of pentylcysteine
. . • +in various species
Table 10.5
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than that employed with the other species studied. That lower 
dose levels of mercapturic acid precursors may result in a 
greater proportion of the dose being excreted as the mercapturic 
acid derivative has already been suggested and it is possible 





Chapter 11 - Pinal Discussion
While the existence of a perfect animal model for the study 
of drug metabolism in man seems unlikely the best model might be 
expected to be found amongst those species most closely related 
to man. The G-reater and Lesser Apes are one step down from man 
on the evolutionary scale (see Table 1.11) but there are many 
factors which make the use of these species impracticable. The 
animals are difficult to obtain, especially in large numbers, 
extremely expensive to purchase and their maintenance cost is 
high; they are also difficult to handle. With the rhesus 
monkey, the species of Old World monkey most commonly used in 
the study of drug metabolism,these problems are substantially 
reduced but their export from India is now severely limited (Wade, 
1978). The Hew World monkeys, the next Family of primates down 
the evolutionary scale, includes the common marmoset, Qallithrix 
.jacchus shown by Poswillo et al. (1972) to be an excellent model 
for the study of teratogenesis in man.
The marmoset is a convenient size for use as a laboratory 
animal and, as reported by Stevenson (1977), was found in this 
study to be relatively easy to handle. Compared with larger 
primates it is not expensive to maintain and it adapts easily to 
experimentation. The supply of feral animals is restricted but 
the animal breeds readily in captivity, a breeding pair giving 
birth to twins or triplets every five months. Thus once a small 
nucleus of animals has been obtained a colony of useful size can 
easily be established in three to four years (see Fig 2.1).
In the present study the metabolism of several xenobiotics 
has been investigated in the marmoset. Oral dosing was found to 
be satisfactory and the dosed animals could be housed in glass
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metabolism cages similar to those originally designed for use 
with the rat, but with extra height to allow the animal greater 
freedom of movement.
Some disadvantages have been encountered with the use of the 
marmoset in metabolic studies. In the majority of cases the 
recovery of the administered dose was lower than in similarly 
dosed rats. Since, in most of these cases, only a small 
proportion of the dose was excreted during the second 24h period 
after dosing it appears that the low recovery is due to the 
practical difficulty of obtaining a complete collection of urine. 
The movement of these animals around the glass metabolism cages 
results in some of the urine which has been excreted onto the 
walls of the living chamber, being adsorbed onto the animals’ 
bushy fur. Attempts were made to wash the urine from the tails 
of the animals under study but this was accomplished with varying 
degrees of success. Other workers have also reported that dose 
recoveries are variable from primate species while Mehta e_t al. 
(1978) reported a relatively low recovery of 1-naphthol from Mew 
World monkeys.
The small size of the marmoset means that it is not possible 
to take large blood samples from any one animal at regular 
intervals. In view of this limitation the use of the marmoset in 
experiments designed to determine blood levels of drugs and/or 
metabolites is only possible where sensitive methods of assay are 
available. In the present study, successful sampling of the 
blood was obtained from the tail vein of the animals although 
the quantity obtained by this method was only small due partly 
to the collapse of the blood vessel but more especially to the 
rema.rkable rate at which marmoset blood was found to clot.
Previous studies of xenobiotic metabolism in the marmoset
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have shown that the metabolic fate of some compounds is similar 
to that in man, while that of others is very different in the two 
species. Thus amphetamine and norephedrine undergo both 
deamination and hydroxylation in man and the tamarin (sp.
Saguimus oedipus - of the same Family as the marmoset) while both 
these species also carry out lactam formation and ring hydroxyl­
ation of phenmetrazine; however the conversion of chiorphentermine 
to its hydroxylamine derivative occurs in man but not in the 
tamarin (Williams et al., 1973; Caldwell et al., 1975a; 1977). 
Conjugation of phenols in man occurs mainly by sulphation (Capel 
et al., 1972; Mehta et. al., 1978) whereas in the tamarin (sp. 
Saguimus oedipus) glucuronidation is the main biotransformation.
The metabolic fate of arylacetic acids in the marmoset is typical 
of that in New World monkeys (see p 44-55) the extent to which 
phenylacetic acid is conjugated with glutamine being less in the 
marmoset than in man, while the extent of conjugation with 
glycine is greater in the non-human primate.
The ability of the marmoset (sp. Callithrix jacchus)to carry 
out the hydroxylation of / \ ^  and A ̂ -tetrahydrocannabinol was 
reported by Just et al. (1975), a biotransformation previously 
reported to occur in man (Lemberger et al., 1971).
In the present study compounds containing different bio­
chemically reactive groups were administered to the marmoset and 
the extent to which this species carried out Phase II reactions 
was measured. Throughout the study the observed metabolic fate 
of the various xenobiotics in the marmoset was compared with that 
in man where data was available and for this reason the dose 
levels employed x̂ ere always similar to those used when the 
metabolic fate had been investigated in man or when the drug 
was used therapeutically.
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The results obtained suggest that the marmoset conjugates 
xenobiotics less readily with glycine than does man or the rat. 
This was evident from the experiments using benzoic acid as the 
test compound. The fate of this acid was found to be dose 
dependent in the adult marmoset, a situation not observed with 
the rat up to a dose level of 100mg/kg body weight. In the case 
of the marmoset, as the dose level was increased the proportion 
of the metabolites excreted accounted for as hippuric acid 
decreased while the proportion of benzoylglucuronide increased 
suggesting that the low conjugation with glycine may have been 
due partly to a low availability of glycine.
At a dose level of 1mg/kg body weight, administered benzoic 
acid was excreted by the marmoset and rat almost exclusively as 
hippuric acid, a similar situation to that shown by Bridges et al. 
(1970) to occur in man. As the dose level was increased and the 
relative importance of hippuric acid formation by the marmoset 
decreased, the capacity of the glucuronidating system appeared to 
be insufficient to compensate completely, particularly at a dose 
level of 1OOmg/kg body weight,and significant quantities of the 
dose were excreted unchanged. Quick (1931) reported that between 
7 and 12/« of a 5»0g dose of benzoic acid in man was excreted 
conjugated with glucuronic acid which when considered together 
with the results of Bridges et al. (1970) confirm the observation 
of Davison (1971) that the fate of this compound in man is dose 
dependent. The metabolic fate of benzoic acid has also been 
shown to be dose dependent in the dog and ferret (Bridges at al., 
1970) in which species the relative importance of glucuronidation 
increases with increasing dose level.
Bridges et al. (1970) studied the metabolic fate of benzoic 
acid (50mg/kg body weight) in the capuchin and squirrel monkeys;
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in the former species the administered dose was excreted almost 
entirely as hippuric acid whereas in the latter species a 
significant proportion of the dose was excreted unchanged.
Neither species excreted more than trace amounts of benzoyl- 
glucuronide so that the high capacity of the marmoset to conjugate 
benzoic acid with glucuronic acid is not a characteristic shared 
by other species of Hew World monkeys.
The metabolic fate of aspirin however did not appear to be 
dose dependent in the marmoset. As described for man considerable 
inter-individual variation in the metabolism of this drug was 
observed. The conjugation of the drug with glycine was, as in
the case of benzoic acid, found to be highly variable in the 
marmoset while some variation was also exhibited by the rat. In 
those animals excreting only a small proportion of the administered 
acetylsalicylic acid as salicyluric acid,the proportion of the 
metabolites accounted for as glucuronic acid conjugates was not 
significantly different from that observed in those animals 
excreting a higher proportion of the dose as salicyluric acid.
Hence glucuronidation did not appear to occur simply as a 
compensatory mechanism for the low conjugation of salicylic acid 
with glycine. In one instance where the metabolic fate of both 
benzoic acid and acetylsalicylic acid was studied in the same 
marmoset, the animal excreted only a small percentage of the 
total urinary metabolites as glycine conjugates. However the 
quantity of glycine utilised by this animal for the synthesis of 
salicyluric acid was less than that utilised to synthesise hippuric 
acid indicating that a low availability of glycine did not 
account for the small extent of salicyluric acid formation. 
Furthermore Davison (1971) reported that in man the extent of 
salicyluric acid formation was not increased by the simultaneous
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administration of glycine. These results suggest that the 
conjugation of benzoic acid and salicylic acid with glycine is 
carried out by different glycine N-acyltransferase enzymes or 
that salicylic acid is a poorer substrate for the enzyme than is 
benzoic acid (see Davison, 1971).
The proportion of a 13mg/kg body weight dose of acetyl- 
salicylic acid excreted by the marmoset conjugated with glucuronic 
acid is similar to that of a 43mg/kg body weight dose in man as 
reported by levy et al. (1972), whereas the proportion of the 
metabolites excreted accounted for as salicyluric acid is five 
times greater in the human emphasising the absence of any 
relationship between the conjugation of salicylic acid with 
glycine and glucuronic acid. The results obtained with the 
marmoset suggested that the major fraction of the glucosiduronic 
acids derived from aspirin consisted of the ester glucuronide 
whereas in the rabbit (Bray ejb al., 1948b)and man (Levy et al., 
1972) the phenolic glucuronide is the major glucuronide formed.
Both man and the marmoset excreted a small quantity of 
administered aspirin as gentisic acid. In the rat a greater 
proportion of the administered dose was metabolised in this way 
and evidence was obtained that in this species some gentisic acid 
was excreted conjugated with glucuronic acid.
Using HPLO it was shown that man and the marmoset both 
excreted a small amount of unchanged aspirin in the urine within 
1 ,5h of the administration of the compound at the same dose level. 
At higher dose levels the marmoset excreted a greater proportion 
of the dose unchanged probably reflecting higher plasma levels of 
the unmetabolised drug. Peak plasma levels of radioactivity were
reached within one hour of the administration of
salicylic acid to the marmoset.
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The marked ability of the marmoset to acetylate aromatic 
amino groups was shorn using jo-aminobenzoic acid, sulphadimidine 
and sulphadiazine. Using sulphadimidine it was found that all 
the adult animals in the colony corresponded to 1fast-acetylators' 
in human populations, based upon the proportion of the drug 
excreted as the acetylated derivatives; the relative proportions 
of the acetyl derivative as compared with the total drug in the 
blood, investigated in three animals, was in agreement with this 
finding.
The high ability of the marmoset to acetylate aromatic amines 
was also seen in the fate of administered j>-aminobenzoic acid.
The small proportion of this drug excreted as £-aminohippurate 
could be due partly to the low availability of glycine as 
described above for benzoic acid but the small proportion of the 
dose excreted as £-aminobenzoylglucuronide suggests that unlike 
the situation with benzoic acid, glucuronidation is not compensat­
ing, even fractionally, for the low glycine conjugation. In 
this case it seems probable that a high activity of the 
N-acetylase enzyme system, as compared with that of the glycine 
N-acyltransferase and transglucuronylase systems, results in a 
large proportion of the dose being excreted in the acetylated 
form.
The conjugation of sulphadiazine with glucuronic â cid by
1 4animal species occurs through the N and N nitrogen atoms. The
iextent to which N -glucuronide formation occurred in the marmoset 
was greater than that in the rat although the difference was not 
nearly so great as that reported between primates and non-primates 
for sulphadimethoxine (Adamson et al., 1970a). It is possible 
that the excretion of sulphadiazine as its N -glucuronide is 
relatively low in the marmoset because of the operation of an
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active iT-acetylase system resulting in the excretion of a large 
proportion of the administered drug in the acetylated form. The 
extent of acetylation of sulphadiazine by the marmoset was about 
half that effected by the rabbit, twice that which occurs in the 
rat and slightly less but of the same order as that reported for 
man by Uno and Sekine (1966). Economic considerations 
prohibited the investigation of the excretion of sulphadiazine 
and/or its metabolites in the bile of the marmoset but it seems 
likely that the extent of the biliary excretion of this compound 
would be low since in the rat less than 2fo of a dose of 
sulphadiazine is excreted by this route (Smith,1973 )•■
the marmoset, peak blood levels of radioactivity were attained 
within 5h of dosing. This peak in plasma radioactivity was 
maintained for approximately 2h and was followed by a sharp 
decrease in the plasma content of the drug and/or its metabolites 
which may indicate a rapid rate of metabolism of the drug. This 
rate is greater than that suggested by similar studies reported 
for man (Goodwin et al., 1942; Welch et al., 1949) so that the 
relatively prolonged high blood levels responsible for the long- 
acting therapeutic effect in man are not seen in the marmoset.
Acetylation of the aliphatic amino group of pentylcysteine 
was also extensive in the marmoset, almost 40jo of a 100mg/kg body 
weight dose of the compound being excreted as pentylmercapturic 
acid together with traces of pentylmercapturic acid sulphoxide. 
The deamination of pentylcysteine to pentylthiolactic and 
pentylthiopyruvic acids was not detected in the marmoset which is 
interesting since this species has been shown to deaminate both 
amphetamine and norephedrine to a significant extent (Caldwell 
et al., 1977). This substrate dependence in the deamination of
Following the oral administration of
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xenobiotics is not seen in the rabbit which has been shown to 
deaminate pentylcysteine, amphetamine and norephedrine (Bring 
et al., 1970; James and Needham, 1979; Williams et al., 1973)«
The ability of the marmoset to synthesise mercapturic acids 
was demonstrated using two known mercapturic acid precursors, 
benzyl chloride and 1,2-epoxybutane. When the former compound 
was administered to the marmoset the amount of benzyImercapturic 
acid excreted was similar to that excreted by similarly dosed 
rats; significant amounts of benzylcysteine and benzylmercapturic 
acid sulphoxide were also excreted. Some exidence was obtained 
that deamination of benzylcysteine occurred to a limited extent 
in the marmoset. Benzylthiopyruvic acid was detected as a 
metabolite of benzylcysteine in the rat (Shen and Lewis, 1946) 
but was not seen in the present study.
The excretion of hippuric acid by marmosets dosed with 
benzyl chloride is variable, the percentage of the total urinary
of 30mg/kg body weight,in this form ranged from 0-24.4$. In 
those animals excreting very little or no benzyl chloride as 
hippuric acid the excretion of benzoic acid was not detected 
suggesting that the availability of glycine did not limit the 
formation of hippuric acid.
It is likely that the marmoset possesses the ability to 
detoxicate epoxides by conjugation with glutathione and subsequent 
conversion of the conjugate to a mercapturic acid as shown by the 
metabolism of 1,2-epoxybutane to 2-hydroxybutylmercapturic acid. 
The extent of this conversion was low being of a similar order to 
that observed for the rat (James jet al., 1968). The formation of 
a mercapturic acid by marmosets dosed with -bromostyrene by a 
pathway which probably involves the intermediate formation of an
metabolites of chloride, administered at a dose level
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epoxide has been reported by Dawes et al. (1978). Scanty 
evidence exists for the ability of humans to form mercapturic 
acids and the extent to which this pathway is followed in man 
and the marmoset cannot be compared at present.
The results obtained using quinic acid suggested that the 
marmoset is a typical Few World monkey in its inability to 
aromatize this compound (see Adamson et al., 1970b). however 
like non-primate species which are also unable to aromatize 
quinic acid it is possible that marmosets are able to aromatize 
cyclohexylcarboxylate. The experiments carried out using sodium 
cyclohexylcarboxylate must be regarded as a preliminary study 
only, but the results obtained with quinic acid suggest that the 
gut flora of the marmoset resembles that of other Few World 
primate species and has a low capacity to reduce quinic acid.
A comparative investigation of the in vivo metabolism of two 
compounds in neonatal marmosets and rats was carried out. It 
was found that the metabolic fate of 0 4d  benzoic acid in 
neonatal rats and marmosets was quantitatively very different 
from that in the adult animals of these species. In the 
neonatal animals of both species the metabolic fate of sodium 
f^cjbenzoate was strongly dose dependent, the relative importance 
of benzoylglucuronide formation being much greater in the 
neonates than in the adults of either species. At a dose level 
of 100mg/kg body weight, benzoylglucuronide was found to be the 
major metabolite of administered benzoate in the neonatal marmoset 
and the availability of glycine was shown to be clearly limiting.
Bilirubin-UDPG-T activity was detected in the liver of 
neonatal marmosets although the activity was lower than that 
found in the liver of adult rats and marmosets. It is recognised 
that the tissue used had not been obtained until some hours after
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death and that the enzyme levels found were likely to be lower 
than those present in fresh tissue. In the human infant it is 
probable that bilirubin-UDPG-T is not fully developed at birth 
which may to some extent be responsible for the physiological 
jaundice of the newborn.
The development of the Phase II enzyme systems responsible 
for the metabolism of jo-aminobenzoate follow different trends in 
the rat, marmoset and man. In the rat the extent of the 
formation of ja-aminohippurate increased with age while the 
relative extent of glucuronidation decreased. The percentage of 
the total urinary metabolites that were acetylated increased with 
age although the extent of this change was less than the increase 
in glycine conjugation. In the marmoset, comparatively little 
change in the extent to which jo-aminobenzoate was conjugated with 
glucuronic acid occurred throughout development, although a slight 
increase was detected. Similarly the relative importance of 
jD-aminohippurate formation did not change significantly throughout 
development although a slight decrease in its excretion was 
observed. The main changes in the metabolic fate of jD-amino- 
benzoate in the developing marmoset occurred in the proportion of 
the doses which were excreted unchanged or as the H-acetyl 
derivative. During early development there was a substantial 
increase in the percentage of the total metabolites excreted that 
was accounted for by £-acetamidobenzoate with a corresponding 
decrease in the percentage of unchanged ja-aminobenzoate. In 
developing children, Vest and Salzberg (1965) showed that the 
activity of the acetylating system decreased with age and that an 
increased excretion of unchanged jD-aminobenzoate occurred. Hence 
in man and marmoset the metabolic fate of p-aminobenzoate in the 
neonate appears to be controlled mainly by developmental changes
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in the activity of the acetylase, or possibly a de-acetylase, 
enzyme system, changes which are directionally opposite in the 
two species.
Therefore although no qualitative differences have been 
observed in comparing those biotransformations of xenobiotics 
involving synthetic reactions in the marmoset, man and rat 
marked quantitative differences occur; these are particularly 
evident in the neonates of these species. While the marmoset 
is undoubtedly a useful primate species for the study of the 
metabolic fate of xenobiotics, the frequently quoted lines from 
Alexander Pope’s 'An Essay on Mari' must always be borne in mind,
"Know then thyself, presume not G-od to scan,
The proper study of mankind is man."
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METABOLISM OF [14 CJ-BENZOIC ACID IN THE DEVELOPING RAT
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It is generally recognised that the level of activity of drug-metabolizing enzymes is low in the neonate as compared with 
the adult. Glycine N-acyltransferase (EC 2.3.1.17) activity was not detected in mitochondria from neonatal rat liver 
using p-aminobenzoic acid as substrate; the activity increased with age reaching 10% of the adult value at 10 days after
(1). By contrast hepatic UDP-glucuronyl transferase (EC 2.41.17) act­
ivity is relatively high in the neonatal rat, falling to adult levels after 
about 10 days (2). The extent to which these enzymes are involved in 
the metabolism of benzoic acid in rats of different ages has been invest­
igated by quantitation of the metabolites excreted in urine.
Methods: [Ring-U-14C] -labelled benzoic acid, in solution as the sod­
ium salt, was administered to female rats (Wistar strain) aged from 5 days 
to adult, at a dose level of 0.33 mmol (4.6 pCi) kg-1 and the radioactivity 
of the 24 h urine determined by scintillation counting. The procedure 
followed for dosing the rats and the collection of urine samples has been 
described (3). The distribution of the radioactivity between benzoic acid, 
hippuric acid and benzoyl glucuronide was determined by chromatograph­
ic examination of aliquots of the urine of dosed rats on Whatman 3 MM 
paper or on thin layer plates coated with silica-gel-G (300 pm thick) (Merck, 
A.G., West Germany). Solvents used were butan-l-ol:ethanol:acetic acid: 
water (30:10:1:10 by vol), in which benzoic acid, hippuric acid and ben­
zoyl glucuronide had Rp values 0.91, 0.82 and 0.51, respectively, on paper
and 0.85, 0.70 and 0.42 on tic, and chloroform:cyclohexane:acetic acid 
excreted to urine In 24 h after dom e. The result, are (g 2 ;, b vol) jn which the corresponding Rp values on tlc were 0.87, 
expressed as a percentage o f  the dose and vertical bars v J r  °  r ’
represent ± S.E.M. for groups o f  animals numbering 2-5. 0.17 and 0.00. Urine samples were also incubated for 24 h with limpet
|3-glucuronidase (Sigma Chemical Co Ltd) to hydrolyse benzoyl glucuronide to benzoic acid and then similarly examined.
The radioactivity on the chromatograms were scanned and the chromatograms then fragmented into 0.5 or 1.0 cm zones, the
D . . .  . ,  .. „ j  • n  a  u  • x x j  -i radioactivity of each being measured by scintil-Relative am ounts o f  radioactive com pounds in 24 h urine o f  rats dosed
w ith  [ X*C ]-benzoate .______________________  lation counting.
Results and discussion: The total percent­
age of the dosed [14 C]-benzoate excreted in 
urine in 24 h is shown in the figure. The distrib­
ution of the radioactivity is shown in the table 
which includes also the effect of hydrolysis 
with j3-glucuronidase. Whereas, as has been 
shown by other workers (4), adult rats excrete 
benzoate almost entirely as hippuric acid, in 
neonatal rats about 20% of the radioactivity 
in the urine of dosed animals corresponds to 
benzoyl glucuronide. Although the level of 
hepatic glycine-N-acyltransferase is low in the 
ten-day old rat a considerable proportion
Aqe at dosinq (days)












Adult (a) 0.33 ND 98.0 1.6
(b) 2.5 3.5 (5.6) 94.2 (93.8) 2.3 (0.7)
5 days* 0.33 ND 64.2 18.5
10 days (a)* 0.33 ND 52.7 20.7
(b) 0.83 0.5 77.8 21.7
(c) 0.83 0.5 (19.4) 76.4 (76.6) 23.1 (4.0)
(d) 0.83 ND 82.1 17.9
(e) 0.83 0.4 62.5 34.8
(f) 0.83 ND (16.8) 75.9 (81.4) 19.7 (ND)
Figures in parentheses are the values found after 0-glucuronidase hydrolysis. ND= 
not determined. *In the urine o f  these two animals only an unidentified radio­
metabolite was detected.
of the dosed benzoate is converted to hippuric acid. It is therefore possible that extra-hepatic tissues contribute to this 
synthesis.
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